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 Abstract 
SP-D is a large hydrophilic protein, consisting of four collagenous trimers, which is secreted by 
alveolar type II and non-ciliated bronchiolar epithelial cells and participates in calcium-dependant 
agglutination of inhaled microorganisms. Known high-resolution crystal structures of mono- and 
disaccharide bound recombinant human SP-D include a heptose disaccharide that mimics the 
inner core fragment of bacterial lipopolysaccharide. This thesis focuses on the structural 
characterisation of SP-D binding to lipopolysaccharides from Gram-negative bacteria. Intact LPS 
and several hydrolysed smooth and rough mutants were soaked into native crystals of a 
recombinant head and neck fragment of SP-D. Those soaked with hydrolysed Escherichia coli J5 
and Salmonella minnesota R7 LPS showed electron density corresponding to ligand in the ligand-
binding site. All crystals processed conformed to spacegroup P21, all with unit cells close to a= 55, 
b= 108, c= 55 Å, = 91°. The maximum resolution diffraction observed was 1.63 Å.  
The R7-soaked structure was refined at 1.77 Å, with a final R-factor of 18.71% and R-free 
of 22.05%. The structure reveals a well-defined trisaccharide unit of two heptose saccharides and 
a single Kdo residue in protein chains B and C.  The Kdo is present as a five-membered, anhydro 
residue known to form during mild acid hydrolysis. The third, outermost heptose of the R7 inner 
core is not visible in the electron density. 
The refined structure demonstrates binding of LPS via the O6 and O7 hydroxyl groups of 
the glycerol sidechain of HepI, the innermost heptose, demonstrating for the first time 
structurally not only the binding of a physiologically relevant bacterially derived ligand but also 
the recognition of a non-terminal monosaccharides by SP-D.  No direct interaction is observed 
between the second heptose and the protein, but two hydrogen bonds are seen between the 
anhydro-Kdo and the amino acids Arg343 and Asp325 which flank the SP-D ligand binding pocket. 
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Chapter 1: Introduction to Collectins: pathogen recognition molecules 
1.1 The immune system 
The mammalian immune system exists as two distinct mechanisms - the evolutionarily ancient 
innate immune system and an adaptive or acquired immune system. The former acts as the first 
line of defence for all species, characterised by rapid target recognition of general non-self-
antigenic moieties, while the latter arose during early vertebrate evolution to detect specific 
microbial antigens. The acquired immune system requires an initial encounter with the invading 
pathogen to provide protection against re-infection and has evolved to provide a more versatile 
means of defence. Activation is slow however, and begins when a pathogen is ingested by 
dendritic cells in the infected area. Precursor cells such as macrophages then migrate from the 
bone marrow and ‘survey’ the local environment. Eventually dendritic cells migrate through the 
lymphatic system to lymph nodes where they interact with lymphocytes. If the dendritic cells fail 
to become activated, the immune system is said to be tolerant of the antigen. The function of 
dendritic cells is not to directly neutralise the invading pathogen, but to present the antigen to 
peripheral lymphoid organs where it becomes an antigen-presenting cell. All adaptive immune 
responses are mediated by lymphocytes. Lymphocytes are a class of white blood cells that bear 
cell-surface receptors for an antigen. There are two main classes of lymphocyte: B lymphocytes (B 
cells) which mediate humoral responses in which antibodies produced by B cells cause the 
destruction of extracellular microorganisms and prevent the spread of intracellular infections; 
and T lymphocytes (T cells) which evoke cell-mediated immunity, whereby infected cells are 
destroyed by cytotoxic T cells, or intracellular pathogens are destroyed by macrophages activated 
by T-helper, TH1, cells.  
Lymphocytes that have been activated by an antigen give rise to clones of antigen-specific cells 
that mediate adaptive immunity. The result is production of antibodies of different specificities 
that serve as antigen receptors. The process is therefore not instantaneous. After a naive 
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lymphocyte has been activated, it takes 4 to 5 days before clonal expansion is complete and 
the lymphocytes have differentiated. When a recirculating lymphocyte encounters its specific 
foreign antigen it proliferates and its progeny then differentiate into effector cells that can 
eliminate the infectious agent. A subset of these proliferating lymphocytes differentiate into 
memory cells, ready to respond rapidly to the same pathogen if it is encountered again (Janeway, 
2001). 
1.1.1 Innate immunity 
Given the time taken for the adaptive immune system to eliminate infectious agents, the 
importance of a rapid response is clear. Most infectious agents induce immune responses by 
activating innate immunity, as microorganisms such as bacteria that penetrate the epithelial 
surfaces of the body are met immediately by cells and molecules that elicit this response. For 
example, phagocytic macrophages have surface receptors able to recognise and bind common 
components of many bacterial surfaces. Binding of these moieties triggers the macrophage to 
engulf the bacterium and induce secretion of biologically active molecules such as cytokines and 
chemokines that affect the behaviour of other cells that bear receptors for them. Chemokines 
attract cells such as neutrophils and monocytes from the bloodstream and initiate inflammation, 
which may trigger a complement cascade on the bacterial cell surface. Examples of innate 
immunity in the form of chemical and physical barriers are vast: the skin serves as a primary 
barrier to microbial entry; epithelial cells produce secretions which contain antimicrobial peptides 
and enzymes that inhibit pathogen growth; the mucus lining of the throat and lungs acts as a 
physical barrier that prevents adherence of pathogens and cilia facilitate clearance; orifices such 
as the eyes and mouth contain enzymes such as lysozyme and continuously wash away microbes; 
while highly acidic secretions in the stomach ensure few organisms survive if ingested.  
Despite these barriers, pathogens may still enter the body and once inside, other mechanisms 
induce further innate immune responses. Pattern recognition receptors (PRRs) such as Toll-like 
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receptors (TLRs), Nod-like proteins, and collectins act as sensors of intracellularly encountered 
microbial motifs (Ozinsky et al., 2000, Fritz et al., 2006; Lu, 2002). Present round the body in the 
form of soluble proteins and cell surface receptors, PRRs induce various signalling pathways 
including opsonisation of the microbe, recruitment of phagocytic and natural killer cells, and 
upregulation of the complement cascade (Medzhitov & Janeway, 2000). 
These molecules are able to distinguish microbial pathogens from healthy self-antigens through 
recognition of molecular arrays known as pathogen-associated molecular patterns (PAMPs), 
which are highly conserved among the different classes of pathogens. However, invading 
pathogens are not the only causative agents of cell damage; trauma and associated tissue-
damage are also recognised at the cellular level by receptor-mediated detection. For instance, 
intracellular proteins released by dead or apoptotic cells elicit similar responses, and are referred 
to as damage-associated molecular patterns, or DAMPs (Bianchi, 2006).  
1.1.2 Lectins 
Molecules that recognise carbohydrate moiety PAMPs are termed lectins, and are 
classified into distinct subgroups on the basis of their amino acid sequences and biochemical 
properties: P-type lectins such as the mannose 6-phosphate receptor and the insulin-like growth 
factor II/mannose 6-phosphate receptor which recognise and bind phosphorylated mannose 
residues (Dahms, 2002); I-type lectins, glycan-binding proteins that belong to the immunoglobulin 
superfamily (Varki, 1999); Gal-lectins which bind galactose and N-acetylgalactosamine (Boettner 
et al., 2002); and C-type lectins whose members contain carbohydrate-recognition domains 
(CRDs) that are homologous even though they mediate a variety of interactions by binding 
selectively to specific monosaccharides.  
C-type lectins are further divided in to two distinct subgroups: selectins which bind 
fucosylated and sialylated glycoproteins, found on endothelial cells, leukocytes and platelets (Ley, 
2003), and collectins.  
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1.1.3 The Collectin family 
The collectins are calcium-dependent pattern recognition molecules found in mammals, 
and represent a non-clonal, innate host defence system. Various collectins have been 
characterised in the following major locations: lung surfactant proteins A and D (SP-A, SP-D), 
found on the epithelial lining of lungs to provide protection against inhaled pathogens and 
allergens; hydrophobic surfactant proteins B and C (SP-B, SP-C) which stabilise the respiratory 
surface of mammalian lungs (Parra et al., 2013); mannose-binding lectin (MBL) found in the serum 
and liver (Weis et al., 1998); conglutinin, collectin-43 and collectin-46, bovine serum proteins 
closely related to SP-D (Håkansson & Reid, 2000); and the more recently discovered collectin-liver 
(CL-L1), collectin-kidney (CL-K1) and collectin-placenta (CL-P1) molecules (Ohtani et al., 1999; Jang 
et al., 2008; Axelgaard et al., 2013). Each are involved in protein-carbohydrate interactions and 
have important roles in two distinct aspects of the innate immune response: initial pathogen 
recognition and the subsequent cellular interactions that lead to the pathogen’s neutralisation 
and clearance. The localisation and carbohydrate binding preference of these molecules are 
summarised in the following table: 
Table 1-1 Localisation of collectins in tissues, and relative carbohydrate specificity. Lu et al., 
2002. 
Collectin Localisation in tissues Carbohydrate specificity 
SP-A 
Lung epithelium, prostate, thymus, 
intestinal mucosa, Eustachian 
tube, middle ear, paranasal sinuses, 
mesothelium, synovial fluid 
ManNAc>L-fucose/maltose> 
glucose>mannose/galactose 
SP-D 
Lung epithelium, gastrointestinal 
epithelium, kidney, brain, testis, pancreas, salivary 
gland, heart, prostate, small 
intestine, urinary tract, placenta, uterus, 
stomach, mammary glands, spleen, adrenal gland, 
and liver 
maltose>L-fucose>mannose> 
Glucose>>>glucosamine 
MBL Serum and liver 
GlcNAc>mannose/L-fucose> 
ManNAc>>>maltose>glucose 
Conglutinin Bovine liver 
GlcNAc>>>mannosamine> 
L-fucose/mannose>glucose> 
CL-43 Bovine liver 
mannose>>>ManNAc>>>L-
fucose>GlcNAc>glucose> 
galactose 
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Table 1-2 Localisation of collectins in tissues, and relative carbohydrate specificity. Lu et al., 
2002. 
Collectin Localisation in tissues Carbohydrate specificity 
CL-46 
Bovine thymus, liver, 
mammary glands and 
digestive system 
GlcNAc>>>ManNAc 
/mannosamine>>maltose> 
glucose/L-
fucose/mannose>>galactose 
CL-L1 Tissues except skeletal muscle mannose 
CL-K1 
Kidney, vascular endothelial 
cells and placenta 
fucose>>mannose 
CL-P1 
Placenta, alveolar 
macrophages and tonsils 
lactose> 
GalNAc>L-fucose>galactose 
ManNAc - N-acetyl mannosamine; GlcNAc - N-acetyl glucosamine; GalNAc - N-acetyl 
galactosamine 
 
Collectins target non-self pathogens such as viruses, bacteria, fungus and allergens by binding to 
their characteristic surface carbohydrates, and the broad range of recognised monosaccharides 
reflects the variety of pathogenic surfaces to which they bind. Binding is mediated by the 
conserved calcium-recognition domain. Collectins bind glycoconjugates and lipids moieties on a 
broad range of microorganisms, fungi and allergens, as well as receptors on host cells. Through 
these interactions, a range of effector mechanisms are induced, such as agglutination through 
formation of bridges between ligands on a pathogen’s surface (van Rozendaal et al., 2000); 
activation of the complement cascade (Hajela, 2002); opsonisation and activation of phagocytosis 
by binding of receptors on phagocyte cell surface (Beharka et al., 2002); inhibition of microbial 
growth by increasing cell permeability of the bacterial membrane (Wu et al., 2003); modulation of 
the inflammatory response by recruitment of chemokines, cytokines and production of reactive 
oxygen and nitrogen species (Tino & Wright, 1998); modulation of the adaptive immune response 
by inhibition of T-cell proliferation (Borron et al., 1998); modulation of the allergic response by 
inhibition of IgE binding to allergens and subsequent suppression of histamine release (Strong et 
al., 2002); stimulation of apoptotic cell clearance by alveolar macrophages (Schagat et al., 2001); 
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as well as various methods of inhibiting uptake of microorganisms by self-cells (Hartshorn et al., 
2006). 
1.1.3.1 Collectin structure 
Soluble collectins are large homo-oligomers that comprise a collagenous N-terminal 
region, a coiled-coil neck and a C-terminal calcium recognition domain (Drickamer & Taylor, 
1993). Two subgroups of collectins are distinguished by the length of the collagenous domain: 
those with a smaller number of Gly-X-Y repeats in the collagen domain form ‘bouquet’-like 
structures, while those with more repeats form cruciform (see Fig 1-1).  
  
 
 
 
 
 
 
 
 
Figure 1-1 Domain organisation of collectins. The left structure shows a single trimeric building 
block and its constituent parts, the right represents the bouquet and cruciform oligomers. 
Adapted from Weis et al., 1998. 
 
Collectins contain four distinct regions of primary structure: a short amino-terminus that form 
inter- and intra-chain disulphide bonds that stabilise the trimeric building block (Wallis & 
Drickamer, 1997); a section of Gly-X-Y repeats that form a collagen domain; an α-helical coiled-
coil neck of about 30 amino acids; and a carboxy-terminal carbohydrate recognition domain 
(CRD).  
Bouquet 
Cruciform 
CRD 
α-helical  
coiled-coil 
Collagen-like  
domain 
N-terminus 
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The following diagram (Fig 1-2) shows a sequence alignment, comparing the head and 
neck region of the four aforementioned human collectins SP-A, SP-D, MBL and CL-L1: 
                                 neck | CRD domain  
hSP-D numbering       220       230       240       250       260 
                       |         |         |         |         | 
Human SP-A     89 ATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEA 
Human SP-D    215 QGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLL 
Human MBL      89 ASERKALQTEMARIKKWLTFSLGKQVGNKFFLTNGEIMTFEKVKAL 
Human CL-L1     --EMDNQVSQLTSELKFIKNAVAGVRETESKIYLLVKEEKRYADAQLS 
 
                        270       280        290       300       310 
 
                         |         |          |         |         | 
Human SP-A      CARAGGRIAVPRNPEENEAIASFVK-KYNTYAYVGLTEGPSPGDFRYSDGT 
Human SP-D      CTQAGGQLASPRSAAENAALQQLVV-AKNEAAFLSMTDSKTEGKFTYPTGE 
Human MBL       CVKFQASVATPRNAAENGAIQNLIK----EEAFLGITDEKTEGQFVDLTGN 
Human CL-L1     CQGRGGTLSMPKDEAANGLMAAYLAQAGLARVFIGINDLEKEGAFVYSDHS 
 
                         320          330       340       350  
                          |            |         |         |       
Human SP-A      PVN-YTNWYRGEPAGRGK----EQCVEMYTDGQWNDRNCLYSRLTICEF   
Human SP-D      SLV-YSNWAPGEPNDDGG---SEDCVEIFTNGKWNDRACGEKRLVVCEF   
Human MBL       RLT-YTNWNEGEPNNAGS---DEDCVLLLKNGQWNDVPCSTSHLAVCEFPI 
Human CL-L1     PMRTFNKWRSGEPNNAYD---EEDCVEMVASGGWNDVACHTTMYFMCEFDKENM 
Figure 1-2 Sequence alignment diagram of the neck and head domains of some human 
collectins. Sequences were taken from UniProt.org and aligned using ClustalW2 (Larkin et al., 
2007). 
 
1.1.3.1.1 N-terminus 
The N-terminal region which stretches from the N-terminus to the first collagenous triple-
helix residue, a cysteine-rich domain that stabilises trimers through disulphide bridging that links 
the collectin oligomers together (Holmskov et al., 1995). There is no overall homology between 
collectins in the N-terminal region, but collectins can be divided into four subclasses: in SP-D, 
conglutinin and CL-43 they are similar in length at 25-28 amino acids; SP-A has a much shorter 
domain, one isoform with seven residues, the other consisting of ten; the third group, which 
includes MBL, is capable of forming larger oligomers; and the final group, so far only represented 
by CL-L1, has a much longer N-terminal sequence. Fig 1-3, below, demonstrates the lack of 
similarity between N-terminal regions of human collectins SP-A, SP-D, MBL and CL-L1: 
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Human SP-A      ------------------------EVKDVCVGSPGIPGTPGSHGLPGRDG  
Human SP-D      ---------------AEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDG  
Human MBL       ------------------ETVTCEDAQKTCPAVIACSSP-GINGFPGKDG  
Human CL-L1     MNGFASLLRRNQFILLVLFLLQIQSLGLDIDSRPTAEVCATHTISPGPKG  
        
Figure 1-3. Sequence alignment diagram of the N-terminal domains of some human collectins. 
The N-terminal region is highlighted in yellow, and cysteine residues are pink. Sequences were 
taken from UniProt.org and aligned using ClustalW2 (Larkin et al., 2007). 
 
1.1.3.1.2 Collagen region 
The presence of a collagen-like region is necessary for the protein’s trimeric structure, 
which is essential for proper function. High-order organisation strengthens the carbohydrate-
protein interactions - and as such assembly of collectins in to larger entities allows cross-linking of 
several target particles, and permits the multiple CRDs to interact simultaneously with a single 
microbe (Håkansson et al., 2000). There are however, no experimentally determined structures of 
native collagens, and current knowledge is based mainly on fibre diffraction studies, model 
building and crystallographic studies of short compounds (Kramer et al., 1998). Collagen 
structures can be recognised by their Gly-X-Y repeat pattern, where X and Y can be any amino acid 
but are typically proline, and form a left-handed helix. The three oligomers coil round one another 
in a right-handed superhelix and interchain hydrogen bonds between Gly amine groups and X 
carbonyl groups stabilise the structure (Kramer et al., 1999). The helix is further stabilised by a 
network of water molecules that surround it. Its high tensile-strength and relative resistance to 
proteolysis mark the collagen region as an ideal domain cross-linker. In addition, this region has 
been shown to mediate binding to other macromolecules, such as the C1q receptor and 
macrophage scavenger receptor (Stuart et al., 1997). 
1.1.3.1.3 α-helical coiled-coil neck 
α-helices often show a distinct heptad repeat pattern a-b-c-d-e-f-g, where a and d are 
hydrophobic amino acids that form the interior of the coil. α-helices typically make 8 or 9 turns in 
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total (Weis & Drickamer, 1994) and offer an explanation for the ability of collectins to distinguish 
self from non-self: a hydrophobic interface between the neck and C-terminal CRD maintains a 
fixed spatial relationship, such that the binding sites are roughly 45 Å apart in the trimer. 
Pathogenic surfaces present dense, repetitive arrays of ligands that span this distance perfectly 
(Weis & Drickamer, 1994).  It is thought that the primary role of the neck domain in molecular 
assembly is to align the collagen chains and thereby facilitate subsequent folding of the collagen 
helix (Zhang et al., 2001). 
1.1.3.1.4 Carbohydrate recognition domain 
The carbohydrate recognition domain (CRD) is a well conserved domain of 110-140 amino acids, 
characterised by a double lobe structure (see Fig 1-4, panel A).  
 
Figure 1-4 Crystal structure of the CRD. Panel A highlights the two lobes of the CRD fold, shown 
in red and green; Panel B displays the disulphide bridges, shown in red; Panel C demonstrates 
the carbohydrate binding site and interactions of key residues; and panel D shows the two 
binding-groove regions of the CRD in green. Image adapted from Veldhuizen et al., 2011. 
 
 
Up to four calcium-binding sites can be identified across the collectin family, which differ in their 
relative affinity for the metal ion. Location of calcium sites 1, 2 and 3 is considered to be crucial 
for the stability of the domain, as removal of these sites increases the protein’s susceptibility to 
protease degradation and conformational change (Cooley et al., 2008); while site 4 is directly 
involved in saccharide binding and the calcium-dependency of collectin ligand binding.  
Collectins can be divided into two groups based on their specificity for either mannose or 
galactose. With the exception of CL-P1, all the described collectins have a binding preference for 
A B C D 
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mannose-type ligands over galactose-type. SP-A, SP-D and MBL have also been shown to have 
even broader binding specificity, including nucleic acids, phospholipid and nonglycosyalted 
proteins (Palaniyar et al., 2004; Kuroki & Sano, 1999; Ip et al., 2009). Studies of the preference of 
simple monosaccharides provides a general understanding of binding specificity of the collectins, 
and despite the overall similarities, it becomes clear that additional structural factors are 
involved; crystallographic studies have revealed some of the underlying mechanisms of binding by 
the CRD and highlighted involvement of several key residues in the binding pocket. 
The majority of studies concerning collectin binding have so far focused on binding to 
monosaccharides representative of terminal carbohydrate residues. It has been shown that 
multiple CRDs can bind simultaneously to monosaccharide units of different polysaccharide chains 
and computational docking studies suggest that amino acids outside the binding pocket may also 
be necessary for longer ligand binding by collectins (Allen et al., 2001). SP-D has also been shown 
to bind longer ligands such as maltotriose and p-nitrophenyl maltoside whereby in addition to the 
terminal carbohydrate binding, a phenylalanine residue outside the binding site interacts with the 
third saccharide (Crouch et al., 2006). 
In addition to the surface structure of the collectins, multimerisation of oligomers may 
also influence multivalent binding to ligands (Lee & Lee, 2000). Although the CRD structures of 
collectins are very similar, the actual trimeric structures vary significantly. For instance, the angle 
between the neck and lectin domain of SP-A is close to 90°, creating a flat, T-shaped trimer, 
whereas a larger kink between the head and neck domains in SP-D and MBL results in a Y-shaped 
trimer (see Fig 1-5). 
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Figure 1-5 Crystal structures of trimeric SP-A and SP-D in side-view. The CRD domain is shown in 
yellow and white and calcium ions are shown as green spheres. Coordinates taken from the 
Protein Data Bank: accession numbers 3PAK (left) and 3G83 (right). 
Spatial positioning of CRDs in the collectins affects the array of monosaccharides the protein can 
bind to - and the pattern of oligosaccharides on an invading pathogen must fit the spatial 
organisation of binding sites for the specific collectin (Seaton et al., 2010). 
1.1.4 Receptors for collectins 
In addition to recognition and binding of physiological ligands on the surface of invading 
pathogens, collectins display specific interactions with host cells. A crucial function of the 
collectins lies in their ability to enhance phagocytosis and induce opsonisation, which in most 
cases is mediated by calcium-dependant binding to microorganisms. The following table 
summarises the binding of collectins MBL, SP-A and SP-D to cell surface receptors and the 
biological consequences that ensue: 
Table 1-3 Binding of collectins to cell surface receptors and the biological consequences. 
Haczku, 2008. 
Receptor Cells Collectin 
Binding 
site 
Consequence 
CR1 
(CD35, complement 
receptor 1) 
B-cells, monocytes, 
neutrophils 
SP-A, 
MBL 
Collagen 
tail 
Phagocytosis 
SP-A       SP-D 
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Table 1-4 Binding of collectins to cell surface receptors and the biological consequences. 
Haczku, 2008. 
Receptor Cells Collectin 
Binding 
site 
Consequence 
Calreticulin-CD91 complex 
Macrophages, 
neutrophils 
SP-A, SP-D, 
MBL, 
conglutini
n, CL-43 
Collagen 
tail 
All: apoptotic 
cell clearance 
SP-A and SP-
D: pro-
inflammatory 
cytokine 
release, p38 
and NF-κβ 
activation 
SP-R210 
(SP-A receptor 210) 
Macrophages, T-cells SP-A CRD 
Phagocytosis, 
increased 
nitric oxide 
and TNFα 
production, 
reduced T-cell 
proliferation 
CD14 Myeloid lineage cells 
SP-A, SP-D, 
MBL 
SP-A: neck 
region 
SP-D: CRD 
MBL: CRD-
independen
t 
Reduced 
cytokine 
production 
TLR2 (Toll-like receptor 2) Alveolar macrophages SP-A, SP-D CRD 
Reduced TNFα 
production 
TLR4 (Toll-like receptor 4) Macrophages SP-A, SP-D CRD 
Increased NF-
κβ activation 
SIRPα (signal- inhibitory 
regulatory protein α) 
Macrophages SP-A, SP-D CRD 
Reduced 
cytokine 
production 
 
1.2 Functions of pulmonary Surfactant Protein-D 
Pulmonary surfactant is a mixture of lipids (90%) and proteins (10%) that establishes the 
liquid phase of the alveolar epithelium and maintains surface tension to prevent lung collapse. 
Surfactant is stored as lamellar bodies - then secreted into the alveolar spaces and airways where 
it forms a lattice, referred to as tubular myelin. This is considered to be an intermediate product 
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that forms the lipid film that coats the alveoli. Surfactant protein-D was originally identified as a 
surfactant-associated protein responsible for pulmonary surfactant homeostasis and constitutes 
0.6% of surfactant proteins (Weaver & Whitsett, 1991; Kishore et al., 2006). Subsequent structural 
and functional characterisation have since proved that in addition to this, SP-D is a potent innate 
immune molecule involved in a wide range of immune responses, such as recognition and 
clearance of viruses, bacteria, fungi, apoptotic and damaged cells, downregulation of allergic 
reactions to pollen and dust-mites, as well as orchestration and modulation of the innate and 
adaptive immune systems (Kishore et al., 2006; Cormack & Whitsett, 2002).  
 SP-D is a large hydrophilic protein that is secreted by by alveolar type II and non-ciliated 
bronchiolar epithelial cells as dodecamers consisting of four collagenous trimers cross-linked by 
disulphide bonds (Kuan et al., 1992). 
1.2.1 Biosynthesis and genetic organisation 
Crouch and co-workers characterised cDNA specific for human SP-D and demonstrated 
that the SP-D gene has a coding sequence spanning >11kilobases, situated on the long-arm of 
chromosome 10. Sequencing studies have shown that the signal peptide/amino-terminus, neck 
domain and CRD are each encoded by a single exon, like those of SP-A and MBL. However, a 
unique split-intron-exon structure is present for the collagen region which is encoded by five 
exons, including four tandem exons. The latter exons reveal a marked conservation in the 
structure of the collagen domain, consistent with replication of this sequence during evolution, 
and distinguishes SP-D from other collagenous C-type lectins. Split sequences may offer certain 
evolutionary advantages for collagen-containing proteins, since splicing of the genes will 
reconstitute an intact glycine codon, maintaining the Gly-X-Y triplet (Crouch et al., 1993). 
 SP-D is extensively modified post-translationally, and mass spectrometric analysis 
of intact proteins indicate modifications are heterogeneous in nature. Modifications include 
cleavage of the signal peptide, partial hydroxylation of proline and lysine residues in the collagen 
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domain to stabilise the triple helix, and assembly in to subunits and high-order oligomers through 
disulphide linkages and non-covalent interactions. (Leth-Larsen et al., 1999). 
Native SP-D is composed of oligomers of a 130kDa subunit comprising three identical 
polypeptides chains of 43kDa. It is assembled into a 520kDa tetrameric structure with four 
homotrimeric subunits linked via their N-terminal regions in a cruciform (see Fig 1-1). Electron 
micrographs of rat SP-D show that the subunits emanate from a central pore into two opposite 
pairs. Each subunit measured approximately 46nm in length and was terminated by a globular 
region 8-9nm in diameter. Preparations also showed high-order multimers, referred to as fuzzy 
balls, consisting of SP-D molecules associated at their N-termini (see figure below). 
 
Figure 1-6 Electron micrograph of rat SP-D showing the dominant structure in cruciform 
assembly (top) and multimers (bottom). Figure adapted from Crouch et al., 1994.  
 
1.2.2 Pathogens recognised by SP-D 
One of the first studies indicating surfactant’s involvement in pulmonary immunity was completed 
by LaForce et al., 1973 and demonstrated enhanced killing, but not the phagocytosis of 
Staphylococcus aureus by alveolar macrophages. Although found elsewhere in the body, SP-D’s 
primary location is in bronchoalveolar lavage fluid of the lung where it acts as a first line of 
defence against inhaled pathogens; the enormous surface area of the lung epithelium is 
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constantly exposed to particles as large as 5μm in diameter that are deposited in the terminal 
airways of alveoli (Holgate, 1999). The physiological response to pathogen binding by SP-D has 
been observed for a wide range of microorganisms and allergens, and is summarised in the table 
below. In addition to its antimicrobial properties SP-D plays a vital role in the control of 
inflammatory responses triggered by allergens and clearance of diseases cells. The response to 
binding of a pathogen includes various innate immune mechanisms, such as agglutination or 
aggregation to create a clumped mass and inhibit colonisation, enhanced phagocytosis and 
clearance of the pathogen by opsonisation, increased production of reactive oxygen species by 
neutrophils and monocytes, recruitment of chemokines and cytokines, and modulation of the 
immune system (Kishore et al., 2006). 
Table 1-5 Interactions of SP-D with pathogens, showing the target of binding and subsequent 
immune response. Cells labelled ‘tbd’ are to be determined. 
Microbe Target ligand 
Consequence of 
binding 
Reference 
Gram-negative bacteria 
Escherichia coli Lipopolysaccharide 
Agglutination, ↑ 
phagocytosis, growth 
inhibition 
Kuan et al., 1992; Wu 
et al., 2003 
Salmonella minnesota Lipopolysaccharide 
Agglutination, ↑ 
phagocytosis 
Kuan et al., 1992; 
Bufler et al., 2003 
Haemophilus 
influenzae 
Lipopolysaccharide ↑ phagocytosis (moderate) Restrepo at al., 1999 
Klebsiella pneumonia 
(unencapsulated) 
Lipopolysaccharide Inhibits growth Restrepo et al., 1999 
Legionella pneumophila Lipopolysaccharide Inhibits growth Sawada et al., 2010 
Pseudomonas 
aeruginosa 
Lipopolysaccharide ↑ phagocytosis Lim et al., 1994 
Helicobacter pylori 
Lipopolysaccharide O-
antigen 
Agglutination Khamri et al., 2005 
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Table 1-6 Interactions of SP-D with pathogens, showing the target of binding and subsequent 
immune response. Cells labelled ‘tbd’ are to be determined. 
Microbe Target ligand 
Consequence of 
binding 
Reference 
Gram-positive bacteria 
Bacillus subtilis Bacillus subtilis Bacillus subtilis Bacillus subtilis 
Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus 
Streptococcus 
pneumoniae 
Carbohydrate moieties 
(tbd) 
Agglutination, ↑ 
phagocytosis (failure to 
enhance killing by 
neutrophils) 
Jounblat et al., 2004 
Mycobacteria    
Mycobacterium avium Lipoarabinomannan ↑ phagocytosis Kudo et al., 2004 
Mycobacterium 
tuberculosis 
Lipoarabinomannan 
Agglutination, 
↓ phagocytosis 
Ferguson et al., 1999 
Mycoplasma 
pneumoniae 
Glycolipids (Ca2+ 
independent) 
Neutralisation, ↑ 
phagocytosis, ↑ TNFα 
production 
Chiba et al., 2002, 
Chiba, 2003 
Viruses 
Influenza A 
High-mannose 
glycoproteins 
haemagglutinin, 
neuraminidase 
Neutralisation, ↑ 
phagocytosis 
Hartshorn et al., 2000 
Human 
immunodeficiency 
virus 
Glycoprotein-120 Neutralisation Meschi, 2005 
Rotavirus (bovine) VP7 glycoprotein 
Agglutination, 
neutralisation 
Reading et al., 1998 
Respiratory syncytial 
virus 
G protein 
F protein 
Neutralisation Hickling et al., 1999 
SARS coronavirus Spike glycoprotein ↑ phagocytosis 
Leth-Larsen et al., 
2007; Wu et al., 2009 
Fungi 
Aspergillus fumigatus Glycoprotein-45 & -55 
Agglutination, ↑ 
phagocytosis 
Madan et al., 1997; 
Madan et al., 2001 
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Table 1-7 Interactions of SP-D with pathogens, showing the target of binding and subsequent 
immune response. Cells labelled ‘tbd’ are to be determined. 
Microbe Target ligand 
Consequence of 
binding 
Reference 
Blastomyces 
dermatitidis 
β-glucan 
↑ phagocytosis, 
↓TNFα production 
Lekkala et al., 2006 
Candida albicans 
Mannan 
polysaccharides 
Agglutination, growth 
inhibition, ↑ 
phagocytosis 
Awasthi et al., 2004; 
Van Rozendaal et al., 
2000 
Coccidioides posadasii 
Mannose-containing 
Coccidiodal antigens 
(tbd) 
Surfactant 
modification, ↑ 
phagocytosis 
Ampel et al., 2005; 
Awasthi et al., 2004; 
Cryptococcus 
neoformans 
Glucuronoxylomannan, 
mannoprotein-1 
Agglutination, ↑ 
phagocytosis 
Awasthi et al., 2004; de 
Wetering et al., 2004b 
Histoplasma 
capsulatum 
Glucuronoxylomannan, 
mannoprotein-1 
Agglutination Schelenz et al., 1995 
Pneumocystis jiroveci 
Surface glycoprotein-A, 
β-glucan, glycoprotein-
120 
Agglutination, 
attachment to 
macrophages 
Yong et al., 2003 
Saccharomyces 
cerevisiae 
β-glucan Agglutination Allen et al., 2001 
Protozoa 
Schistosoma mansoni 
Fucosylated 
glycoconjugates 
↑ phagocytosis 
 
de Wetering et al., 
2004b 
Pollen 
Carbohydrate 
structures on pollen 
starch granules 
(tbd) 
↑ phagocytosis, ↓ 
allergic hypersensitivity 
Currie et al., 2000 
Dust mites Glycoprotein (tbd) 
↑ phagocytosis, ↓ 
allergic hypersensitivity 
Erpenbeck, 2005; 
Strong et al., 2003 
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1.2.2.1 Gram-negative bacteria 
Gram-negative bacteria are a class of prokaryotic microorganisms that do not retain crystal violet 
when Gram-stained, due to a thin peptidoglycan layer in the cell wall. They can cause infections 
including pneumonia, bloodstream infections, wound or surgical site infections and meningitis, 
and are becoming increasingly resistant to antibiotics (cdc.gov). Numerous in vitro studies have 
shown that SP-D increases receptor-mediated uptake of a variety of bacteria by enhancing 
phagocytosis via opsonisation, but also directly by upregulating cell-surface receptors on 
macrophages independent of microbial binding.  
The outer membrane of Gram-negative bacteria consists predominately of lipids which 
make up ~75% of the total membrane surface, attached to which are long chain polysaccharides.  
 
 
Figure 1-7 The cell wall of Gram-negative bacteria, showing the cytoplasmic membrane 
(bottom, internal to the bacterium), the periplasm consisting of a thin peptidoglycan layer, and 
an outer membrane to which lipopolysaccharides are anchored - a single LPS molecule is shown 
in the hashed box. Alexander & Rietschel, 2001. 
 
 
 
Polysaccharide 
surface layer 
Cytoplasmic 
membrane  
Periplasm   
Outer  
membrane  
Lipoglycans 
Phospholipids  
Peptidoglycan layer 
Proteins  
Transmembrane 
proteins  
LPS 
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1.2.2.1.1 Lipopolysaccharide inner core 
Lipopolysaccharide (LPS), also known as endotoxin, is an established SP-D ligand and constitutes a 
major component of the cell wall of Gram-negative bacteria. In 1884 Richard Pfeiffer and Robert 
Koch discovered that lysates of cholera-inducing bacteria caused toxic shock in guinea pigs, and 
postulated that these heat-stable toxins were located inside the bacterial cell, hence the 
pseudonym endotoxin (Brade, 1999). It exists on the outer layer of the membrane and is, in 
noncapsulated strains which contain no polysaccharide cell-envelope, exposed on the cell surface 
- among them several human pathogenic species such as Escherichia coli, Salmonella enterica, 
Neisseria meningitidis, Haemophilus influenzae, Bordetella pertussis, Pseudomonas aeruginosa, 
Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila and Chlamydia trachomatis 
(Alexander & Rietschel, 2001).  
 Much of the understanding of LPS biosynthesis and structure is founded on 
characterisation of E. coli and Salmonella, which demonstrated that LPS is composed of a 
hydrophobic region (lipid A) covalently linked to polysaccharide. The latter can be divide into two 
groups: an inner core region proximal to the lipid A; and an outer core that provides a site of 
attachment for longer O-polysaccharides. 
 
Figure 1-8 The general structure of LPS showing hydrophobic region (lipid A), core region made 
up of an inner and outer portion, and the O-antigen. The terminal structure (hashed box) is the 
repeating unit of the O-antigen. GlcN - glucosamine; Kdo - 3-deoxy-D-manno-octulosonic acid; 
Hep - D-glycero-D-manno-heptose. Image adapted from Alexander & Rietschel, 2001.  
O-antigen            Core region      Lipid A 
Outer core        Inner core 
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The toxicity of LPS is associated with the lipid component, lipid A, which is understood to be a 
potent activator of innate immunity (Raetz & Whitfield, 2002). It exists as a glucosamine-based 
phospholipid situated in the outer membrane of the bacterial cell surface of most Gram-negative 
bacteria. A single E. coli bacterium contains roughly 106 lipid A residues, and a minimal number 
are required for growth. Given their conserved architecture, most lipid A molecules are detected 
at picomolar levels by the innate immune system by receptors such as TLR-4 present on 
macrophages. Activation triggers biosynthesis of a range of inflammatory mediators, such as 
upregulation of TNFα and interleukin-1 or stimulation of the adaptive immune response (Dinarillo, 
1991; Werling & Jungi, 2003). When overproduced, lipid A can cause severe sepsis - Gram-
negative septic shock can be accompanied by disseminated intravascular coagulation and multiple 
organ failure (Engelmann & Massberg, 2014). In a case that gained public interest in 2011, an E. 
coli outbreak in Germany caused haemolytic uraemic syndrome and the death of 31 people. The 
first and largest bioterrorism attack in United States history involved infection of salad bars with 
Salmonella typhimurium in which 751 people contacted salmonellosis as a result (Tucker, 1999). 
The structure of the inner core is well conserved within a bacterial genus, and as distantly 
related bacteria share structural features, this reflects its importance in membrane integrity. The 
inner core typically consists of Kdo and heptose residues and is often decorated with additions of 
other monosaccharides or phosphate-containing residues such as phosphoethanolamine and 
phosphorylcholine.  
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Figure 1-9 The structure of lipopolysaccharide inner core region from E. coli and Salmonella. 
Residues and bonds in red are conserved, while type-specific additions are shown by hashed 
lines. Hep - L-glycero-D-manno-heptose, Kdo - 3-deoxy-D-manno-octulosonic, GlcN - 
glucosamine, GlcNAc - N-acetylglucosamine, PEtN - phosphoethanolamine, Gal - galactose and 
Rha - rhamnose. All bonds in α-conformation. Adapted from Heinrichs et al., 1998. 
 
The inner core structure described in Figure 1-8 is conserved across a wide range of bacterial 
genera including Bordetella, Burkholderia, E. coli, Klebsiella, Providencia, Salmonella, Serratia, 
Shigella and Yersinia species (Caroff & Karibian, 2000; Ortega et al., 2009; Kondakova et al., 2006; 
Holst, 2011; Helander et al., 1996; Vinogradov et al., 2003; Kondakova et al., 2010; Vinogradov et 
al., 2002). Similarities exist between both Neisseria and Pseudomonas cores which contain only 
the first two, inner heptose residues (Cox et al., 2003; Bystrova et al., 2004) and Haemophilus, 
Helicobacter, Pasteurella and Vibrio species, which differ only in that they contain an α1-2-linked 
outer heptose residue (Orgeig et al., 2010; Holst, 2011). Members of the Chlamydia family contain 
a unique LPS structure, expressing a Kdo triplet only (Erridge et al., 2002). 
Modification of the core with phosphates contributes to membrane integrity and is 
required for transport of LPS and transport to the outer membrane. Expression of a mutant strain 
of Psuedomonas aeruginosa that lacked the enzyme responsible for phosphorylation showed 
halted growth, an accumulation of saccharides inside the cell and disruption of the outer 
membrane permeability barrier (DeLucia et al., 2011).  
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 The understanding of E. coli, Salmonella and Klebsiella biosynthetic genes involved in core 
assembly is aided by the clustering on a single chromosome. This locus, termed waa, encodes all 
the transferases required for inner core assembly and genomes of distantly related bacteria show 
similar clusters of genes. Neisseria and Haemophilus show no significant clustering of waa-type 
genes, which may explain the difference in structure of these two species (see Fig 1-10).  Waa 
enzymes involved in the assembly of the inner core include WaaA, a bifunctional Kdo transferase 
responsible for addition of one or more Kdo residues to the lipid A moiety; WaaC, a 
heptosyltransferase responsible for the addition of the first heptose to Kdo; WaaF that adds the 
second heptose to the first; WaaP, a kinase that phosphorylates the first heptose; WaaQ that 
adds a third heptose to the second; and WaaY that phosphorylates the second heptose.  
 
Figure 1-10 Structure and biosynthesis of the inner core from E. coli and Salmonella. Waa 
transferases that form the core are shown in red, the dashed lines indicate the position in the 
structure to which specific gene products are added. All bonds in α-conformation. Adapted 
from Heinrichs et al., 1998. 
 
1.2.2.1.2 Lipopolysaccharide Outer core 
The outer core of LPS shows a greater structural diversity than the inner, and reflects the 
increased exposure of this region to the pressures of the immune response. For example, there 
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are five known outer core types in E. coli: R1, R2, R3, R4 and K-12, and each utilises similar Waa 
enzymes depending on the type-specific residues in the structure.  
The additional Waa transferases required for assembly of the outer core vary according to 
bacterial subtype. For instance, E. coli R1 cores employ WaaG which adds a glucose to the 
outermost heptose of the inner core; WaaO, adds a second glucose; WaaV, adds a third glucose; 
WaaT, which adds a galactose residue to the second glucose; WaaW, adds a second galactose to 
the first; and WaaL, which ligates the polysaccharide to an O-antigen (See Fig 1-11).  
 It has been suggested that the outer core of Gram-negative bacterial LPS is required for 
bacterial entry into epithelial cells of the host. It was demonstrated that the outer-most glucose 
residue in the chain was crucial for recognition and internalisation by the polar membrane of 
epithelial cells (Hoare et al., 2006). 
 
Figure 1-11 Structure and biosynthesis of the outer core from E. coli R1. The adjoining 
outermost heptose that links the inner and outer cores is shown in blue. Waa transferases that 
form the core are shown in red, the dashed lines indicate the position in the structure to which 
specific gene products are added. All bonds in α-conformation. Adapted from Heinrichs et al., 
1998. 
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The structure of the Salmonella outer core shows similarities to the E. coli types, and the same 
waa gene types are responsible for its assembly.  
Figure 1-12 Structure and biosynthesis of the outer core from Salmonella. The adjoining 
outermost heptose that links the inner and outer cores is shown in blue. Waa transferases that 
form the core are shown in red, the dashed lines indicate the position in the structure to which 
specific gene products are added. The residue denoted by * can be glucose or N-
acetylglucosamine. All bonds in α-conformation. Adapted from Heinrichs et al., 1998. 
 
Mutant strains deficient in one or more of the aforementioned Waa enzymes are termed rough 
mutants, and show truncated inner and outer cores. 
 
Figure 1-13 The structure of rough mutants in the core region of Salmonella LPS. Truncation 
ranges from the shortest mutant, Re, that contain Kdo residues only, to Ra mutants that contain 
the whole inner and outer core structures. The residue denoted by * can be glucose or N-
acetylglucosamine. Adapted from Mansfield et al., 1996. 
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1.2.2.1.3 Lipopolysaccharide O, K and H-antigens 
Lipopolysaccharide can be described as either rough or smooth depending on the presence or 
absence of an O-antigen. Additional core and O-antigen polysaccharides, although not vital for 
growth, enable bacteria to resist antibiotics and evade the immune system. Evasion of the 
immune system by molecular mimicry has been observed in strains of Helicobacter pylori, 
whereby the O-antigen expresses Lewisx and Lewisy antigens identical to those occurring in the 
human gastric mucosa (Appelmelk et al., 1997).   In the vast majority of LPS structures, the O-
antigen chain is characterised by an extremely high structural variability and is comprised of a 
repeating oligosaccharide unit of two to six saccharides.  The distinctive O-antigen structures are 
used to allocate serogroups to bacteria and over 160 serogroups in E. coli alone have been 
assigned (Stenutz et al., 2006). 
In addition to O-groups, other antigens exist on the pathogen cell surface:  capsular 
polysaccharides of Gram-negative bacteria, also called K-antigens, maintain structural integrity of 
the cell and contribute significantly to virulence. They form a defensive barrier against host 
immunity and grant the ability of bacteria to adhere to epithelial cells as well as other bacteria 
(Aduse-Opoku et al., 2005). Furthermore, flagella of motile Gram-negative bacteria also 
contribute to bacterial virulence, chemotaxis and invasion of host cell. Composed of the protein 
flagellin, they are post-translationally modified through addition of various glycosylation sites. 
Families of Gram-negative bacteria known to contain flagella include E. coli, Helicobacter, 
Pseudomonas, Salmonella and Vibrio, and the antigenic moieties present on flagella are termed H-
antigens (Ni et al., 2008). Both capsular polysaccharide and flagellin have been shown to induce 
upregulation of, and be bound by SP-D. 
1.2.2.2 Gram-positive bacteria 
Gram-positive bacterial infections are a leading cause of pneumonia, a significant source of 
morbidity and mortality throughout the world. Of the pathogens that cause pneumonia, 
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Streptococcus pneumoniae and Staphylococcus aureus are the most common, both of which have 
been shown to be recognised by SP-D (Osiyemi & Dickinson, 2000; de Wetering et al., 2001). 
 Unlike Gram-negative, Gram-positive bacteria retain crystal violet stain due to a thick 
peptidoglycan layer on the cell wall. They lack an outer membrane and as such tend to be more 
receptive to antibiotics, and in addition they express no lipopolysaccharides. Instead, the two 
major cell wall components expressed by Gram-positive bacteria are peptidoglycan (PepG) and 
Lipoteichoic acid (LTA) which can induce inflammation (Percy & Gründling, 2014). SP-D has been 
shown to bind both LTA and PepG components of Gram-positive bacteria (de Wetering et al., 
2001). 
1.2.2.2.1 Peptidoglycan 
Peptidoglycan, PepG, consists of alternating β-linked N-acetylmuramyl and N-
acetylglucosaminoglycan residues, cross-linked by short peptides. Bacteria are encapsulated by 
multiple layers of cross-linked PepG, and it is therefore the most prevalent component of the cell 
wall - accounting for up to 40% of the weight of the bacterial cell (Shockman & Barrett, 1983).   
1.2.2.2.2 Lipoteichoic acid 
Lipoteichoic acid, LTA, is a member of the amphiphile family of glycolipids composed of a 
hydrophobic diacylglycerol membrane anchor and a hydrophilic side chain that varies across 
species. They usually consist of glycerophosphate repeats substituted with D-alanine or glycosyl 
groups.  
1.2.2.3 Mycobacteria 
Mycobacterium tuberculosis is a highly pathogenic bacterial species of the family 
Mycobacteriaceae, and the causative agent of tuberculosis; M. avium is an opportunistic 
bacterium that causes localised and disseminated infection of the lung, bone and intestine, 
common in immunocompromised individuals.   They contain a unique, waxy coating on its cell 
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surface that renders it impervious to Gram staining (Trifiro et al., 1990). This layer is composed of 
peptidoglycan, peripheral lipids and surface glycolipids called lipoarabinomannan – mannosylated 
moieties that act to suppress the immune response (Carlson et al., 2009). 
1.2.2.4 Viruses 
Many viruses have been shown to be recognised and neutralised by SP-D. Influenza 
viruses are RNA viruses of the family Orthomyxoviridae, and are divided in to genera A, B and C. 
Influenza A viruses (IAV) are further classified by the presence of proteins on their cell surfaces: 
Haemagglutinin (HA) and Neuraminidase (NA) and are known to infect humans and other 
mammals, vertebrates and birds. The only subtypes currently circulating in humans (designated 
by their HA and NA proteins) are H1N1, H3N2 and H5N1. 
The HA glycoprotein is expressed on the viral membrane as a single polypeptide that is 
cleaved by host trypsin-like proteases to produce two peptides HA1 and HA2 in order to become 
infectious. Once cleaved, a newly exposed N-terminus of the HA2 peptide is able to fuse the viral 
envelope to cellular membranes of host cells via sialic acid residues. The sialic acid binding site is a 
crucial component of IAV, and strains vary in their affinity - determining the animal species which 
they are able to infect. For instance, avian influenza strains such as H5N1 preferentially bind to 
sialic acids bound to galactose via an α2,3 linkage, a major sialic acid present on epithelial cells of 
avian digestive systems. Human IAVs show preference for α2,6-linked residues, consistent with 
those found on the epithelial surface of the human respiratory tract. Interestingly, cells of the pig 
trachea express both α2,3 and α2,6-linked sialic acids, and as such can be infected with both 
human and avian influenza viruses. They are thus considered the ‘mixing vessel’ for the 
emergence of new viruses (Olufsson et al., 2005). Carbohydrate addition by IAV has both positive 
and detrimental effects on virulence; activation by protease cleavage is required for entry to the 
host cell, but the HA molecule is exposed to the immune system - if carbohydrate moieties on the 
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protein are in close proximity to the sialic acid binding site they may become blocked, rendering 
the virus neutralised (Vigerust et al., 2007). 
Rotaviruses are encapsulated, double-stranded RNA viruses of the family Reoviridae and cause 
acute viral gastroenteritis. They are unusual in that an expressed glycoprotein, VP7, acts as one of 
two capsid proteins; VP7 forms a smooth surface on the virus, whereas the other, VP4, protrudes 
as spikes (Reading et al., 1998). VP4 acts as a host-cell attachment protein and viral 
haemagglutinin (Kalica et al., 1983). The glycans of VP7 are all of the high-mannose type. 
Respiratory Syncytial Virus is a negative-sense, single stranded RNA virus of the family 
Paramyxoviridae that causes respiratory tract infections. They express G proteins which contain 
O- and N-linked oligosaccharide chains, typically high-mannose N-linked polysaccharides (Wertz & 
Lichtenstein, 1988). Protein N-glycosylation was analysed and illustrated that the carbohydrate 
moieties are complex-oligosaccharides (see Fig 1-14), comprised of fucose, glucosamine and 
galactosamine, with a mannose core (Rixon et al, 2002). S proteins are membrane glycoproteins 
that contain a single N-linked glycosylation site that although not fully elucidated, is believed to 
be a high-mannose oligosaccharide (Zhou et al., 2010).  
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Figure 1-14 High-mannose (left), hybrid (centre) and complex oligosaccharides (right). Mannose 
(green), GlcNAc (blue), galactose (yellow) or fucose residues (purple). Adapted from Sigma-
Aldrich, 2015. 
 
1.2.2.5 Fungal pathogens 
Fungi are a large family of eukaryotic organisms that include yeast, moulds and mushrooms, some 
of which are known to be neutralised by SP-D. Opportunistic fungal pathogens represent a 
significant health burden, especially in immunocompromised individuals. Cryptococcus 
neoformans and Histoplasma capsulatum express capsular polysaccharide glucuronoxylomannan 
(consisting of mannose, xylose and glucuronic acid), and mannoprotein-1 - a protein of about 100 
kDa attached to β1-6-glucan through a glycosylphosphatidylinositol anchor, containing five alpha-
linked mannosyl residues (Richardson, 1993; Kollar et al., 1997). Blastomyces dermatitidis and 
Pneumocystis jirovecii specifically express β1-6-glucan. 
1.2.2.6 Schistosomes 
Schistosoma mansoni, known as blood flukes, are parasitic flatworms responsible for 
schistosomiasis infections - considered by the World Health Organisation as the second most 
socioeconomically devastating parasitic disease after malaria (Who.int, 2015). Adult S. mansoni 
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reside in the veins of mammalian hosts, where they produce eggs that penetrate the digestive 
tract. When these eggs are excreted, they develop into miracidia which infect freshwater snails. 
The snail then releases motile cercaria larvae that are able to infect humans by penetration of the 
skin, where they migrate to the heart and lungs (Crabtree & Wilson, 1986).  
 S. mansoni express fucose-containing glycoconjugates on their cell surface, which like 
those of Helicobacter strains of Gram-negative bacteria, contain Lewisx antigens (blood group 
antigens displayed on the terminus of glycolipids present on the cell surface, see Fig 1-15) 
identical to those occurring in the human gastric mucosa (Appelmelk et al., 1997). Details of the 
SP-D binding mechanism are detailed in subchapter 1.4.5. 
 
 
 
 
 
 
 
 
    
Figure 1-15 Schematic representation of the fucose-containing glycoconjugates of Schistosoma 
mansoni tested for SP-D binding. F-Gn - Fuc(α1–3)GlcNAc; LDN - GalNAc(β1–4)GlcNAc; F-LDN - 
Fuc(α1–3)GalNAc(α1–4)GlcNAc; LDN-F - GalNAc(β1–4(Fucα1–3))GlcNAc; LewisX - Gal(β1–
4(Fucα1–3))GlcNAc; FF-Gn - Fuc(α1–2)Fuc(α1–3)GlcNAc. de Wetering et al., 2004b. 
 
1.2.3 Surfactant homeostasis 
Along with preventing pathogen entry into the body, pulmonary surfactant is essential for gas 
exchange in the lung, and deficiencies in both quality and quantity are associated with respiratory 
distress. Levels are regulated during synthesis, secretion, reuptake by epithelial cells and 
degradation by alveolar macrophages to maintain a steady concentration. It has been suggested 
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that the effect of SP-D on uptake of pathogens may influence macrophage function and signalling, 
and the role of SP-D in surfactant homeostasis was identified using SP-D-null (-/-) genetically 
altered mice and by comparing their host defence to mice with the SP-D gene present (±) (Botas 
et al., 1998). 
 The absence of SP-D caused no structural abnormalities in the lung as a whole and no 
alterations to the airway epithelial cells was observed. However, abnormalities were seen in the 
lung tissue itself - enlarged alveoli and increased bronchus-associated lymphocytic tissue 
(lymphoid tissue that is formed upon inflammation and infection (Randall, 2010)) were 
consistently detected. Also present were numbers of large, foamy alveolar cells, which appeared 
to be alveolar macrophages with abundant cytoplasmic vesicles. In tested alveolar lavage fluid, 
macrophage concentration was 4-fold higher and the mean diameter of cells was 18.75μm 
compared to 11.75μm in normal, SP-D± mice. Phospatidylcholine levels were 3-fold higher in -/- 
mice, and large masses of lipids were found to aggregate in the lung. 
 The results suggest a clear role for SP-D in maintaining phospholipid structure and 
preventing accumulation of lipid in the lung. It remains unclear whether changes to macrophage 
numbers and size reflect changes to the surfactant itself - increased accumulation of surfactant 
may cause increased uptake by macrophages - or represent a primary abnormality as a result of 
SP-D absence. Lipid aggregation most likely represents the crucial role of SP-D in lipid regulation, 
but it is unclear how phospholipid homeostasis is modulated, specifically at the level of synthesis 
and/or catabolism by alveolar epithelial cells or by macrophages (Korfhagen et al., 1998).  
1.2.4 Lung hypersensitivity and inflammation 
The role of SP-D in development of allergen-induced airway inflammation involves an immune 
response that reduces inflammation. Levels progressively increase up to 48 hours after allergen 
challenge, reducing progression of eosinophilia and hypersensitivity. SP-D’s interaction with house 
dust mite and pollen starch granules were demonstrated by administering of intranasal SP-D in a 
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murine model of pulmonary hypersensitivity. Binding to carbohydrate moieties and glycoproteins 
of the allergens in a calcium-dependent manner was observed, and resulted in the blocking of IgE-
mediated histamine release by stimulated basophils. Overall levels of IgG and IgE were lowered in 
serum, peripheral and pulmonary eosinophilia was reduced, and allergic Th2 T-helper cells were 
polarised to protective Th1 phenotypes. Th2 cells subsequently lowered levels of proinflammatory 
IL-4 and IL-5, while elevating IFN-γ - which influences macrophage function during infection 
(Madan et al., 2001; Schroder et al., 2003).  
 
1.2.5 Extra-pulmonary presence 
Several studies have provided evidence of SP-D expression in tissues other than the lung. 18 
extra-pulmonary tissues were tested by Madsen et al., 2000 for the presence of SP-D, and 
significant levels were detected in the human trachea, brain, testes, salivary glands, heart, 
prostate, kidneys, small intestine, pancreas and placenta. Weaker expression was seen in the 
uterus, stomach, mammary glands, spleen, adrenal glands and liver. SP-D expression in epithelial 
cells of exocrine glands and loops of Henle, ureter and bladder of the urinary tract suggests a 
major role in the muscosal defence system against invading pathogens. Because SP-D colocalises 
with gp340 (a glycoprotein receptor reported to be responsible for SP-D membrane binding) in 
collecting ducts of the kidney, as well as the lung, salivary glands, pancreas and small intestine - it 
has been suggested that their possible interactions involve processes other than 
immunprotection (Madsen et al., 2000).  
 The presence of SP-D in extra-pulmonary environments, especially in organs and tissues 
most exposed to pathogens, supports its role as an important immune molecule even outside the 
lung. For instance, the presence of SP-D in the stomach is necessary as this organ is potentially in 
direct contact with ingested microorganisms. The hydrophobic gut lining bears a strong 
resemblance to pulmonary surfactant in terms of phosphatidylinositol being the major 
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phospholipid. More recent studies have found SP-D in other tissues susceptible to infection, such 
as the paranasal sinus mucosa and Eustachian tube epithelium (Woodsworth et al., 2006; 
Paananen et al., 2001). The potential role of SP-D in mucosal immunity is yet to be fully 
understood, but its main function is to prevent microbial colonisation and inhibit growth of 
pathogens once attached to the epithelium.  
 It has been proposed that despite its presence elsewhere, the site of primary synthesis of 
SP-D is the lung. Quick upregulation of serum SP-D in response to acute airway inflammation 
supports the notion that SP-D is translocated from the airways into the vascular system, in favour 
of being synthesised systemically (Gaunsbaek et al., 2013). 
1.2.6 SP-D in health and disease 
Finely-tuned activity of SP-D is vital for a first line of defence against invading pathogens in the 
lung and elsewhere, and varying levels of both serum and bronchoalveolar lavage are associated 
with a number of diseases. Physiological levels in the lung undergo changes when challenged by 
external stimuli such as allergens and asthma, but altered expression in extra-pulmonary locations 
are also observed. The following table describes a number of disease states and subsequent SP-D 
levels. 
Table 1-8 Changes in SP-D levels in various lung and extra-pulmonary diseases 
Disease/disorder Comments Reference 
Sarcoidosis 
SP-D levels increase but vary 
according to organ. 
Kucejko et al., 2009; 
Kitaichi et al., 2010 
Idiopathic pulmonary 
fibrosis 
Damaged lung epithelium and 
scar tissue may increase 
alveolar-membrane permeability 
Kuroki et al., 1998; Green 
et al., 2001; Barlo et al., 
2009 
Pulmonary alveolar 
proteinosis 
SP-D accumulates in alveoli and 
airways, high-order oligomers 
common 
Kuroki et al., 1998; Lin et 
al., 2008 
Tuberculosis 
Levels increase but depend on 
severity of infection 
Kondo et al., 1998; Kishore 
et al., 2006 
Acute lung 
injury/respiratory 
distress syndrome 
Levels significantly increase at 
onset but return to normal 
levels 
Greene et al., 1999 
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Table 1-9 Changes in SP-D levels in various lung and extra-pulmonary diseases 
SARS 
Levels increase  but upregulation 
of SP-D is inversely proportional 
to IgG levels 
Q. Ashton Acton, 2012; Wu 
et al., 2009 
Smoking 
Decreased levels cause 
increased risk of progression of 
bronchial dysplasia and lung 
cancer 
Moré et al., 2010; Winkler 
et al., 2011 
COPD 
Levels increase during acute 
attacks 
Winkler et al., 2011 
Asthma/allergen-
induced airway 
inflammation 
Higher levels cause 
downregulation of IgE 
production, and supress 
hypersensitivity 
Koopmans et al., 2004; 
Gemou-Engesaeth et al., 
2014 
Cystic fibrosis High-order oligomers common 
Krane & Griese, 2003; 
Griese et al., 2004 
 
In addition to levels of SP-D, investigations into the role of SP-D in health and disease 
have been conducted through the effects of various polymorphisms in gene knock-out mice. 
Besides reduced pathogen clearance, mice deficient in SP-D show abnormalities in surfactant 
homeostasis and alveolar cell morphology, and exhibit progressive accumulation of lipids and 
apoproteins in the alveolar space, hyperplasia of alveolar type II cells, massive enlargement of 
lamella bodies that store SP-D, and aggregation of foamy alveolar macrophages. These mice 
spontaneously develop emphysema and pulmonary fibrosis, which suggests a continuous 
background function of SP-D in otherwise healthy lungs. Lack of SP-D also results in significant 
lung inflammation when challenged with pathogens compared to wild-type mice, demonstrating 
SP-D’s anti-inflammatory role. Mice also showed substantial increase in broncho-alveolar lavage 
(BAL) phospholipid and protein levels, as well as increased macrophage content. 
1.2.6.1 Pulmonary disorders 
Synthesis and secretion of SP-D is increased with injury to the lung. Surfactant 
abnormalities arise and BAL SP-D levels are raised in lung diseases such as asthma, bronchiolitis, 
chronic obstructive pulmonary disorder (COPD), lung transplantation, respiratory distress 
syndrome, pulmonary oedema, sarcoidosis, pulmonary fibrosis, alveolar proteinosis, cystic 
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fibrosis, pneumonia and infections caused by influenza A viruses or Pneumocystis pneumonia 
(Kuroki et al., 1998). Interestingly, cigarette smoking - which is associated with increased risk of 
COPD, pneumonia and other lung infections - appears to reduce SP-D levels in otherwise healthy 
individuals; it is unclear as to whether lowered levels are a cause or consequence of smoking-
related diseases (Honda, 1996).  
 Altered expression of SP-D acts as a useful marker for lung disease, and is considered 
diagnostic for a number of respiratory infections. For instance, SP-D production is used as a 
measure of lung maturity in neonates and infants with respiratory distress syndrome, and levels 
are measured from amniotic fluid and tracheal aspirates respectively (Chida et al., 1997). 
A study investigating the role of genetic variants in lung-associated diseases shows that some 
individuals have increased susceptibility to certain respiratory infections. Genetic polymorphisms 
of the SP-D gene result in genotypes that show higher association with disorders such as COPD in 
Mexican populations, tuberculosis in people of Mexican and Indian origin, and RSV infection in 
people of Finnish descent (Guo et al., 2001; Floros et al., 2000; Lahti et al., 2002).  
1.2.6.2 Extra-pulmonary disease 
SP-D in sites other than the lung also exhibits varying expression patterns in response to disease. 
For example, attacks of chronic rhinosinusitis, which involved inflammation of the nasal cavities 
triggered by infection or allergy, result in upregulation of SP-D (Ooi et al., 2007).  
 Consistent with the surfactant-related function of SP-D, levels have also been detected in 
the synovial fluid of joints in rheumatoid arthritis sufferers. It has been suggested that, as with the 
lung, SP-D may be involved in phospholipid homeostasis within the joint as well as acting as a dual 
pro- and anti-inflammatory mediator (Kankavi, 2006). Reduced levels of SP-D in serum and raised 
levels in synovium may contribute to the persistent low-grade joint inflammation seen in 
rheumatoid arthritis patients (Brown et al., 2006). 
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 SP-D synthesis has been demonstrated in localised vascular endothelial cells in both mice 
and humans. SP-D-null mice fed an atherogenic diet showed significant protection against 
atherosclerotic legions in the aorta, and a small foamy macrophage count compared to control 
mice. Nevertheless, foamy macrophage masses were found in the lung - a typical feature in SP-D 
deficiency. When treated with a recombinant SP-D fragment anti-inflammatory Th1 T-helper cells 
were polarised to allergic Th2 phenotypes, and an upregulation of pro-inflammatory TNFα was 
observed. Also seen was a reduction of plasma lipid concentrations: High-density lipoprotein 
levels were significantly elevated, while low-density cholesterol was decreased. Overall, SP-D is 
viewed as pro-atherogenic in the mouse model used - probably due to disturbances of plasma 
lipid metabolism and alteration of the inflammatory process (Sorensen et al., 2006). 
Skin diseases such as psoriasis and atopic dermatitis have recently been linked to changes 
in SP-D levels in tissues. When immunohistochemically stained, affected skin biopsies showed no 
difference in SP-D reactivity compared to normal skin. However, in the stratum spinosum (the 
middle layer of the epidermis where keritinisation is initialised), SP-D showed higher 
immunostaining intensity. Serum SP-D levels were unchanged, suggesting that - unlike pulmonary 
disorders - there is no spill-over of SP-D from affected lesions. The same study also reported that 
production of SP-D transcripts was not upregulated, and the increase in infiltrating inflammatory 
cells may be the source of the protein in the lesions (Hohwy et al., 2006).  
1.2.7 Pregnancy and development 
Pulmonary surfactant is secreted from the foetal lung into the amniotic fluid where it accumulates 
during the third trimester of pregnancy (Bayer et al., 1973). Respiratory failure is a major cause of 
neonatal death in preterm babies, especially those born before 32 weeks and survival is closely 
associated with development of surfactant. During labour, intrauterine tissue macrophages 
release prosataglandin, along with other macrophage-associated cytokines such as pro-
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inflammatory TNFα. Surfactant provides the amniotic epithelium with a source of constituents 
used for prostaglandin synthesis during labour. 
SP-D can be detected in human amniotic fluid as early as 26 weeks’ gestation, and has 
been found in foetal membranes of the amniotic epithelium and chorionic membrane as well as 
certain layers of the late pregnant uterus (Miyamura et al., 1994). It is likely that the presence of 
SP-D is necessary for clearance of pathogens and activation of macrophages - especially with 
regards to intrauterine infections. SP-D serves as a well-suited, non-specific immune molecule in 
the uterus, as well as maintaining integrity of the foetal membranes (Hills, 1994). 
The biological role of SP-D in pregnancy is not fully understood, but involvement in tissue 
remodelling has been suggested, due to an interaction with decorin - a proteoglycan that binds 
collagen and other extracellular matrix components (Nadesalingam et al., 2003). SP-D and decorin 
interact by either the CRD of SP-D binding to the carbohydrate moieties of decorin, or by decorin 
binding to SP-D’s collagen region. Decorin induces expression of matrix metalloproteases and 
disrupts collagen fibres to facilitate cervical dilation during labour. Co-purification of SP-D with 
decorin in amniotic fluid suggests a possible role in intrauterine tissue remodelling during 
parturition (Kishore et al., 2005).  
Extensive localisation of SP-D in the female reproductive tract suggests a crucial role in 
local host defence against microorganisms, especially during the secretory phase of the menstrual 
cycle when it is necessary to protect the uterus during implantation of the embryo. SP-D has been 
shown to enhance phagocytosis of chlamydial pathogens, and inhibit Chlamydia trachomatis 
infection of cervical epithelial cells (Oberley et al., 2004). 
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1.2.8 Immune-related functions of SP-D 
In addition to phagocytosis, SP-D regulates multiple cellular responses by controlling 
inflammatory function. As mentioned previously, SP-D shows both pro- and anti-inflammatory 
signalling properties and recent focus on the effect of S-nitrosylation of N-terminal cysteines has 
shed light on exactly how SP-D is able to regulate inflammation (see Fig 1-16). 
 Nitric oxide (NO) is required for control of vessel and airway dilation in the lung and is a 
key mediator of acute lung injury, bronchopulmonary dysplasia, respiratory distress syndrome 
and asthma (Ricciardolo et al., 2004). The role of NO in signal transduction pathways has gained 
significant attention in recent years, especially in regards to its capability to induce signalling 
functions via post-translational modification of proteins (Stamlet et al., 2001). S-nitrosylation, the 
covalent modification of thiols by formation of S-nitrosothiol (SNO) groups, has emerged as an 
important regulator of protein function. As mentioned previously, oligomerisation of SP-D is 
dependent on cysteine residues at positions 15 and 20 in the N-terminal region - and mutations of 
these results in SP-D being unable to form quaternary structures larger than single trimers 
(Brown-Augsburger et al., 1996). It was proposed that these residues were likely targets for NO 
activity, and as such may alter the oligomer structure and regulate inflammation. Subsequent 
studies by Guo et al., 2008 demonstrated that nitrosylation results in a functional ‘switch’ that 
activates the pro-inflammatory ability of SP-D.  
 Their results demonstrated that SP-D can be nitrosylated both in vivo and in vitro and that 
this is associated with disruption of the multimeric structure. Multimers in the lung are able to 
interact with invading pathogens and with cell surface receptor signal-inhibitory regulatory 
protein (SIRP) α. Binding to the latter causes a suppression of p38 phosphorylation by SHP-1, 
which in turn reduces activation of NF-κβ. Conversely, it is presumed that interactions of the CRD 
with pathogenic molecules results in more trimers of SP-D being ‘pulled’ from the multimer, 
exposing their tail domains - which are then able to interact with calreticulin/CD91. Binding of this 
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complex rather than SIRPα causes the opposite effect on p38, which is phosphorylated to activate 
NF-κβ and its downstream inflammatory responses.  
 
Figure 1-16 The pro- and anti-inflammatory functions of SP-D. Under non-inflammatory 
conditions SP-D remains in a dodecameric forms with the tail domains buried, CRDs bind to 
SIRPα and activates SHP-1 which in turn inhibits p38 and NF-κβ activation. Under inflammatory 
condition SP-D multimeric structure is disrupted and binds to calreticulin, p38 is phosphorylated 
via CD91 and NF-κβ is stimulated to induce a response. Image edited from Guo et al., 2008. 
 
 
1.3 Characterisation of SP-D 
Meticulous characterisation of a recombinant head and neck fragment by Shrive et al., 2003, 
detailed the high-resolution structures of both native and ligand-bound human SP-D. Both the 
native and maltose-bound structures contain residues 205-355 in chains A and B, and 206-355 in 
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chain C. The overall structures reveal a trimeric assembly of an extended α-helical coiled-coil neck 
(residues 203-235) which transitions at a cis-proline at position 235 into three globular CRD 
domains (residues 236-355). The N-terminal collagen region (the first 24 residues, 179-202) was 
not visible in the electron density maps, along with the first few residues of the neck-region. 
Three calcium ions per CRD are clearly visible in the map, with an additional fourth ion located in 
the central pore formed by the three subunits, at the neck-CRD interface. 
 
Figure 1-17 Crystal structure of the native recombinant head and neck fragment of human SP-D 
showing the general trimeric assembly and three calcium ions per CRD (green spheres), as well 
as the fourth calcium ion in the central pore. The left-hand image shows the structure viewed 
down the molecular 3-fold axis, the right-hand image show the perpendicular view. Images 
generated using JMol, coordinates taken from PDB code 1PW9. 
 
1.3.1 Calcium ions in the CRD 
The distances of coordinating bonds of the ligand-binding calcium ion (here on referred to as Ca1) 
vary across the three chains, and involve the sidechains of Glu321, Asn323, Glu329, Asn341, 
Asp342 and their carbonyl group. Two hydroxyl groups from the incoming carbohydrate ring 
complete coordination; in the absence of bound ligand coordination is completed by two water 
molecules (see Fig 1-18). Native structures see bonding distances between 2.23 and 2.76 Å, and 
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between 2.28 and 2.70 Å for maltose-bound SP-D, with no overall difference visible between 
native and ligand-bound protein structures.  
 
Figure 1-18 Coordination of calcium sites in SP-D. The left-hand image depicts coordination of 
Ca1, as well as interaction of maltose via two vicinal hydroxyl groups on the pyranose, in the 
absence of ligand coordination is completed by two water molecules. The right-hand image 
shows coordination of calcium ions Ca2 and Ca3. Image adapted from Shrive et al., 2003. 
 
In addition to Ca1, the CRDs of both ligand-bound and native structures contain two additional 
ions, Ca2 and Ca3 in each chain. Located on the surface of the CRD, they lie in close proximity to 
Ca1, separated by 3.9-4.0 Å. Ca2 is coordinated by the acidic sidechains of Asp297, Glu301, 
Asp324, Asp330, a water molecule and the main-chain carbonyl group of Glu329 whose sidechain 
also participates in coordination of Ca1; while Ca3 is coordinated by the acidic sidechains of 
Glu301 and Asp330, as well as four water molecules (see Fig 1-18). The fourth calcium, seen in the 
native SP-D structure only, is coordinated by Glu232 of all three chains and three water 
molecules. 
The following table details the interactions of calcium with amino acid sidechains and 
water molecules/maltose hydroxyl groups, along with their distances. 
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Table 1-10 Coordination of calcium by amino acid sidechains and water molecules in the CRD 
domain. Distances are for native SP-D (with exception of Ca1 coordination by ligand hydroxyl 
groups) and show the range in chains A, B and C. Values taken from Shrive et al., 2003. 
Calcium atom Amino acid sidechain atom Distance in  Å 
Ca1 
Glu321OE1 2.53-2.73 
Asn323OD1 2.37-2.52 
Glu329OE1 2.30-2.41 
Asn321OD1 2.36-2.37 
Asp342OD1 2.23-2.34 
Asp342O 2.68-2.76 
Ligand/water 2.51-2.58 
Ligand/water 2.54-2.68 
Ca2 
Asp297OD1 2.59-276 
Asp297OD2 2.42-2.52 
Glu301OE1 2.57-2.60 
Glu301OE2 2.50-2.68 
Asp324OD1 2.47-2.58 
Glu329O 2.38-2.49 
Asp330OD1 2.49-2.59 
Water 2.23-2.36 
Ca3 
Glu301OE1 2.36-2.57 
Asp330OD1 2.46-2.58 
Asp330OD2 2.50-2.57 
Water 2.16-2.23 
Water 2.30-2.57 
Water 2.25-2.45 
Water 2.25-2.49 
Ca4 
Glu232OE1 2.21-2.38 
Water 2.22-2.45 
 
There is a marked asymmetry in the conformation of tyrosines at position 228 in the neck 
region due to depletion of calcium 4. The sidechain of Tyr228 in the C chain is shifted into the 
centre of the coiled-coil, with the remaining two directed outward. Although the conformation of 
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the tyrosine is fundamentally identical in both native and maltose-bound structures, the 
interactions between it and Glu232 in the neck, and Lys246 in the CRD, are significantly different 
(see Fig 1-19).  
  
Figure 1-19 Crystal structure of maltose-bound SP-D showing three calcium ions per CRD in 
green, and the asymmetric tyrosine positioned into the central pore. Image taken from Shrive 
et al., 2003. 
 
In the absence of Ca4, two of the three glutamate residues at 232 interact with each other as well 
as with Lsy246 in the same chain, while the third (in the B chain) adopts a conformation whereby 
it interacts with the asymmetric tyrosine 228. In the structure without bound ligand (and with 
calcium 4 present) all three glutamate residues assume similar conformations and interact with 
both Lys246 in the same chain, and with each other.  
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The electron density of native SP-D suggests that the asymmetric Tyr228 interacts with 
the main-chain carbonyl of Tyr228 in the B chain through a hydrogen-bond bridge with a water 
molecule. This water molecule may occupy the position otherwise taken by the shifted Glu232; 
however, it is more likely an indication of two conformations of Glu232 (Shrive et al., 2003). The 
resulting asymmetry of Tyr228 and the interactions of Glu232 do not disrupt the geometry of the 
neck-CRD relationship. 
1.3.2 Other crystal structures of ligand-bound SP-D 
Surfactant protein D has been shown to bind a range of monosaccharides via two vicinal hydroxyl 
groups on the pyranose ring or by the glycerol sidechain in heptose. Binding mechanisms can be 
divided into subgroups depending on the vicinal hydroxyl groups that SP-D binds:  
 Mannose-type via O3 and O4 hydroxyl groups on the pyranose ring (including glucose, 
maltose, maltotriose, p-nitrophenyl maltoside, N-acetyl mannosamine, α-methyl 
mannoside, trimannose, α1-2mannobiose and α1-4mannobiose) 
 galactose via O1 and O2 
 myoinositol via O1 and O6 
 fucose via O2 and O3 
 phospholipid type binding/inositol-phosphate via O4 and O5 
 heptose via the glycerol tail groups O6 and O7. 
Despite this, the mechanism of binding is similar with regards to the spatial positioning of the 
interacting hydroxyl groups of the carbohydrate, and involves a conserved group of amino acids. 
An example of hydroxyl-pair positioning is given below to illustrate this similarity.  
 
 
 
Chapter 1  Introduction 
45 
 
 
Figure 1-20 Binding of glucose via vicinal hydroxyl groups O3 and O4 (Glc, blue) and heptose via 
hydroxyl groups of the glycerol side chain O6 and O7 (Hep, red). Bonds shown in alternate 
colours share the same coordinates in binding. OH1 can be the O2 of galactose, O3 of α1-
2mannobiose and α1-4mannobiose (in chain A only), O4 of α1-4mannobiose (in chains B and C), 
O4 of inositol-1-P (in chains B and C) and the O3 of maltose. OH2 can be the O1 of galactose, O4 
of α1-2mannobiose and α1-4mannobiose (in chain A only), O3 of α1-4mannobiose (in chains B 
and C), O5 of inositol-1-P (in chains B and C) and the O4 of maltose. Binding of myoinsoitol 
utilises the O1 and O6 hydroxyl groups which can take positions OH1 and OH2 reversibly. Image 
generated using CCP4MG using PDB accession codes 1PWB and 2RIB. 
 
Numerous ligand-bound SP-D structures have been characterised, comprising mainly of 
monosaccharides but also longer chain ligands such as di- and trisaccharides.  
Table 1-11 Ligand-bound SP-D structures deposited in the Protein Data Bank in chronological 
order, their spacegroup and hydroxyl groups of the terminal saccharide involved in binding. 
Ligand Spacegroup 
Mechanism of SP-D 
binding 
Accession code and 
reference 
Maltose P21 Via O3 and O4 
1PWB, Shrive et al., 
2003 
Maltotriose P21 Via O3 and O4 
2GGU, Crouch et al., 
2006 
 
OH
1
 
Glc O3 
Hep O6 OH
2
 
Glc O4 
Hep O7 
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Table 1-12 Ligand-bound SP-D structures deposited in the Protein Data Bank in chronological 
order, their spacegroup and hydroxyl groups of the terminal saccharide involved in binding. 
p-nitrophenyl maltoside P21 Via O3 and O4 2GGX, Crouch et al., 2006 
N-acetyl mannosamine P21 Via O3 and O4 2ORJ, Crouch et al., 2007 
Inositol-1-phosphate P21 Via O4 and O5 2ORK, Crouch et al., 2007 
Myoinositol P21 
Via O1 and O6 
(reversible) 
2OS9, Crouch et al., 2007 
D-glycero-D-manno-
heptose 
P21 Via O3 and O4 2RIA, Wang et al., 2008 
L-glycero-D-manno-
heptose 
P21 Via O6 and O7 2RIB, Wang et al., 2008 
L-glycero-D-manno-
heptopyranosyl-(1-3)-L-
glycero-D-manno-
heptopyranose 
P21 Via O6 and O7 2RIC, Wang et al., 2008 
Allyl 7-O-carbamoyl-L-
glycero-D-manno-
heptopyranoside 
P21 Via O3 and O4 2RID, Wang et al., 2008 
2-deoxy-L-glycero-D-
manno-heptose 
P21 Via O6 and O7 2RIE, Wang et al., 2008 
α-methyl mannoside P21 Via O3 and O4 3G81, Crouch et al., 2009 
α1-2 mannobiose P21 Via O3 and O4 3G83, Crouch et al., 2009 
α1-4 mannobiose P21 Via O3 and O4 3G84, Crouch et al., 2009 
Galactose P21 Via O1 and O2 3IKN, Shrive et al., 2009 
Inositol-1-phosphate P21 Via O4 and O5 3IKP, Shrive et al., 2009 
α1-2 mannobiose P21 Via O3 and O4 3IKQ, Shrive et al., 2009 
α1-4 mannobiose P21 Via O3 and O4 3IKR, Shrive et al., 2009 
Haemophilus Eagan 4A 
polysaccharide 
P21 
Via O6 and O7 of 
heptose 
4E52, Clark et al., 
unpublished 
 
Four residues that coordinate the calcium Ca1 also interact with the carbohydrate: the OE2 of 
Glu321 and ND2 of Asn323 interact with the OH1 hydroxyl group, and the OE2 of Glu329 and ND2 
atom of Asn341 interact with the OH2 group (see Fig 1-18 and 1-20). 
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Figure 1-21 Glucose coordination by the amino acid sidechains of Glu321, Asn323, Glu329 and 
Asn341 in the C chain. Protein shown in light-blue, glucose in dark blue and calcium ion Ca1 
shown as the green sphere. Image generated using CCP4MG, from coordinate file 1PWB. 
 
As mentioned previously, in a protein crystal contacts occur between atoms of macromolecules. 
They are as such, an artefact of crystallisation, but may influence the binding of ligands if in close 
proximity to the CRD. The amino acid Asp325 which flanks the binding site, has been directly 
implicated in influencing crystal contacts by Shrive et al., 2009; in all three chains it forms bonds 
with neighbouring trimers via a contact region spanning residues 322-326. Chains B and C form 
similar, but non-identical contacts: both chains include charge-charge interactions between 
Asp325 and Lys230 of the neighbour, hydrogen bonds between the carbonyl group of Pro322 and 
Gln222, and between Asn323 and Ser226. The latter contact formed by Asn323, which 
coordinates bound ligand, causes a rotation of this sidechain, moving the ND2 atom towards 
serine and away from the ligand-binding pocket compared to chain A. The result is a small but 
significant shift in ligand orientation (see Fig 1-22). 
 
 
Glu329OE2 
Asn341ND2 
Glu321OE2 
Asn323ND2 
OH
2
 
OH
1
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Figure 1-22 Influence of crystal contacts on bound α1-2mannobiose in chain A (left), B (centre) 
and C (right). The primary protein main-chain is shown in yellow, coordinating residues involved 
in ligand-binding are shown in white and the neighbouring crystal contact protein in grey. 
Figure taken from Shrive et al., 2009. 
 
The crystal contact between the A chain and neighbouring protein is considerably different to that 
seen in the B and C chains as the neighbouring molecule sits in closer proximity to the CRD, 
resulting in a more restricted ligand binding site. Contacts include bonds between the main chain 
carbonyl of Asp324 (whose sidechain coordinates Ca2) and the sidechain of ligand-binding Asn323 
with Lys339 of the neighbouring molecule, and the main chain N of Gly326 with Asn316. In 
addition, Asp325 forms a hydrogen bond with Tyr314 of chain B of the neighbour and the 
sidechain adopts a different conformation to that seen in the B or C chain.  
 The position of Asp325 affects the position and coordination of bound ligand, which in 
turn influences the sidechain conformation of Arg343 on the opposite side of the binding pocket. 
As such, the orientation of Arg343 varies between native and maltose-bound structures. The 
‘penultimate’ glucose saccharide that does not interact with Ca1 is only visible in the electron 
density in this chain, as it forms a stabilising hydrogen-bond bridge with the main chain carbonyl 
group of Ala275 of chain B of the symmetry-related trimer. This contact results in an approximate 
10° tilting of the bound, terminal glucose toward Arg343 rather than Asp325. The altered 
configuration of both glucoses is such that they interact through a 2.7 Å hydrogen-bond (Shrive et 
al., 2003). This mechanism is not seen in either mannobiose structures, but orientation of Arg343 
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differs between various ligand-bound structures (Shrive et al., 2009). It has been suggested that 
Arg343 plays a role in discrimination between ligands by influencing entrance to the binding 
pocket (Allen, 2004), but in some cases multiple ligand orientations are observed. It is more likely 
that the crystal environment itself is responsible; variations in side-chain and/or ligand orientation 
illustrate flexibility of the protein, and how SP-D is able to make minor adjustments to bind 
different patterns of surface carbohydrates on pathogen surfaces.  
 SP-D has also been shown to bind longer ligands such as maltotriose and p-nitrophenyl 
maltoside whereby in addition to the terminal carbohydrate binding, phenylalanine 335 outside 
the binding site interacts with the third glucose saccharide. Site-directed mutagenesis 
demonstrated that this residue (or equivalent aromatic amino acid at this position) is necessary 
for ‘stacking’ of the ligand over it (Crouch et al., 2006). 
 
Figure 1-23 Crystal structure of p-nitrophenyl maltoside (green) binding by SP-D; showing the 
ligand coordination by Val343, Phe335 and Thr336.  Coordinating SP-D residues are shown in 
blue, with calcium as the grey sphere. Image generated using CCP4MG using PDB accession 
code 2GGX 
Modelling studies have demonstrated that binding via the principal CRD calcium ion can 
also occur through non-terminal saccharides. Unlike other structures, trimannose (Man-α1,2-
Man-α1,2-Man) was crystallised in the P212121 spacegroup due to site-directed mutagenesis of Ala 
Val343 Phe33
5 
Thr336 
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to Asp at position 325, and Val to Arg at 343. As Asp325 and Arg343 are directly implicated in 
forming crystal contacts, the spatial arrangement of symmetry-related protein molecules results 
in a more spacious binding pocket - and an elongation of the long loop in the CRD that increases 
flexibility.  Binding was essentially similar to that seen of maltose, and coordination occurred via 
the O3 and O4 hydroxyl groups. However binding was observed for the non-reducing saccharide 
in the chain, rather than through either terminal mannose (Goh et al., 2013). 
In addition, a recently elucidated structure of bound polysaccharide illustrates SP-D’s 
ability to bind non-terminal monosaccharides in longer chain trisaccharide ligands. The 
polysaccharide, consisting of glucose, L-glycero-D-manno-heptose and 3-Deoxy-D-manno-oct-2-
ulosonic acid (Kdo) is bound via the O6 and O7 groups of the non-reducing heptose (Clark et al., 
unpublished). 
1.4 Pathogen binding by SP-D 
The following subchapter details the structural evidence for the binding mechanism of SP-D to 
pathogens known to be neutralised by SP-D. 
1.4.1 Bacterial recognition 
Surfactant protein D has been shown to bind predominantly to heptose residues in the 
inner core of bacterial lipopolysaccharides. Studies by Wang et al., 2008 demonstrated that 
binding to heptose occurs via the O6 and O7 hydroxyl groups, and presented models of both 
monosaccharide and disaccharide heptose binding (see Fig 1-24). Interactions with the glycerol 
sidechain provide a potential mechanism of bacterial recognition that does not involve hydroxyl 
groups on the pyranose ring - and because the core structure of LPS is highly conserved, this 
suggests a common binding mode of SP-D to a range of Gram-negative bacteria.  
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Figure 1-24 Crystallographic complex of SP-D with heptose monosaccharide (left, orange) and 
diheptose (right, cyan). The diheptose is linked via an α1-3 bond, corresponding to the first two 
heptose residues in LPS. Ligand-coordinating CRD residues are green and red, with calcium ions 
shown as green spheres and electron density in blue. Image generated using CCP4MG using PDB 
accession codes 2RIB and 2RIC. 
 
In addition to recognition of the inner core structure of LPS, SP-D has been shown to bind some 
bacterial species via the O-antigen. Helicobacter pylori and nonencapsulated Klebsiella strains 
(with O-antigen repeating units that contain fucose and mannose residues with accessible 
hydroxyl pairs, respectively) are bound and agglutinated by SP-D and initiate the same innate 
immune response as strains that bind by the inner core (Khamri et al., 2005; Sahly et al., 2002). 
No evidence has yet demonstrated SP-D’s ability to directly bind H-antigens, however recent 
studies have shown that SP-D binds to toll-like receptors that do (Wright, 2005). 
Strains of Klebsiella pneumoniae that express mannose-rich capsular polysaccharides have 
been shown to be recognised by certain C-type lectins, which results in phagocytosis of the cell 
(Kostina et al., 2005), but studies with SP-D have yet to be undertaken. Furthermore, studies 
reveal that SP-D is able to bind PepG of S. aureus in a calcium-dependant manner, strongly 
Glu321 
Asp342 
Glu329 
Asp325 
Glu321 
Asp342 
Glu329 
Asp325 
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suggesting that the binding occurs via the CRD (de Wetering et al., 2001). Binding of Gram-
negative bacteria by SP-D results in agglutination, upregulated phagocytosis by macrophages and 
inhibited growth (Kuan et al., 1992; Wu et al., 2003). 
SP-D is able to bind lipoteichoic acid moieties of Gram-positive bacterium B. subtilis in a 
calcium-dependant manner, strongly suggesting that binding occurs via the CRD (de Wetering et 
al., 2001). When binding profiles of LTA and PepG were compared it was observed that higher 
concentrations of the latter were required to block binding to LTA, suggesting that SP-D has a 
higher affinity for LTA than to PepG. This may reflect the greater importance of lipoteichoic acid in 
lung infection as it is shed during growth and plays a role in attachment of the bacteria to host 
epithelial cells (Sutcliffe & Shaw, 1991). Although aggregation occurred, no enhanced killing of 
Gram-positive Streptococcus pneumoniae was seen (Jounblat et al., 2004).  
1.4.2 Mycobacterial recognition 
SP-D binds lipoarabinomannan (LAM) present on both M. tuberculosis and M. avium and 
reduces uptake of the former - reducing adherence of bacteria to macrophages while inducing 
agglutination, but enhances phagocytosis of the latter. It has been suggested that these opposing 
effects are due to slight structural differences between LAM molecules on bacterial cells. The 
arabino terminus of LAM derived from M. avium is capped with a single mannose residue, rather 
than the more common dimannose (Ferguson et al., 1999; Kudo et al., 2004). The enhanced 
phagocytosis of M. avium is believed to be as a result of upregulation of cell surface receptors on 
macrophages, achieved without the need for direct binding (Beharka et al., 2002).  
1.4.3 Viral recognition 
SP-D is known to bind a number of viruses resulting in their neutralisation and upregulated 
phagocytosis. SP-D has been found to bind mannosylated, N-linked carbohydrates on the 
Influenza A virus haemagglutinin and neuraminidase domains via the CRD (Hartshorn et al., 2000). 
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Sensitivity of IAV recognition by SP-D is dependent on glycosylation at specific sites, which must 
be in close proximity (<20 Å) to the sialic binding site (Hartshorn et al., 2008).  
Studies by Meschi and coworkers in 2005 demonstrated that SP-D also binds the envelope 
protein gp120 of human immunodeficiency virus (HIV), containing a highly conserved 
mannosylated oligosaccharide (see Fig 1-14).  Glycoprotein gp120 contributes to the antibody 
resistance of HIV and evades binding of cell surfaces of macrophages and dendritic cells, but SP-D 
was shown to bind gp120 and inhibit HIV infectivity. Binding is mediated by calcium-dependant 
carbohydrate binding, and like that of IAV is governed by the glycosylation extent of the viral 
protein.  
SP-D has also been shown to bind bovine strains of non-enveloped rotavirus via VP7 glycoproteins 
on the viral surface, resulting in a range of antiviral activities including agglutination, 
enhancement of interactions with neutrophils and neutralisation of infectivity. Glycans of VP7 are 
all of the high-mannose type (Reading et al., 1998). 
SP-D binds to RSV via viral envelope glycoproteins G and F in vitro and in vivo in a calcium 
dependent-manner, inhibiting viral growth and reducing levels of the virus in the lung by 80% 
(Hickling et al., 1999). G proteins contain O- and N-linked oligosaccharide chains, typically high-
mannose N-linked polysaccharides (Wertz & Lichtenstein, 1988). F-protein N-glycosylation was 
analysed and illustrated that the carbohydrate moieties are complex-oligosacchrides, comprised 
of fucose, glucosamine and galactosamine, with a mannose core (Rixon et al, 2002). The exact 
mechanism of SP-D recognition has yet to be elucidated. 
SP-D serum levels have been shown to rise during infection with the SARS (severe acute 
respiratory syndrome) coronavirus. Viral particles contain nucleocaspid proteins that interrupt 
normal host cell cycles to reduce interferon production. SP-D has been shown to strongly inhibit 
coronaviral activity by binding directly to ‘spike’ (S) glycoproteins and induce agglutination (Wu et 
al., 2009). S proteins contains a single N-linked glycosylation site that facilitates this inhibition, 
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and although not fully elucidated, it is believed to be a high-mannose oligosaccharide (Zhou et al., 
2010).  
The recognition of high-mannose oligosaccharides by SP-D is yet to be fully understood, 
but in 2011 Goh and coworkers modelled a possible binding mechanism through a large-scale 
molecular dynamics simulation. They hypothesised that the Man-α1,2-Man-α 1,2Man 
trisaccharides were the likely target of binding, and using the known conformation of the two 
terminal residues by Shrive et al., 2003, superimposed the remaining saccharides (see Fig 1-25). 
They concluded that despite the flexibility of glycosidic linkages, high mannose glycans such as 
those found on viral surfaces have a limited number of possible conformations. Sensitivity of IAV 
recognition by SP-D is dependent on glycosylation at specific sites, which must be in close 
proximity (<20 Å) to the sialic binding site (Hartshorn et al., 2008).  
 
Figure 1-25 Simulated structure of a high mannose oligosaccharide (orange) in proximity to the 
sialic acid binding site of haemagglutinin (pink). The remainder of the HA molecule shown in 
cyan and SP-D is shown in green. The orange spheres represent calcium ions of the CRD. Taken 
from Goh et al., 2011. 
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1.4.4 Fungal recognition  
Phagocytosis and killing of Aspergillus fumigatus and Cryptococcus neoformans by 
alveolar macrophages and neutrophils has been observed as a result of SP-D binding. A. fumigatus 
is bound by SP-D calcium-dependently, through N-linked oligosaccharides on glycoproteins 45 and 
55 (Madan et al., 1997). C. neoformans and Histoplasma capsulatum are bound by capsular 
polysaccharide glucuronoxylomannan (consisting of mannose, xylose and glucuronic acid), and 
mannoprotein-1 - a protein of about 100 kDa attached to β1-6-glucan through a 
glycosylphosphatidylinositol anchor, containing five alpha-linked mannosyl residues (Richardson, 
1993; Kollar et al., 1997).  
Blastomyces dermatitidis and Pneumocystis jirovecii are bound specifically by β1-6-glucan, 
resulting in aggregation and increased attachment to macrophages. Glucans containing β1-3 links 
are not bound by SP-D, as the otherwise occupied O3 hydroxyl group is required for calcium-
dependent recognition (Allen et al., 2001b). 
SP-D has been shown to bind to Candida albicans and directly inhibit growth by 
aggregation of the organism without involvement of macrophage dependent phagocytosis. 
Binding occurs through mannan polysaccharides present on surface proteins of the cell wall 
(Gauglitz et al., 2012). 
Reduced levels of pulmonary SP-D are observed during infection with Coccidioides 
posadasii in mice suggest that pulmonary SP-D may be involved in uptake and phagocytosis by 
antigen presenting cells and downstream immune regulation (Awasthi et al., 2004). Coccidial 
antigens have been suggested to be the target of SP-D binding, but the exact mechanism has yet 
to be elucidated (Nayak et al., 2012). 
Saccharomyces cerevisiae aggregation was seen in the presence of SP-D. S. cerevisiae, like 
C. neoformans and Histoplasma capsulatum contains mannoproteins, but removal of these did 
not reduce binding. The presence of chitin and β-glucans present on the cell wall were assessed; 
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chitin and β1-3-glucan had no agglutinating effect, suggesting that β1-6-glucan is the primary site 
of SP-D binding (Allen et al., 2001b). 
 
1.4.5 Schistosome recognition 
de Wetering and coworkers identified the fucose-containing ligands present on the 
surface of S. mansoni which are known to be bound by SP-D, and determined that the terminal 
residue is required to be in a specific conformation to be recognised.  
It has been shown that SP-D binds in a calcium-dependent manner to F-LDN and F-Gn with 
relatively high affinity; no binding was seen with LDN, LDN-F and FF-Gn; and only weak binding 
was seen with LewisX antigens (see Fig 1-15). The fact that the terminal fucose of FF-Gn was not 
bound by SP-D suggests that binding must occur via interactions with the equatorial hydroxyl pair 
O2 and O3 of the carbohydrate ring. Binding of Lewisx antigens, even as low affinity ligands, was 
suggested as a possible mechanism by which SP-D binds neutrophils and monocytes, and it is 
conceivable that fucose-containing glycoconjugates serve as endogenous ligands on leukocytes. 
Once bound to schistosomes SP-D causes agglutination by cross-linking or by attachment to cells 
in the alveoli, preventing further migration (de Wetering et al., 2004b).  
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1.5 Aims and objectives 
 
The atomic structure of a physiologically relevant bacterial cell surface carbohydrate bound to SP-
D is yet to be solved, and the aim of this thesis is to successfully characterise SP-D binding to 
lipopolysaccharide of Gram-negative bacteria - and provide structural insights into longer 
oligosaccharide binding. This will be achieved via crystallisation of a biologically active 
recombinant head and neck fragment of human SP-D. Following the growth of reproducible, 
diffraction quality crystals, the goal is to soak an inner core region of an appropriate LPS into the 
crystal during the cryoprotection phase. Following data collection and structure solution, the 
result will be an SP-D electron density map which defines the binding determinants of the 
introduced ligand. The potential of recombinant SP-D therapy to reduce inflammation in neonatal 
lung disease, cystic fibrosis and emphysema has long been suggested. Insights into the exact 
mechanism of ligand binding may lead to enhanced understanding of the physiological 
interactions of SP-D, and thus open novel possibilities for potential therapeutics in a clinical 
setting. 
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Chapter 2: Protein Crystallography 
X-ray crystallography provides highly detailed molecular structures, and as of March 2016, over 
102,000 protein structures deposited in the Protein Data Bank have been elucidated in this 
manner (rcsb.org). Crystallography now provides the foundation of modern structural biology; 
whole viruses, ribosomes and gene-regulating proteins are but three examples of how 
crystallography has vastly improved understanding of the structural basis of biomolecular 
function. The quest for new drug therapies has invited momentous commercial and public 
interest, and crystallography plays a significant role in protein and drug-target discovery.  
 The first x-ray diffraction patterns were obtained in 1912 by Walther Friedrich and Paul 
Knipping from crystals of simple materials such as diamond and rock salt, and confirmed the 
atomic construction of matter and the interactions and bonds of the matter itself. The 
understanding of atoms and quantum mechanics were in their infancy, and these experiments 
provided the much needed evidence and support to develop the atomic theory of matter. 
Interestingly, it was already known that proteins could form crystals, but it would take another 
three decades before the first diffraction pattern of protein crystals would be recorded - and 
another two decades before the first macromolecular structure, myoglobin, would be 
determined.  
 It is often easy to take the tool of modern biomolecular crystallography for granted; how 
it is possible to tackle the task of elucidating structures the size of a single protein. We are spoiled 
by recombinant production techniques, robotic automation and powerful synchrotron radiation 
sources - the first protein crystallographers were pioneers and their efforts to obtain structures 
were no less than gallant. With good reason, the field of crystallography and structural biology is 
highly populated with Nobel Laureates. 
Obtaining a molecular model from a protein crystal is deceptively simple: a single crystal 
is placed into a finely focussed x-ray beam, and diffraction images are recorded. Electron density 
that represents the atomic structure of the protein is reconstructed from the data, and an atomic 
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model is built into it. But both practical and fundamental challenges arise. For instance, well-
diffracting protein crystals need to be produced. Proteins by their nature are large and flexible, 
and seldom readily self-assemble into regular, repeating arrangements typical of crystals. 
Producing pure protein and growing the crystals is often problematic, and biological material itself 
is susceptible to radiation damage during the diffraction experiment. In principle, crystallography 
poses challenges: it is important to recognise that it is not an imaging technique. X-ray diffraction 
patterns do not provide a direct image of the molecular structure and electron density must be 
reconstructed by Fourier Transform techniques, which require both amplitudes and relative phase 
angles of each reflection, the latter not being directly accessible from the data. Refinement of the 
structure is also theoretically demanding, and requires prior stereochemical knowledge to be 
successful.  
One can readily appreciate that the crystallographic determination of protein structures is 
no mean feat. So why do it? Because it provides very detailed molecular information; atoms in a 
protein as well as atomic details of ligands, inhibitors, ions, and other molecules that are 
incorporated into the crystal. 
 
2.1 Crystallisation  
Determining the structure of a protein by x-ray crystallography requires growing high-quality 
crystals of a purified protein sample. Under certain circumstances proteins separate from solution 
and self-assemble into a periodic, repeating crystal lattice. A solution of sufficiently high 
concentration (usually 2-50 mg/mL, Dessau & Modris, 2011) becomes supersaturated with 
addition of precipitants that slowly reduce protein solubility. Once the solubility limit of the 
protein is reached and nucleation sites form (from which phase separation proceeds, either due 
to homogeneous formation at supersaturation or heterogeneous introduction of nuclei through 
seeding or foreign matter) crystals may start to grow. 
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 Conditions that yield well-diffracting crystals are not easily predicted, and trials are often 
necessary - varying the reagent concentration, pH and temperature is required to optimise 
growth. The most popular manual technique for growing crystals is the vapour diffusion method, 
illustrated below via the sitting drop system. Chosen reagents are placed in a well (referred to as 
the reservoir solution), and microliter amounts of protein is added to an equal volume of the 
reagent mixture which is placed in a Micro-Bridge - a small inverted “U” made from clear plastic 
with a concave depression on top. A glass slide seals the well (see Fig 2-1). 
 
 
 
 
 
 
Figure 2-1 Diagram of the sitting drop method of protein crystallisation. The droplet is 
composed of an equal volume and protein sample and reservoir solution that, due to the sealed 
environment, undergoes vapour diffusion with a net movement of water from the drop - until 
the solubility limit of the protein is reached. Once a supersaturated state is achieved crystal 
nucleation may occur. Edited from Dessau & Modris, 2011. 
 
The drop on the bridge contains a lower reagent concentration than the reservoir solution, and 
over time the net result is that water evaporates from the drop in to the reservoir; as partial 
pressure is higher in the droplet, water evaporates until equilibrium exists between the drop and 
the reservoir. As a result, concentrations of both protein and precipitant in the drop increase 
slowly until the protein’s solubility limit is reached, and equilibrium is achieved when the reagent 
concentration of the drop equals that of the reservoir. The drop solution becomes 
supersaturated, nucleation and phase separation occur, and crystals may form. 
Cover slide 
 
 
Protein & reservoir droplet 
 
 
Micro-Bridge 
 
 
Reservoir solution 
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2.1.1 Protein preparation  
The development of techniques for producing and purifying protein has been essential for the 
advances made in structural biology. The ability of molecular biology to provide large quantities of 
proteins that are otherwise difficult to obtain ensures pure samples of target proteins are readily 
available. The objective of recombinant protein expression is typically to produce a sample that 
will illustrate a certain biological function, such as enzyme catalysis or protein-ligand interaction - 
and as such it is often not necessary to express the full-length protein. A bewildering array of 
methods may be employed in producing a protein recombinantly, including various choices of 
expression systems, host system, expression vector and affinity tags that can be used to simplify 
protein purification. The cells must then be harvested and the protein extracted and purified. 
2.2 Crystal nucleation and growth  
A practical way to represent the change of protein solubility with precipitant concentration is with 
a solubility diagram (see Fig 2-2). This visualises the general observation that the higher the 
precipitant concentration of a solution, the lower the maximal protein concentration and vice 
versa. The solubility lines in the diagram separate the regions of individual phases of the protein 
solution, and describe the entropic contributions that drive crystallisation. The energy barrier 
from the undersaturated zone where protein is in solution to supersaturation must be overcome 
in order to achieve nucleation. Once the activation barrier is overcome and nucleation sites are 
created, excess protein comes out of solution, and a protein-rich phase in equilibrium with the 
saturated solution occurs in the form of a crystal.  
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Figure 2-2 Protein crystallisation phase diagram of crystal growth via vapour diffusion, showing 
the solubility of protein in a solution as a function of the concentration of precipitant. The red 
arrow represents phase transition from protein in solution to nucleation, having crossed the 
nucleation energy barrier. The blue arrow represents growth of the crystal nuclei and 
subsequent drop in free protein concentration. Adapted from Asherie, 2004. 
 
2.2.1 Nucleation 
 A protein is stable when net attractive interactions between the solvent and protein 
occur. Since the 19th century, it has been known that crystals form in solution by accretion, that is, 
the gradual accumulation of additional layers of matter - growth units freely moving in a solution 
attach to the crystal surface under appropriate conditions. Energetic forces contribute toward 
formation of stable crystal nuclei: self-assembly of proteins requires a net drop in free entropy to 
occur due to the significant loss in conformational freedom upon formation of crystal contacts, 
ΔSprotein, around -25 to -75 kilocalorie per mole (kcal/mol).  
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 This large loss of entropy results in a positive destabilising contribution to the 
crystallisation energy, ΔGc, and so must be compensated by some other effect to render it 
negative, required for driving equilibrium from protein in solution to a crystalline solid. Enthalpic 
contributions, ΔHc, have been shown to be weakly negative or practically insignificant for crystal 
formation (Derewenda & Vekilov, 2006) and as such the remaining stabilising contribution must 
come from elsewhere.  
 Disorganisation of the well-ordered water molecules that otherwise form clathrate cages 
round hydrophobic residues provides a strong entropic gain of the solvent, ΔSsolvent - the release of 
water molecules across polar and hydrophobic surface residues during the formation of crystals. 
Release of just 5-30 water molecules from the surface of protein during crystal formation is equal 
to the entropic gain in the range of 25-150 kcal/mol, and provides the remaining stabilising 
contribution required to render the total free energy of crystallisation negative. 
 The equation for the free energy of crystallisation is as follows, and describes a loss of 
entropy for the protein, and a gain in entropy for the solvent: 
ΔGc = ΔHc - T(ΔSprotein + ΔSsolvent) 
It emphasises the fine balance between enthalpic gains and entropic changes during 
crystallisation, and how minute changes can upset the delicate equilibrium between a crystal and 
its surrounding solvent. Protein-solvent interactions compete with intramolecular interactions 
holding the protein crystal together, and one aims to shift the equilibrium toward increasing the 
latter gently, without denaturing the protein and driving it out of solution in the form of 
precipitation. 
Reducing protein solubility allows us to move into the metastable region of the phase diagram 
(see Fig 2-2), but the occurrence of phase separation and self-assembly of molecules in to a 
crystal often requires some perturbation or activation event to overcome the kinetic barriers. In 
Chapter 2  Protein Crystallography 
64 
 
the metastable, supersaturated region, nucleation must ensue and phase transition in to a new 
protein-rich phase occurs. Given that molecules in a supersaturated solution are rather 
concentrated, and collide frequently some of these impacts result in the formation of favourable 
contacts, and the consequential binding energy may overcome entropic loss of decreased order. 
This is referred to as homogeneous nucleation, and likelihood of stable nuclei formation in this 
manner increases with supersaturation. Heterogeneous nucleation on the other hand, is the 
artificial induction of nucleation and the basis of ‘seeding’ techniques whereby external 
crystallisation nuclei are introduced to a supersaturated solution to induce nucleation. 
 If supersaturation is too high, rapid growth of nuclei form a shower of tiny crystals to 
appear, and this occurs when the protein solution is maintained in the labile zone for too long. To 
obtain large, useable crystals (usually a few hundred µm down to roughly 10µm), a solution must 
approach the labile nucleation zone slowly. 
2.2.2 Growth 
When the solution is metastable, and nucleation has occurred successfully, it separates in to two 
forms: a protein-rich phase in the form of crystal clusters, and a saturated solution. This causes a 
shift into the growth phase where additional growth units accumulate in to the characteristic 
arrangement of a crystalline lattice. The actual growth of protein crystals can be observed 
through atomic force microscopy, whereby a microscopic needle of silicon nitride scans over a 
forming crystal surface, and deflections are measured by a laser while leaving the growth process 
undisturbed (McPherson et al., 2003).  
 During nucleation, the effect of newly generated surface energy is minimised when new 
growth units attach themselves to ledges or steps in the crystal - which generally cause spiral-like 
growth patterns in crystals, see figure 2-3.  
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Figure 2-3 images of crystal growth using atomic force microscopy. The left panels show step- 
and spiral-growth patterns of crystal growth. The right panels show 2-dimension nuclei 
formation (indicated by arrows) and generation of a new nucleus from which a new growth-
step develops. Images taken from Rupp, 2010. 
 
These images also allow investigation into solution contamination and its effect on crystal growth. 
Because only the macromolecule of choice is stacked in to crystal form, contaminant 
concentration increases, and eventually inhibits further aggregation. New nucleation ‘islands’ may 
form on the crystal surface which may not perfectly align with the original crystal - a new, slightly 
misaligned domain forms (see Fig 2-4). If strongly misaligned nuclei inter-grow as one crystal, 
macroscopic twinning can be observed using a simple microscope. In this case, the crystal clusters 
can often be dissected into individual fragments (as they are single crystals in their own right), 
and can be used for diffraction. Merohedral twinning however, is not visually detectable. Domains 
alternate in orientation and generate diffraction patterns virtually indistinguishable from normal, 
abnormal only in their intensity distribution. A real crystal is rarely a single crystal, but rather a 
mosaic of near perfectly aligned domains. Misalignments of no more than a few tenths of a 
degree are useful for diffraction. 
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Figure 2-4 Schematic drawing of a highly mosaic crystal growing in solution. Protein molecule 
(blue spheres) are interrupted by small impurities (red) and debris (green). New molecules 
preferentially attach to ledges or steps, shown with red arrows. Contamination occurring within 
the growing crystal causes defects and misalignment, in this case of around 6°.  Image taken 
from Rupp, 2010. 
 
2.2.3 Creating a supersaturated state 
A strategy employed to induce crystallisation is to gradually guide the protein toward a state of 
reduced solubility by modifying the properties of the solvent; this can be accomplished by either 
increasing the concentration of precipitating agents or by altering some physical property of the 
protein such as disturbing the protein’s electrostatic requirements or minimising the dielectric 
shielding between potential bonding partners. Common approaches to reducing a protein’s 
solubility include: 
 Dialysis - as a means of changing the properties of the protein-containing solution, 
whereby the protein gradually acquires the desired properties of the exterior fluid: pH, 
ionic strength etc 
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 Vapour diffusion - the most common technique, as previously described, whereby 
evaporation of water from a protein droplet causes increased protein concentration 
 pH adjustment and temperature adjustment - to perturb the protein’s electrostatic 
requirements and alter the surface features or conformation to reach a solubility 
minimum 
 Addition of precipitating agents - to form transient, nonspecific aggregates with the 
protein 
 Addition of a ligand that reduces solubility - which may cause an increased degree of 
conformity amongst protein molecules (Hassell et al., 2006) 
 Addition of a polymer - such as poly(ethylene glycol) to reduce volume in the solution. 
Polymers lack consistent conformation and occupy large amounts of space due to large 
hydrodynamic radii. They compete with other macromolecules for available space 
 Addition of a cross-linking agent - to bridge and stabilise intermolecular contacts between 
protein molecules (Yeh et al., 2005) 
 Removal of a solubilising agent 
 Surface Entropy Reduction – replacement of high-entropy surface residues that may 
hinder formation of intermolecular contacts (Derewenda & Vekilov, 2006). 
Any combination of these may be employed to refine the parameters of the system to ensure the 
slow phase transition from protein in solution to an aggregated cluster of molecules in the form of 
a crystal lattice. If supersaturation has proceeded too extensively or rapidly, the protein forms an 
amorphous precipitate; too slowly, and nucleation doesn’t occur at all. It is almost always 
necessary to screen conditions to optimise crystal growth as each protein is unique, and few 
means are available to predict the conditions that will result in successful crystal growth. 
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2.2.4 Factors affecting crystallisation 
The following table represents some, but probably not all, the physical, chemical and biological 
variables that influence crystallisation of proteins.  
Table 2-1 Physical, chemical and biological variables that influence crystallisation of proteins 
Physical Chemical Biological 
Temperature pH Purity of sample 
Surface Precipitant type Ligands 
Method Precipitant concentration Aggregation state of molecule 
Gravity Ionic strength Posttranslational modification 
Pressure Specific ions Source of protein 
Time Degree of supersaturation Proteolysis/hydrolysis 
Vibration/sound Redox environment Chemical modification 
Electrostatic field Protein concentration Genetic modification 
Dieletric property of medium Metal ions Inherent symmetry of molecule 
Viscosity Cross-linking Stability of molecule 
Rate of equilibrium Detergents or surfactants Isoelectric point 
Nucleation method Impurities Sample history 
 
2.3 Data collection and measurements  
The goal of data collection is to determine the indices and record the intensities of as many 
reflections as possible, as quickly as possible. When collecting data, many factors must be 
considered; sidechain conformation becomes clear at around 3 Å resolution but given the length 
of a carbon-carbon bond, individual atoms are resolved at around 1.5 Å. It is therefore desirable 
to collect data at the highest resolution achievable. According to Bragg’s law, shorter interplanar 
spacings are resolved with higher scattering angles which are also associated with a fall-off of the 
form factor, f. This can be partially compensated for by increasing the intensity of the incident 
radiation. 
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 For a successful diffraction experiment, a reliable source of x-rays is necessary. Three 
general types of x-ray sources are available: laboratory (or in-house) generators, which rely on 
emission of characteristic radiation from materials when electrons from outer shells fall back in to 
core level holes generated from electron bombardment; synchrotron sources, which generate x-
rays by accelerating electrons at high energy; and Compton sources, which utilise high repetition 
lasers to excite oscillation in electron beams to generate x-rays. Unlike in-house generators in 
which anode elements emit radiation at specific wavelengths (chromium at 2.29 Å, copper at 1.54 
Å or molybdenum at 0.71 Å) synchrotron radiation sources are ‘tuneable’ to a required 
wavelength - and they allow collection of data from very small crystals which would otherwise 
show little detectable diffraction. 
 Data for this thesis was collected at Diamond Light Source, the UK’s synchrotron. The 
machine itself is an assembly of components that produce, confine and maintain high-energy 
electron beams in a closed orbit to produce synchrotron light. The Diamond machine is composed 
of the following main features: 
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Figure 2-5 Birdseye view of the Diamond Light Source Synchrotron showing the nine 
components of the machine. In numerical order the components are: the injection system, 
booster synchrotron, storage ring, the beamline, front ends, optics hutch, experimental hutch, 
control cabin and radiofrequency cavity. Image adapted from diamond.ac.uk 
 
1. An injection system. A high voltage cathode is heated under vacuum to give electrons in 
the material sufficient thermal energy to ‘evaporate’ and escape. They are accelerated by 
earthed anodes to produce a stream of electrons with an energy of 90keV. A linear 
accelerator accelerates the electrons to extreme energy of 100MeV using radiofrequency 
(RF) cavities 
2. A booster synchrotron. Electrons follow a circular trajectory, along which dipole bending 
magnets curve the electrons round. RF voltage sources further accelerate the beam. The 
magnetic field produced by the bending magnets increases up to a maximum of 0.8 Tesla. 
The electron energy is raised to a final 3GeV 
3. A storage ring consisting of twenty-four straight sections, angled to form a closed loop, 
produce a closed ring of over 560 metres. The entire ring is maintained under vacuum to 
minimise electron scattering by particles and atoms in air 
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4. Beamlines. The research station, which in itself consists of the four following areas 
(hutches) 
o Front ends. Where synchrotron light is channelled into a beamline. It monitors 
the light, and protects the storage ring in case of leaks, as well as removes heat to 
allow safe access to the optics hutch 
o Optics hutch. The first room that synchrotron light enters, where the beam is 
filtered and focussed 
o Experimental hutch. Where the experimental equipment is housed. The crystal is 
placed in the x-ray beam on a rotating, robotic arm which is surrounded by 
detectors 
o Control cabin. The final hutch of the beamline. Where the experiment is 
monitored - the alignment and position of the crystal can be controlled, as well as 
specifics of data collection 
5. A radiofrequency cavity. As electrons circulate in the storage ring they pass through 
bending magnets and insertion devices which radiate energy in the form of synchrotron 
light. The cavity provides an additional energy boost to compensate for energy losses, and 
maintain a fixed orbit round the storage ring. 
Once x-rays have been diffracted by a crystal, they need to be efficiently detected. 
Crystallography experiments utilise area detectors which cover large solid angles of diffracted 
radiation. Examples include x-ray sensitive film and imaging plates; multiwire array detectors in 
which x-ray photons are absorbed by a beryllium cathode and ionise a gas which generate an 
electronic pulse that can be recorded; charged-coupled devices (CCDs)  whereby a semiconductor 
array transforms radiation in to an electric signal; phosphor-based, analogue Complementary 
Metal-Oxide Semiconductor (CMOS) detectors; and more recently, hybrid pixel array detectors, 
such as PILATUS which employ an array of silicon sensor pixels that directly detect x-ray photons 
of a desired energy. 
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In order to collect a set of diffraction data, the entire asymmetric unit of reciprocal space must be 
sampled, which requires rotation of the crystal round at least one of its axes, denoted φ. The 
instrument that facilitates this is the goniostat or goniometer, which also allows translational 
movement in x, y or z to centre the crystal in the beam.  All data sets presented in this thesis were 
collected on synchrotron beamlines at Diamond Light Source Ltd, Diamond House, Harwell 
Science and Innovation Campus, Fermi Avenue, Didcot, Oxfordshire OX11 0QX, United Kingdom.  
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Figure 2-6 Diffraction pattern from a crystal of recombinant Surfactant Protein-D. Reflections 
form a regular pattern but intensity (spot darkness) varies, and fade toward the outer regions of 
the image - corresponding to the data set’s resolution. Image collected on MX beamline I03 at 
Diamond Light Source. 
2.3.1 Radiation damage and cryoprotection 
A cause of urgency during data collection is that crystals deteriorate in an x-ray beam due to the 
heat and reactive free radicals that are generated. A vital tool in modern crystallography is the 
availability of cryocooling equipment during data collection to maintain crystal integrity. It has 
been shown that lowering the temperature of protein crystals improves the lifetime of the crystal 
during x-ray irradiation - improvements of at least 1000-fold can be obtained by cooling crystals 
to liquid nitrogen temperatures.  
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 When crystals have grown to an appropriate size, they need to be harvested from the 
crystallisation droplet and mounted on the diffractometer. They do however, need to remain in 
the mother liquor to prevent drying out and eventually disintegrating. There are two methods of 
mounting crystals: capillary mounting where the crystal (and solution) are sucked up in to a thin-
walled, quartz capillary tube, the solution is wicked out and the tube itself is sealed with wax then 
centred on a goniostat; and cryomounting whereby a single crystal is scooped out of the droplet 
with a fine nylon loop, then directly placed into liquid nitrogen - a process referred to as flash-
freezing.  
   
 
 
 
 
Figure 2-7 Photograph of a single crystal in a harvesting loop following cryocooling. The 
crosshairs indicate the crystal location and are typically used to position the crystal in the 
beamline during data collection. Image adapted from Watts et al., 2010. 
 
Freezing crystals while they are still in their aqueous mother liquor causes formation of ice 
crystals which can disturb the protein crystal lattice, lessen diffraction quality and cause 
undesirable rings, arising from ice crystals scattering the x-rays, on diffraction images. This 
process can be overcome in three ways: by rapidly freezing the crystal, on a timescale too fast for 
ice formation to occur; cooling at high-pressure to circumvent formation of typical, hexagonal ice 
forms; and by modifying the physiochemical properties of the solvent prior to flash-freezing by 
addition of a cryoprotectant to replace the majority of the water in the solution. The latter is the 
most common method employed by crystallographers, and typical choices of cryoprotective 
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agents include glycerol, ethylene glycol, 2-Methyl-2,4-pentanediol (MPD), sucrose and low 
molecular weight PEGs, which should be in a buffer compatible with the mother liquor. 
Unfortunately, it is not possible to predict which cryoprotectant will be suitable for a specific 
protein, and screening is generally necessary (Řezáèová, 2002). 
2.3.2 Indexing and merging 
Once images are collected computational programs such as iMosflm within the CCP4 suite (Battye 
et al., 2011) are used to find the diffraction spots on the images and index them. Indexing is the 
assignment of the reflections in terms of the reciprocal lattice parameters a*, b* and c*, which 
correspond to unit cell dimensions in real space. Depending on the quality of the data, it may be 
possible to index the diffraction pattern from a single frame. Multiple possibilities exist when 
defining lattice vectors this way, for instance any lattice can be indexed with arbitrary triclinic 
vectors a ≠ b ≠ c, α ≠ β ≠ γ. Indexing programs match all 44 possible combinations of crystal 
systems plus Bravais centerings and rank them by a penalty function. After initial indexing, a data 
collection strategy is devised and gives suggestions of rotation ranges suitable for maximal 
coverage of the asymmetric unit in reciprocal space. It is seldom a disadvantage to collect 
redundant data, and given the high-throughput capability of synchrotrons and inherent symmetry 
of crystals, general strategies suffice to obtain complete data. It is possible at this point to 
estimate the mosaicity of a data set, a measure of the spread of crystal plane orientations. As 
seen in Fig 2-6 a real crystal is rarely a single crystal, but rather a mosaic of near perfectly aligned 
domains. Misalignments of no more than a few tenths of a degree are useful for diffraction and as 
long as the mosaicity value is lower than the rotation angle, integration of the data is unimpeded. 
Partial reflections (that is, spots recorded partially on more than one successive image) can be 
summed appropriately, but in some cases high mosaicity or very long unit cell axes cause 
reflections to overlap on the images which renders the data more difficult to interpret. 
Chapter 2  Protein Crystallography 
76 
 
 Once diffraction images have been indexed and a strategy deduced, the cell constants and 
experimental parameters are refined using 5-10 images. Although the unit cell is determined as 
part of the indexing process, it is possible to obtain more accurate measurements using a 
procedure that requires integration of the data, ideally from two or more separate data segments 
at different φ values. Integration combines partial reflections from multiple frames in to a single 
reflection, and multiple cycles are often required for convergence. If the shift in unit cell 
parameters is greater than 2.5 standard deviations, another cycle of refinement and integration is 
performed.   
The end result is integrated raw data - essentially long lists of indices and intensities of each 
reflection that must be reduced and scaled.  
 Data reduction begins with the merging and scaling of multiple measurements from 
identical reflections, dependent on the initial indexing, to give a reduced data set that contains all 
reflections. Intensity of the data becomes weaker at high resolution due to fall off of scattering, 
and merging statistics are provided at this point for the entire data set, as well as binned 
resolution shells. 
An increased error in the measurement of weak reflections corresponds to a poor signal to noise 
ratio, expressed as average <ǀIǀ/σ(I)>, summed over all N reflections in a resolution shell, where 
I(hkl) is the average of symmetry related observation of a unique reflection: 
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The most commonly used quality indicator when merging reflections within a resolution range is 
the linear merging R-value, or Rmerge: 
        
∑ ∑      
   ̅   
 
    
∑ ∑      
 
    
 
where the inner summation extends over all N redundant observations for given reflection h, and 
  ̅    is the averaged intensity. The outer summation extends over the desired resolution range. 
Rmerge measures the differences between the same reflections measured at different points in the 
data collection. As a consequence of increasing relative error in the measurement of weak 
reflections, merging R-values increase rapidly with resolution. The lower the value, the more 
agreement. Rsym describes merging of symmetry-related reflections. 
 As a general rule of thumb, quality indicators of high data quality should include a signal 
to noise ratio, <ǀIǀ/σ(I)> of roughly 2 at the limit, a low Rmerge, completeness that allows full 
sampling of the reciprocal unit cell, as well as a resolution that gives enough definition for 
accurate map fitting.  
 
2.4 Macromolecular structure solution 
Determining the structure of a protein from its diffraction pattern is a matter of converting the 
reciprocal space information in the pattern itself to that of real space inside the unit cell. We 
understand from Bragg’s equation that the direction of reflected x-rays relates to the direction of 
the corresponding reciprocal lattice vector; with the unit cell and crystal orientation defining 
where each reflection hkl will be collected on the detector. 
As previously mentioned, the intensities of all unique reflections are collected in a diffraction 
experiment to reconstruct the electron density of a molecule, that is a reduced set of recorded 
reflections that belong to one and the same asymmetric unit of reciprocal space. The next step is 
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to define the relationship between unit cell contents and the intensity of each and every one of 
the diffracted x-ray maxima.  
2.4.1 Calculating electron density maps 
To produce an image of a molecule from the crystallographic data, the electron density within the 
unit cells must be calculated from a list of indexed intensities. Fourier transforms are a 
mathematical relationship between the contents of the crystal unit cell and its corresponding 
diffraction pattern. As each reflection can be described by a structure factor equation, containing 
information for each atom in the unit cell, the electron density can be described as a Fourier 
series in which each term is a structure factor.  
Fhkl can be written as a sum of contributions from each volume element of electron density in the 
unit cell.  The electron density of a volume element centred at x, can be taken as the average 
value of ρ(x) in that region. In effect, the volume elements can be made infinitely small, and the 
structure factor can be thus expressed in terms of electron density and the reciprocal lattice as: 
      ∫                 
    
 
where ∫ is the integral over all values of x, y and z in the unit cell. Each volume element 
contributes to Fhkl, with a phase determined by its coordinates.  
2.4.2 Electron density maps 
The final result of data collection is a molecular model of the unit cell contents, using 
measurements from the native data sets as well as calculated phases. At this point, the phases are 
usually rough estimates and so only a crude model can be discerned. Once a model is built in to 
the density map it is used to calculate new, more precise structure factors and add more terms to 
a Fourier series description of ρ(x,y,z). This produces a clearer map and allows more accurate 
location of atoms, which in turn produces more accurate phases and calculated structure factors. 
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2.4.3 Phase improvement 
Phase improvement requires modification of the model, through methods such as solvent 
flattening, histogram matching or introduction of a partial atomic model. It is also possible to 
adjust the atomic coordinates to improve agreement between amplitudes calculated from the 
current model and those observed in the “native” data set. The outcome of phase improvement is 
to add information to the map, while simultaneously reducing noise. 
 Solvent flattening exploits the fact that disordered solvent regions in the map are 
essentially flat at about 0.33 e-/Å3, compared to protein which has an average electron density of 
roughly 0.44 e-/Å3. A necessity of electron density maps is that the protein map must be of 
sufficient quality to allow solvent regions to be distinguished from the molecule, and a solvent 
mask to be generated. Density modification programs such as DM (Cowtan, 1994) set a density 
cut-off value: density above the cut-off such as protein is kept, while density below the cut-off is 
removed. New structure factors are calculated using both the protein map and newly flattened 
solvent to give an improved map.  
 In addition to the aforementioned phase improvement methods, the presence of more 
than one copy of an asymmetric unit can advance phase improvement if it is assumed that each 
crystallographically independent subunit is near-identical. This is referred to as 
noncrystallographic symmetry averaging and is not always advisable at high resolution, as there 
may be slight variations between independent molecules arising from crystal packing, or in 
symmetry which is often vital for the protein’s function.  
At some point the electron density map becomes clear enough that a protein chain can be traced 
through it and defined structural motifs such as alpha-helices can be recognised. Graphical 
interfaces such as O (Jones et al., 1991) and Coot (Emsley & Cowtan, 2004) allow the construction 
and manipulation of stick-models of known sequence in to the map, map fitting. From the 
resulting model, new structure factors are calculated using phases which contain information 
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from the new molecular model rather than an approximation of ρ(x,y,z). Additional structural 
components are then added to improve the map further; the new, more accurate structure 
factors improve phase and density become clearer.  
2.4.4 FO and FC maps 
With each successive map new molecular features are added as they are defined, and errors in 
the model such as side-chain conformations are corrected. As the model nears completion 
difference maps are used to distinguish any remaining disagreements between the model and the 
data. Two distinct parts of the Fourier synthesis are required for electron density reconstruction: 
structure factor amplitudes, and phase. Electron density reconstructed using calculated structure 
factor amplitudes as the coefficients in the electron density equation and calculated phases is 
referred to as the FC map; while maps calculated from the observed structure factor amplitudes 
and calculated phases are referred to as FO maps. 
 By selecting a combination of map coefficients the interpretability of the electron density 
map is greatly improved. For example, a difference density map of FO-FC indicates errors in the 
model by showing areas of positive density where the model has missing elements which are 
present in the protein structure as well as areas of negative density which indicate areas that 
should have no model. Regions where the map shows no contours represent agreement between 
the model and actual density. 
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Figure 2-8 FO-FC map showing a large area of positive density, red, corresponding to a missing 
ligand (left), and an area of negative density, green, indicating a conformational irregularity of 
an amino acid sidechain.  
 
In cases where a ligand has been soaked in to a macromolecule, areas of positive density may 
indicate the ligand’s presence and position (see Fig 2-8, left panel). The absence of density in 
areas that are correct makes FO-FC maps suitable for detecting errors in the model or finding 
missing density, but not for initial model building. In this case 2FO-FC maps are used. A 2FO-FC map 
can be imagined as a summation of the difference map and the FO map, and is useful not only for 
visualisation of the model (see Fig 2-9), but also for amplifying positive density during the early 
model building stage. Incomplete models that have missing atoms or other errors are 
reconstructed at half the density or less for the missing atoms. Using 2FO-FC as a Fourier 
coefficient, the missing atoms are sigma-weighted up to normal density levels, allowing for easier 
model adjustment (Read, 1990). 
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Figure 2-9 A 2FO-FC map used for initial model building. It shows the current, best estimate of 
the electron density for the structure 
 
2.4.5 The final model 
Specific details of the structure are crucial for understanding the protein’s mechanism, as ligand 
binding or functionally significant conformational changes may present as only small areas of 
density in the map. It is therefore necessary to construct the model carefully to provide as clear 
and precise a final model as possible. 
2.4.5.1 Model building and refinement 
Building a protein model in to an empty electron density map is generally unproblematic when 
the map has been reconstructed from accurate phases and high-resolution data, largely because 
side-chain orientations become distinct and the protein can be readily positioned. Manual model 
building starts with placement of Cα atoms into the density to form a Cα trace, then additional 
groups and sidechains are added to assemble a larger fragment. Orientations are adjusted to suit 
the unique electronic and spatial environment. Ligands are built in to areas of negative density in 
the same way. Map fitting becomes a matter of searching for and correcting errors in the model, 
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and the final structure can be assessed by comparison to universally valid stereochemistry, or by 
comparison of FO and FC - called refinement. Programs such as REFMAC (Murshudov et al., 1997) 
and SHELX (Sheldrick, 2010) calculate differences in values that should be equal and express this 
as a percentage called the residual index or R-factor: 
   
             
      
 
The value of R ranges from 0 for perfect agreement of calculated and observed intensities, to 
around 0.6 for total disagreement. An R-factor greater than 0.5 is said to be random, and will not 
respond to improvement unless more data is available or a new model. 
 In addition to monitoring R-factors as an indicator of convergence, other structural 
parameters indicate whether a model is chemically, stereochemically and conformationally 
reasonable. Each atom in the three-dimensional structure has four distinct values: positional 
coordinates x, y and z and a temperature factor, B, which defines its atomic displacement from its 
mean position. For a chemically reasonable model the bond lengths and angles must be near the 
expected values for organic molecules, and a well-refined model exhibits a root-mean-square 
deviation of no more than 0.02 Å for bond lengths and 2° for angles; A stereochemically sound 
model has no accidentally inverted chiral centres (for example, D-amino acids); and a 
conformationally sensible model ensures that peptide bonds ψ (between N and Cα) and φ 
(between Cα and C) are within allowed ranges and torsion angles between bonds lie within a few 
degrees of stable conformations. Numerous rounds of refinement are performed, after each of 
which the above parameters should continually improve.  
2.4.5.2 Validation 
Limited resolution and imperfect phase information make building and refining a protein 
structure from diffraction data a somewhat subjective process, and errors in the final model are 
almost unavoidable. The crystallographer’s task is to recognise and remove as many of these 
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faults as possible, prior to publication and deposition of a structure. With high-resolution data and 
high-accuracy phases, the resulting model is still a consequence of the data, and subjective 
decisions must be made - such as which refinement program to use, whether to include 
alternative conformations, whether to include explicit hydrogen atoms, which restraints to apply 
and so on. Although the purpose of model building and refinement is to detect and fix errors and 
obtain the best possible model, additional quality indicators are useful for final structure 
validation. The following list outlines various methods of model proofing.   
 Ramachandran main chain torsion angle plots - representation of dihedral torsion angles 
of each residue in an energy contour plot, representing potential surface energy. 
Repulsive van der Waals interactions limit the possible torsion angles to certain regions. 
As main chain torsion angles are generally not restrained during refinement, torsion angle 
analysis provides valuable stereochemical validation (example Ramachandran plot shown 
below). 
 
Figure 2-10 A Ramachandran plot. Glycine residues are shown as squares (bottom right of plot). 
Non-glycine residues are shown as crosses (top left of plot) if they fall inside core regions or as 
asterisks if they lie outside. Core regions are shown as the green areas (Kleywegt & Jones 1996).   
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 Kleywegt plot - examine differences between the torsions of NCS-related chains 
 Geometry analysis - A restraints-based geometry analysis of the molecule. Checks for 
improbable bond lengths, angles, etc. against universally valid stereochemistry 
 Chiral volumes - a dictionary is used to identify the chiral atoms of each of the model’s 
residues. Checks for chiral centres with the wrong handedness. 
 Rotamer analysis - checks for unusual protein side-chain conformations. 
 Density fit analysis - identifies parts of the model which don't fit the density 
 B-factor outliers - detects incorrect orientation of amino-carbonyl groups of glutamine 
and asparagine residues 
 Unmodelled density/blobs - check for electron density not accounted for by existing 
atoms. For example, sulphates, ligands and misplaced sidechains  
 Difference map peaks - one of the fastest ways to validate a model and its data. It 
highlights regions where the model and the data do not agree by more than 2 Å 
 Check waters - Sometimes waters can be misplaced or imagined - taking the place of 
sidechains or ligands (Emsley et al., 2010) 
 MolProbity probe clashes - checks for hydrogen atoms with inappropriate 
environments (Chen et al., 2009). 
Once the molecule has been validated and thoroughly checked, one can begin characterising the 
protein and any potential ligand-binding. When the crystallographer chooses to do this, however, 
is a matter of preference and perseverance. The philosopher Paul Valéry once remarked that “a 
work of art is never finished, only abandoned” and he could well have said the same for structural 
models of macromolecules (Terwilliger & Brerendzen, 1996). 
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The following flow chart details the processing steps required to successfully determine a 
protein’s structure from crystal data: 
 
Figure 2-11 Flow chart showing the processing steps from data collection to model validation. 
Adapted from Potterton et al., 2003. 
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Chapter 3: Experimental techniques 
3.1 Protein  
Three protein preparations of a trimeric recombinant head and neck fragment of human SP-D 
were generously donated by Jens Madsen and Howard Clark, University of Southampton, each 
having undergone different purification techniques: 
1. Affinity purified, 0.5ml, 11.29 mg/ml (in TBS and 5mM EDTA) 
2. Affinity purified and size exclusion chromatography, 0.45ml, 10.97 mg/ml (in TBS and 
5mM EDTA) 
3. Affinity purified, size exclusion chromatography and endotoxin treatment, 0.6ml, 8.76 
mg/ml (in PBS) 
3.1.1 Recombinant expression 
A recombinant homotrimeric fragment of human SP-D was expressed using plasmid pUK-D1 
containing cDNA for the neck and CRD (177 residues: Gly179 to Phe355) under bacteriophage T7 
promoter in E. coli BL21(λDE3) pLysS. The expression cassette included a short stretch of eight 
non-terminal Gly-X-Y repeats corresponding to the collagen region (Gly179 to Asp203), with a 
substitution of serine for proline at position 2 (residue 180); followed by an α-helical coiled coil 
neck region (Val204 to Pro235); and a globular carbohydrate-binding head domain (CRD) (Asn236 
to Phe355). The protein was expressed as inclusion bodies containing insoluble recombinant SP-D, 
which was refolded via a denaturation and renaturation procedure, of dialysis against decreasing 
concentrations of urea (6m to zero), which was then purified to varying extent, as described 
above. The protein purity was judged to be pure by SDS-PAGE, Western blotting and amino-
terminal sequencing - and biological activity ability was examined by binding to simple 
carbohydrates (maltose, glucose, mannose, galactose among others), phospholipids and maltosyl-
BSA. The recombinant protein behaved as a homotrimer of roughly 60kDa when examine by gel 
filtration chromatography, and under reducing conditions ran as a monomer of roughly 20kDa. No 
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higher-order multimers were seen under non-reducing conditions, confirming that 
oligomerisation was not a result of disulphide linkages between CRD domains.   
3.1.2 Affinity chromatography 
Affinity chromatography separates macromolecules on the basis of a reversible interaction 
between a protein and a specific ligand which is covalently bound to a chromatography matrix. 
The immobilised ligand retains its specific binding affinity for the target molecule, and subsequent 
protein-ligand interactions may be as a result of hydrophobic interactions, van der Waal’s forces 
and hydrogen bonding. The target protein is then eluted from the medium by use of a 
competitive ligand, or non-specifically by changing the pH, ionic strength or polarity which 
reverses the interaction. When removed, the protein remains in active form. Affinity 
chromatography is also used to remove specific contaminants, such as serine proteases that lack 
binding affinity for the media, and allow many separations to be achieved in one step (Urh et al., 
2009).  
3.1.3 Size-exclusion chromatography 
Purification of protein by size-exclusion, also referred to as gel filtration, is a chromatographic 
technique in which macromolecules are separated by size. Separation is achieved by the 
differential exclusion of the sample solution by the pores of a matrix material. The medium 
consists of spherical, inert beads that form pores of a specific size distribution - and proteins 
separate depending on their ability to be included or excluded from them. Smaller molecules 
diffuse into the pores and their flow through the matrix is determined by their size - as they pass 
through they are eluted in order of decreasing molecular weight; while larger molecules do not 
enter the pores and are eluted in the column void volume. Unlike other forms of chromatography, 
size-exclusion chromatography does not cause molecules to bind to the column media, meaning 
that peak resolution is minimally affected by buffer composition (Mori & Barth, 1999). 
Chapter 3  Experimental Techniques 
89 
 
3.1.4 Endotoxin treatment 
In addition to isolation and purification of the macromolecules themselves, endotoxins liberated 
by Gram-negative bacteria cause frequent contamination of protein solutions derived from 
recombinant production. A general method of endotoxin removal is currently not available; the 
heat-stability and composition of LPS molecules (a hydrophobic lipid A moiety and hydrophilic 
complex carbohydrate region with negative charged phosphate groups) provide unique features 
with respect to possible interactions with other molecules. Techniques to remove endotoxins 
include: 
 Adsorption - whereby solutions are passed through a column containing high-affinity 
adsorbents such as immobilised L-histidine, poly-L-lysine and peptide antibiotic 
polymyxin-B. Contaminant LPS binds to the matrix and purified protein is eluted. 
 two-phase partitioning - whereby an aqueous surfactant solution spontaneously 
separates into two liquid phases, one of which contains a greater concentration of LPS 
micelles (aggregation of molecules formed by non-polar interactions of the alkyl chains of 
lipid A and surfactant tail groups) that can be removed 
 Ultrafiltration - which removes large endotoxin aggregates, but this is not effective if LPS 
exist as monomers or interacts with protein molecules 
 Chromatography - such as ion-exchange chromatography, a common method of 
endotoxin removal in protein preparations, enables the negatively charged phosphate 
groups on LPS molecules to interact with anion exchange resins on a column. Non-bound 
protein is eluted (Magalhães et al., 2007) 
 Kits are also widely available that contain an endotoxin removal resin of porous beads 
that bind selectively to endotoxins.  
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3.1.5 Dialysis 
Dialysis is a common method of diffusion used to remove small, unwanted molecules from a 
protein solution and for buffer exchange of a protein sample. A membrane of suitable molecular 
weight cut-off facilitates movement of molecules in solution from areas of higher to lower 
concentration until an equilibrium is reached (Phillipis & Signs, 2005). The protein preparations 
used in this thesis underwent dialysis in a Medicell Visking nitrocellulose dialysis membrane with a 
12,000-14,000Da molecular weight cut-off to remove EDTA from the sample, as well as for buffer 
exchange in to 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5 prior to crystallisation trial 
setup. 
3.1.6 Concentrating and NanoDrop 
Concentration of dilute protein samples was achieved through centrifugation with Merck 
Millipore and Amicon Ultra centrifugal filter units with a molecular weight cut-off of 10,000Da. 
Preparations underwent centrifugation until a chosen volume was achieved, and post-dialysis 
protein concentrations were tested using a Thermo Scientific NanoDrop 1000 
Spectrophotometer. 1μl samples of a protein solution were placed on the device pedestal and an 
absorbance reading at 280nm was taken, which along with a user-input extinction coefficient of 
0.494 moles per centimetre (based on a protein’s atomic composition, and in particular the 
presence of aromatic amino acids such as tyrosine, tryptophan and phenylalanine which exhibit 
strong UV-light absorption), to give an accurate protein concentration. Dividing the absorbance of 
a sample solution by the molar extinction coefficient gives the molar concentration of the protein 
solution (Gill & von Hippel, 1989). 
3.2 Ligand preparation 
The hydrophobic lipid A moiety of LPS renders the molecule insoluble, and soaking a ligand into a 
crystal require solubility. Lipid A is also large in size, roughly 30 Å by 30 Å (Qiao et al., 2014) and as 
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such often requires removal before ligands are able to enter crystal solvent channels. The bond 
between Kdo and the inner glucosamine of the lipid A is very acid labile, and is typically cleaved 
under mild conditions.  
Lipopolysaccharide from Haemophilus influenzae Eagan 4A was generously donated by Derek 
Hood and Mary Deadman, Univerisity of Oxford, UK; Lipopolysaccharides from E. coli 0111:B4 
(L3012), E. coli 026:B6 (L2762), E. coli J5 (L5014) and E. coli F583 (L6893) were purchased from 
Sigma-Aldrich; Lipopolysaccharide from S. minnesota R7 (ALX-581-018-L002) was purchased from 
Enzo Life Sciences. 
3.2.1 Mild acid hydrolysis of lipid A  
The method of removing the lipid A moiety from LPS was adapted from Phillips et al., 1992, 
whereby intact lipopolysaccharides are boiled in weak acetic acid to hydrolyse the 
aforementioned bond between the inner core and the hydrophobic lipid A. Intact 
lipopolysaccharides were placed in a spherical boiling flask with 1% acetic acid (2 mg LPS in 1ml 
acid) and placed in a preheated, circular dish containing hot sand. An open-top reflux condenser 
was attached, with running water flowing up and outward. The flask temperature was raised to 
100°C and left to reflux for two hours on a hot-plate once a steady temperature was obtained.  
After this time, a cloudy precipitate is present in the solution. The solution was allowed to cool to 
4°C and centrifuged at 5000G for 20 minutes. The lipid A component forms a small brown pellet, 
and the aqueous supernatant (containing the polysaccharide region only) was removed, the pellet 
washed, and placed in a separate tube for drying. 
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Figure 3-1 Schematic diagram of hydrolysis instrumental setup. The boiling flask contains the 
lipopolysaccharide and acetic acid which is raised to and maintained at 100°C boiling 
temperature. The reflux condenser ensures that the resultant vapour is cooled and re-collected 
in the flask. Image adapted from Mayo et al., 1994. 
 
It has been well established that under mild acid conditions the Kdo residue that links the inner 
core to the lipid A moiety undergoes a conformational change and yields oligosaccharides with 
anhydro-Kdo on the reducing terminus rather than intact Kdo (Auzanneau et al., 1991). Formation 
of anhydro-Kdo structures occurs when a phosphate group at the C4 position is β-eliminated 
(Danan et al., 1982; Caroff et al., 1987). This proceeds readily under these conditions because the 
C-4 substituent is β to the C-2 (anomeric) carbonyl carbon. The reaction is believed to give rise to 
olefinic Kdo derivatives, which rearrange to form anhydro ring structures – see figure 3-2.  
Thermometer 
Water in 
Water out 
Boiling flask 
Reflux condenser 
Clamp 
Heated sand 
Hot plate 
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Figure 3-2 Formation of the structures formed during mild acid hydrolysis of 3-Deoxy-D-manno-
oct-2-ulosonic acid (Kdo, a); D-arabino-3-en-2-ulonic acid open-chain (b), the diastereomeric 
forms of the 4,8-anhydro (c and c’) and the 4,7-anhydro (d and d’) derivatives. R represents the 
extended inner core of LPS. Image adapted from Sioud et al., 2010. 
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3.2.2 Lyophilisation  
Both the supernatant and lipid A pellet from the hydrolysis were added to 15ml centrifuge tubes 
and stored at -80°C until frozen, when they were placed in a Savant Speedvac SPD111V with no 
heat, to dry-down the solvent. The vacuuming process was continued until only dry products and 
no liquid remained. 
 
Figure 3-3 Photographs of tubes containing hydrolysed and lyophilised LPS. The left-hand tube 
contains the cleaved lipid A portion in the form of a small brown pellet, the right-hand tube 
contains the remaining polysaccharide region, with a crystalline consistency.  
 
3.3 Crystallisation trials 
Crystals of the recombinant head and neck fragment of human SP-D were grown in sitting drops, 
consisting of an equal volume (1μl) of protein at various mg/ml and precipitant buffer to screen 
for optimum conditions. See Appendix for tables of crystallisation screens and subsequent follow-
up trials. 
Some cocrystallisation trials were attempted. Tray CCS7 consisted of drops of protein preparation 
1, dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, which was incubated with 
intact Haemophilus influenzae Eagan 4A lipopolysaccharide, and then re-concentrated to 8.16 
mg/ml (protein). 
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CCS14 consisted of drops of protein preparation 3 at 6.52 mg/ml, which was incubated with 
18.5mM hydrolysed E. coli B6 lipopolysaccharide and 11.1mM CaCl2, incubated for 2 hours at 
room temperature. 
Wells C1 and D1 of tray CCS16 consisted of drops of protein preparation 3 at 7.42 mg/ml 
incubated with 0.18mM hydrolysed S. minnesota lipopolysaccharide and 10mM CaCl2. 
Initial trials of conditions known to yield crystals (see Appendix table CCS2, 17/12/10) using 
protein preparation 3 were the first to show crystal growth - only after addition of calcium 
chloride eight weeks after the drops were laid down. Wells deemed particularly successful were 
reproduced, namely 16% PEG 6000 at pH6, 16% PEG 4000 at pH8, 16% PEG 10000 at pH6 and 16% 
PEG 8000 at pH7, and the period between drop lay-down and calcium addition was varied to 
assess optimal time. 
3.3.1 Cryoprotection approach and ligand soaks 
Soaking ligands into pre-existing crystals is often the method of choice to obtain protein-ligand 
complexes, owing to the ease of the technique (Hassell et al., 2006). Protein crystals may 
however, be fragile and soaking time and the solvent used to dissolve a ligand may damage the 
crystal itself. Tests were performed to optimise the soaking time and ensure any conformational 
changes that may occur within the protein caused by ligand binding do not disrupt crystal 
contacts. 
Unless otherwise stated, crystals were prepared for cryocooling by addition of successive 2μl 
aliquots of precipitant buffer containing 5%, 10% and 15% 2-Methyl-2,4-pentanediol (MPD), 
followed by two additions of 2μl of buffer containing 20% MPD, and an exchange of 10μl drop 
solution for 10μl of 20% MPD cryobuffer. 
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3.3.2 Data collection 
All data sets presented in this thesis were collected on Macromolecular Crystallography (MX) 
beamlines at Diamond Light Source Ltd, Diamond House, Harwell Science and Innovation Campus, 
Fermi Avenue, Didcot, Oxfordshire OX11 0QX, United Kingdom. 
3.3.2.1 Data processing 
Data collected for crystals from trays CCS2C2, CCS2D6, CCS2D52 and from wells CCS12A33, 
CCS3D41a, CCS16A12 and CCS16A15 was automatically reduced by fast_dp and XIA2 immediately 
following data collection using the Automatic Software Pipeline (diamond.ac.uk). The 
automatically generated MTZ file was then reindexed and had a free-R flag added using Uniqueify.  
 
Figure 3-4 Flow-chart of fast data processing by fast_dp. Images are automatically indexed and 
integrated, the point groups is determined, then the images are scaled and merged to give an 
MTZ file containing the crystal reflection data (image taken from diamond.ac.uk). 
 
Data processing and reduction for crystals from CCS9B3, CCS8C1, CCS3D41 and CCS3D42 was 
performed using the program MOSFLM. First, the diffraction spots were found using Find Spots; 
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indexed; cell refinement was performed to determine the cell parameters accurately using three 
separate segments at a range of different φ values unique and anomalous data; then integrated. 
CCP4 program SCALA was used to scale together multiple observations of reflections. 
For crystal CCS16A11, integrated intensities were calculated using iMosflm. First, the diffraction 
spots were indexed; a strategy was calculated using two initial images, 90° apart in φ to evaluate 
unique and anomalous data (42.00-42.10° and 131.90-132° φ); cell refinement was performed to 
determine the cell parameters accurately using three separate segments at a range of different φ 
values (images 1-32, 450-481 900-932); and finally, all images were integrated. 
After integration, the program Pointless was run to determine the point group, Aimless was run to 
scale together multiple observations of reflections, and CTruncate was run to calculate intensities. 
Using FreeRflag, a tag each for reflection in the MTZ file with a flag for cross-validation was added, 
corresponding to a 4.869% subset of reflections not to be used in the refinement. 
3.3.2.2 Structure solution 
Isomorphism was sufficient to allow the coordinates of a previously determined structure of a 
trimeric SP-D fragment (residues 208–355 in chains A, B and C) to be used as a starting model for 
the structure solution of all processed data sets. For all crystals (with the exception of those from 
tray CCS16), structure solution was carried out using the CCP4 program suite: SIGMAA was used 
to calculate Fourier coefficients from the calculated phases by combining phase probabilities from 
isomorphous phases from the rigid body refinement using a native protein structure without 
water molecules or calcium – completed using CNS of the CCP4 suite. Density modification and 
solvent flattening were performed using program DM. For crystal CCS16A11 only, a rigid body 
refinement was accomplished through CCP4 program REFMAC using a native protein structure 
without water molecules, at a resolution of 1.77 Å chosen to conform to reasonable signal-to-
noise ratio. 20 cycles of refinement were performed automatically. 
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3.3.2.3 Electron density maps and refinement 
For all data sets besides CCS16A11, fast Fourier transforms (FFT) were utilised to generate 
electron density maps, and model building was accomplished using O. No refinement was 
performed. 
For CCS16A11 weighted difference maps were generated during rigid body refinement by 
REFMAC. Ligand was then modelled in JLigand using known structures of heptose 
monosaccharides and 4,7-anhydro Kdo from Sioud et al., 2010. Dictionaries of torsion/bond 
distances and angles were calculated for the regularised ligand using Sketcher. The structure was 
refined once positions of amino acid side- and main-chain conformations had been fitted in the 
electron density using Coot, and repeated. Restrained refinement of the ligand-bound structure 
was carried out, using the aforementioned dictionaries. Water molecules were added using 
FindWaters in the Coot suite, based on density peaks that fit certain criteria: peaks above a 
median electron density of 1.8 rmsd and 2.4-3.2 Å distance to protein atoms. CheckWaters then 
removed molecules with a B-factor greater than 80 Å2 and a map rmsd level less than 1.00 
electron per Å3. After addition of water molecules, resolution was sufficient to complete a final 
round of refinement. Refinement statistics are shown in table 4-6 in the Results chapter. 
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Chapter 4: Results of crystallisation trials of recombinant human SP-D 
This chapter details the outcomes of crystallisation trials and refinements, and subsequent 
collection of successful data sets - along with the electron density maps and solved structure for 
crystal CCS16A11. 
4.1 Crystal trials and crystal growth 
Crystal growth was generally successful, with crystals of SP-D consistently showing a rectangular 
morphology with regular, well-defined edges. Protein preparation 3 which had additional 
endotoxin treatment, was by far the most successful preparation with regards to crystal growth. 
Crystal trays with protein preparations 1 and 2 did not yield any crystals, and cocrystallisation 
trials in trays CCS7 and CCS14, in addition to wells in tray CCS16 yielded no crystals, but formed 
cloudy precipitate (see Fig 4-1). 
 
Figure 4-1 Well CCS7D2 showing typical formation of cloudy precipitate during cocrystallisation 
trials using protein preparation 1 which was dialysed in 10mM Tris, 10mM CaCl2 and 140mM 
NaCl at pH 7.5, then incubated with intact Haemophilus influenzae Eagan 4A lipopolysaccharide 
and reconcentrated. 
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4.1.1 Crystallisation trials 
Initial trials of conditions known to yield crystals (see Appendix table 2) using protein preparation 
3 were the first to show crystal growth – but only after addition of calcium chloride eight weeks 
after the drops were laid down. Wells deemed particularly successful were reproduced, and the 
optimum period between drop assembly and calcium addition was demonstrated to be between 
1 day and 2 weeks.  
4.2 Ligand soaks 
Cryoprotection soaks of pre-existing crystals using cryobuffers with ligand included were tested 
on crystals considered lower quality, to optimise soaking time and ensure the cryobuffer did not 
damage the crystal (see Appendix table 17). The following subchapters detail the 
lipopolysaccharides used in ligand soaks, in addition to the crystals that were soaked. 
4.2.1 Intact Haemophilus influenzae 4A  
 
 
 
 
  
Figure 4-2 Crystals from well CCS2A3. 
 
A trial of soaking intact 4A ligand was attempted by addition of 1µl 6.7mM ligand directly to the 
drop (CCS2B5, Fig 4-3), which resulted in a brown, murky precipitate forming in the centre. 
Crystals gradually degraded from the inside-out and by 24 hours, all had dissolved.  
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Figure 4-3 Crystals from well CCS2B5 test well before and immediately following addition of 
intact H. influenzae Eagan 4A LPS to drop. There was an instant formation of brown precipitate 
and gradual degradation of crystal integrity. 
 
In well CCS2A3, two crystals were cryoprotected and frozen without ligand, then 12µl 6.7mM 
Eagan 4A LPS was added, and two further crystals were frozen just over an hour later. Two weeks 
later the well was re-exchanged and an additional 6µl 6.7mM ligand was added. Three more 
crystals were subsequently frozen within 30 minutes. In total, eight crystals were taken from well 
CCS2A3 and data collected for three (CCS2A34, A35 and A37); the first two of which had data 
collected on beamline I03 while A37 was tested on beamline I04-1 on a different date.  
 
4.2.2 E. coli B4 smooth  
 
Figure 4-4 Crystals from wells CCS2C2 (left) and CCS2D6 (right). 
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Tests for soaking with 30mM hydrolysed E. coli B4 smooth LPS resulted in quick degradation of 
the crystals, and in one case crystals dissolved immediately. During preparation for freezing using 
CCS2C2 and CCS2D6 however, little effect was seen and wells were able to be exchanged after 3 
hours 45 minutes for CCS2C2 and 56 minutes for CCS2D6. Five crystals were frozen from the 
former well, and two from the latter - all of which had data collected on beamline I03.  
4.2.3 E. coli B6 smooth  
 
Figure 4-5 Crystals from wells CCS9B3 (left) and CCS9A4 (right) 
 
Crystals from wells CCS9B3 and CCS9A4 were cryoprotected and soaked with 30mM hydrolysed 
lipopolysaccharide from E. coli B6 and exchanged immediately. Three crystals from CCS9B3 were 
collected and frozen roughly 30 minutes post-exchange, and a single crystal from CCS9A4 was 
frozen after 10 minutes. The three crystals from CCS9B3 had data collected at beamline I04. 
 
 
 
 
 
 
Chapter 4  Results 
103 
 
4.2.4 E. coli F583 rough  
 
Figure 4-6 Crystals from well CCS12D5 (left) and CCS12A3 (right) 
 
Test wells soaked with 10mM E. coli F583 demonstrated that crystals were immediately damaged 
by introduction of the ligand, and within 5 minutes the drop became too cloudy to accurately see 
crystals at all. Therefore, soaking time was limited to as short a period of time as possible: six 
crystals were exchanged and frozen within 14 minutes from well CCS12D5, and three crystals 
were exchanged and frozen within three minutes from well CCS12A3. Data was collected for 
crystals CCS12D51, D51 and D55; and CCS12A32 on beamline I02.  
 
Figure 4-7 Dissolved crystals from test well soaked with hydrolysed E. coli F583 polysaccharide. 
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4.2.5 E. coli J5 rough  
  
 
 
 
 
 
 
Figure 4-8 Crystals from wells CCS8C1 (left), CCS3D4 (right) and CCS13B6 (bottom).  
 
Crystals from wells CCS8C1 (initially assumed to be a chunk of glass) and CCS3D4 were not 
affected by cryobuffers containing 30mM hydrolysed E. coli J5 lipopolysaccharide and as such 
were able to withstand a wait of 44 minutes to over an hour between exchange and freezing. A 
single crystal was frozen from well CCS8C1, and three taken from CCS3D4. Of these four crystals, 
four underwent data collection on beamline I04 (two data sets were collected for crystal 
CCS3D41); crystal CCS3D43 showed no diffraction. Crystals from CCS13B6 were subjected to 
successive aliquots of 5-20% cryobuffer, then were exchanged after 40 minutes and four crystals 
were frozen within 9 minutes. Data was collected for crystals CCS8C1, CCS3D41 and D42 on 
beamline I04. Data sets from well CCS13B6 were not processed.  
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4.2.6 Salmonella minnesota R7 rough  
 
Figure 4-9 Crystals from wells CCS2C6 (right) and CCS16A1 (left). 
 
Test wells which were soaked with cryobuffers containing 30mM hydrolysed S. minnesota R7 
polysaccharide suggested that crystals degraded very quickly once soaked. Nine crystals were 
taken from well CCS2C6, which were frozen as soon as possible after exchange due to immediate 
degradation. Unfortunately, none produced diffraction spots and as such no data sets were 
collected. For well CCS16A1, following addition of the 5%, 10% and 15% MPD + R7 polysaccharide 
cryobuffers, crystals again appeared to be degrading and three crystals were removed from the 
well and frozen before addition of 20% cryobuffer to the well. 1μl of the 20% cryobuffer was then 
added to the well, followed by exchanging 8μl of the well with the 15% cryobuffer with added 
calcium (1μl 100mM CaCl2). The crystals appeared to show no further degradation, and six more 
crystals were frozen between 7 minutes and 1 hour 18 minutes after the buffer exchange. Of the 
nine crystals frozen from well CCS16A1 five had data collected - a diffraction image from crystal 
CCS16A11 (the first crystal frozen from this well) is shown below. 
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Figure 4-10 Diffraction pattern from a crystal CCS16A11. Reflections form a regular pattern but 
intensity (spot darkness) varies, and fade toward the outer regions of the image - corresponding 
to the data set’s resolution of roughly 1.6 Å. Image collected on MX beamline I03 at Diamond 
Light Source and is one of 1,300 images taken for this crystal. 
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4.3 Data collection 
All data sets presented in this thesis were collected on Macromolecular Crystallography (MX) 
beamlines at Diamond Light Source Ltd, Diamond House, Harwell Science and Innovation Campus, 
Fermi Avenue, Didcot, Oxfordshire OX11 0QX, United Kingdom. Details of all collections are shown 
in the table below, including the resolution at which data sets were collected - a diffraction 
pattern collected for crystal CCS16A11 is shown in Fig. 4-10. Details of crystals which were tested 
or soaked can be found in appendix Table 17.  
The following table details the cryoprotection procedure and whether the crystal yielded 
diffraction data. 
Table 4-1 Exposed crystal cryoprotection procedure, ligand concentration and subsequent 
exposures performed, with diffraction resolution, DLS beamline and date of collection where 
applicable. Cryo - cryobuffer; Snap - snapshot taken to assess diffraction quality; DC - data 
collection. See Appendix for full details of crystallisation conditions. Data for crystals 
highlighted in yellow were processed. 
Crystal Cryoprotection procedure 
Ligand 
concentration 
Result 
CCS2 A3 1 
CCS2 A3 2 
Exchanged and frozen, native 
4/5/11 
- 
Snap 1.75 Å 
Snap 1.8 Å 
7/5/11 
I03 
CCS2 A3 3 
CCS2 A3 4 
CCS2 A3 5 
Exchanged and frozen 
+ 12µl 6.7mM Eagan 4A LPS 
4/5/11 
3.3mM 
Snap 9 Å 
Collected 1.8 Å    
Collected 1.8 Å   
7/5/11 
I03 
CCS2 A3 6 
CCS2 A3 7 
CCS2 A3 8 
Reexchanged 
+ 6µl 6.7mM Eagan 4A LPS 
18/5/11 
2.86mM 
Snap 2.5 Å 
DC 1.5 Å     
Snap 2.86 Å 
20/5/11 
I04-1 
CCS2 B1 1 
CCS2 B1 2 
CCS2 B1 3 
CCS2 B1 4 
Exchanged and frozen, native 
1/7/11 
- No diffraction   
4/7/11 
I04-1 
CCS3 C1 1 
CCS3 C1 2 
Exchanged and frozen, native 7/3/12 - 
DC 2.5 Å  
Snap 4.2 Å 
6/5/12 
I04 
CCS2 C2 1 
CCS2 C2 2 
CCS2 C2 3 
CCS2 C2 4 
CCS2 C2 5 
5-20% MPD cryo containing 30mM E. 
coli B4 PS. Exchange after 3h 45m  
15/3/12 
30mM 
DC 2.4 Å 
DC 2 Å 
DC 2.4 Å 
DC 2.5 Å 
DC 2 Å 
17/3/12 
I03 
CCS2 D6 1 
CCS2 D6 2 
5-20% MPD cryo containing 30mM E. 
coli B4 PS. Exchanged after 56m 
15/3/12 
30mM 
DC 1.6 Å 
DC 1.7 Å 
17/3/12 
I03 
CCS9 B3 1 
CCS9 B3 2 
CCS9 B3 3 
5-20% MPD cryo containing 30mM E. 
coli B6 PS. Exchanged immediately. 
4/5/12 
30mM 
DC 1.9 Å 
DC 2.0 Å 
DC 1.9 Å 
6/5/12 
I04 
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Table 4-2 Exposed crystal cryoprotection procedure, ligand concentration and subsequent 
exposures performed, with diffraction resolution, DLS beamline and date of collection where 
applicable. Cryo - cryobuffer; Snap - snapshot taken to assess diffraction quality; DC - data 
collection. See Appendix for full details of crystallisation conditions. Data for crystals 
highlighted in yellow were processed. 
CCS9 A4 1 
5-20% MPD cryo containing 30mM E. 
coli B6 PS. Exchanged immediately. 
4/5/12 
30mM DC 2.0 Å 
6/5/12 
I04 
CCS3 D4 1 
CCS3 D41a 
CCS3 D4 2 
CCS3 D4 3 
5-20% MPD cryo containing 30mM E. 
coli J5 PS. Exchanged after 40 
minutes. 17/7/12 
30mM 
DC 3 Å 
DC 2.5 Å 
DC 2.5 Å 
No diffraction 
22/7/12 
I04 
CCS8 C 1 
Re-exchanged with 20% MPD cryo 
containing 30mM E. coli J5 PS (10µl 
out, 10µl in) 17/7/12 
30mM DC 1.5 Å 
22/7/12 
I04 
CCS13 B6 1 
CCS13 B6 2 
CCS13 B6 3 
CCS13 B6 4 
5-20% MPD cryo containing 30mM E. 
coli J5 PS. Exchanged after 40 
minutes. 6/8/12 
30mM 
Not tested 
DC 1.9 Å 
DC 2.14 Å 
DC 1.7 Å 
9/8/12 
I03 
CCS12 D5 1 
CCS12 D5 2 
CCS12 D5 3 
CCS12 D5 4 
CCS12 D5 5 
CCS12 D5 6 
5-20% MPD cryo containing 10mM E. 
coli F583. Exchanged immediately. 
10/10/12 
10mM 
DC 2.4-3 Å 
DC 3.18 Å 
Not tested 
Not tested 
DC 3.0 Å 
Not tested 
14/10/12 
I02 
CCS12 A3 1 
CCS12 A3 2 
CCS12 A3 3 
5-20% MPD cryo containing 10mM E. 
coli F583. Exchanged immediately. 
10/10/12 
10mM 
DC 1.4 Å 
Not tested 
DC 2-3 Å 
14/10/12 
I02 
CCS2 C6 1 
CCS2 C6 2 
CCS2 C6 3 
CCS2 C6 4 
CCS2 C6 5 
CCS2 C6 6 
CCS2 C6 7 
CCS2 C6 8 
CCS2 C6 9 
5-20% MPD cryo containing 22mM S. 
minnesota R7. Exchanged 
immediately. 15/3/13 
22mM No diffraction 
20/3/13 
I04 
CCS16 A5 1 
5-20% MPD cryo containing 22mM S. 
minnesota R7. Exchanged 
immediately. 15/3/13 
22mM No diffraction 
20/3/13 
I04 
CCS16 A1 1 
CCS16 A1 2 
CCS16 A1 3 
5-15% MPD cryo containing 22mM S. 
minnesota R7. Crystals degrading – 
exchanged before 20% aliquots  
22mM 
DC 1.63 Å 
DC 2.13 Å 
Not tested 
19/5/13 
I03 
CCS16 A1 4 
CCS16 A1 5 
CCS16 A1 6 
CCS16 A1 7 
CCS16 A1 8 
CCS16 A1 9 
As above. 1µl 20% cryo added, 20µl 
removed from drop. Total volume of 
remaining 15% cryo (plus 1µl 
100mM CaCl2) added 
17.6mM 
Not tested 
DC 2.4 Å 
Not tested 
Not tested 
DC 1.7 Å 
DC 2.0 Å 
19/5/13 
I03 
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4.4 Data processing  
As mentioned previously, data collected for crystals from tray CCS2C and from wells CCS12A3, 
CCS3D4, and CCS16A1 was automatically reduced by fast_dp and XIA2 immediately following data 
collection using the Automatic Software Pipeline (diamond.ac.uk). The generated MTZ file 
containing reflection data, symmetry information and cell dimensions was then reindexed and 
had a free-R flag added using Uniqueify.  
Data for crystal data sets CCS9B3, CCS8C1, CCS3D41 and CCS3D42 were processed and reduced 
using MOSFLM. Firstly, the diffraction spots were found using Find Spots; they were then indexed 
and a cell refinement was performed to determine the cell parameters accurately. The data was 
then integrated using the CCP4 program SCALA, which was used to scale together multiple 
observations of reflections. These data sets however, showed no ligand in the binding site, and as 
such are not discussed further in this thesis. The following table details the data collection 
measurements and processing method of each individual data set collected: 
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Table 4-3 Measurements of collected data sets. Data sets with superscript symbols saw a drop 
of diffraction quality during collection. The term ‘Fast’ in the processing method column refers 
to data that underwent fast_dp and XIA2 immediately following data collection using the 
Automatic Software Pipeline; ‘Full’ refers to data sets that were reindexed and integrated 
through MOSFLM, and scaled through SCALA. 
Crystal 
° 
between 
images 
Number 
of 
images 
% 
transmission 
Processing 
method 
Resolution (Å) 
Intact H. influenzae LPS 
CCS2 
A3 4 
0.1 2000 43 Fast 1.8 
CCS2 
A3 5 
0.1 2000 43 Fast 1.85 
CCS2 
A3 7 
0.2 900 100 Fast 1.5 
Hydrolysed E. coli B4 PS 
CCS2 
C2 1 
1 200* 200 Fast 2.4 
CCS2 
C2 2 
0.2 900 100 Fast 2.0 
CCS2 
C2 3 
0.2 1000 50 Fast 2.4 
CCS2 
C2 4 
0.2 900 50 Fast 2.5 
CCS2 
C2 5 
0.2 900 50 Fast 2.0 
CCS2 
D6 1 
0.1 2000 50 Fast 1.6 
CCS2 
D6 2 
0.1 2000 50 Fast 1.7 
Hydrolysed E. coli B6 PS 
CCS9 
B3 1 
1 200 100 Full 1.9 
CCS9 
B3 2 
1 200 100 Full 2.0 
CCS9 
B3 3 
1 200 100 Full 1.9 
Hydrolysed E. coli J5 PS 
CCS3 
D4 1 
1 200 100 Full 3.0 
CCS3 
D4 1a 
0.5 200 100 Fast 2.5 
CCS3 
D4 2 
1 200 100 Full 2.5 
CCS8 C 
1 
0.5 400 50 Full 1.5 
Hydrolysed E. coli F583 PS 
CCS12 
D5 2 
0.1 2000 50 Fast 3.18 
CCS12 
A3 3 
0.1 2000 60 Fast 2.0 
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Table 4-4 Measurements of collected data sets. Data sets with superscript symbols saw a drop 
of diffraction quality during collection. The term ‘Fast’ in the processing method column refers 
to data that underwent fast_dp and XIA2 immediately following data collection using the 
Automatic Software Pipeline; ‘Full’ refers to data sets that were reindexed and integrated 
through MOSFLM, and scaled through SCALA. 
Hydrolysed S. minnesota R7 PS 
CCS16 
A1 1 
0.1 1310 40 Full 1.63 
CCS16 
A1 2 
0.1 1800 60 Fast 2.13 
CCS16 
A1 5 
0.1 1800 50 Fast 2.4 
* Quality drop after image 80, + after image 600, # after image 200. 
 
Table 4-5 Results of data sets that underwent processing to generate preliminary electron 
density maps that showed no ligand in the binding site 
Crystal Soaked with Processing details Result 
CCS2 A3 3 
CCS2 A3 4 
CCS2 A3 7 
Haemophilus 
influenzae 4A 
Automatically reduced by 
fast_dp (viewed with O). 
No ligand density was 
seen in the binding site 
CCS2 C2 1 
CCS2 C2 2 
CCS2 C2 3 
CCS2 C2 4 
CCS2 C2 5 
CCS2 D6 1 
CCS2 D6 2 
E. coli B4 
smooth 
Automatically reduced by 
fast_dp (viewed with O). 
No ligand density was 
seen in the binding site 
CCS9 B3 1 
CCS9 B3 2 
CCS9 B3 3 
E. coli B6 
smooth 
Processed through MOSFLM 
and SCALA (viewed with O). 
No ligand density was 
seen in the binding site 
CCS3 D4 1 
CCS3 D41a 
CCS3 D4 2 
CCS8 C1 
E. coli J5 rough 
for CCS8C1, CCS3D41 and D42 
was processed through 
MOSFLM and SCALA; data for 
CCS3D41a was automatically 
reduced by fast_dp; data sets 
from well CCS13B6 were not 
processed 
Large areas of electron 
density were seen in 
the ligand-binding site - 
however, the definition 
was ambiguous and no 
definite carbohydrate 
could be discerned. 
CCS12 D5 1 
CCS12 D5 2 
CCS12 D5 5 
E. coli F583 Automatically reduced by 
fast_dp (viewed with O). 
No ligand density was 
seen in the binding site 
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The following figure, Fig. 4-11, shows an electron density map of the ligand binding site with a 
marked absence of bound lipopolysaccharide, and is representative of each of the data sets in 
Table 4.5. 
 
Figure 4-11 A 2Fo-Fc difference map showing no ligand in the CRD. The central white cross is 
calcium 1 - the site of carbohydrate binding, while the pink crosses are water molecules whose 
positions are otherwise occupied by hydroxyl pairs of a ligand. Image generated using Coot. 
 
For crystal CCS16A11 (soaked with hydrolysed S. minnesota R7 PS), integrated intensities were 
calculated using iMosflm. First, the diffraction spots were indexed; a strategy was calculated using 
two initial images, 90° apart in φ to evaluate unique and anomalous data (42.00-42.10° and 
131.90-132° φ); cell refinement was performed to determine the cell parameters accurately using 
three separate segments at a range of different φ values (images 1-32, 450-481 900-932); and 
finally, all images were integrated. 
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After integration, the program Pointless was run to determine the true Laue symmetry, Aimless 
was run to scale together multiple observations of reflections, and CTruncate was run to calculate 
cumulative intensity distributions and a Wilson plot as well as to perform any anisotropy 
correction.  
Using FreeRflag, a tag each for reflection in the MTZ file with a flag for cross-validation was added, 
corresponding to a 4.869% subset of reflections not to be used in the refinement. 
Table 4-6 Data collection and merging statistics for crystal CCS16A11. 
Wavelength (Å) 0.97625 
Temperature (K) 100 
Spacegroup P21 
a (Å) 55.32 
b (Å) 108.28 
c (Å) 55.68 
α (°) = γ (°) 90.00 
β (°) 91.75 
Max resolution (Å) 1.7 
Observations 224,221 
Unique reflections 99,332 
Completeness (%) 94.1 
Rmerge 0.085 
B-factor (protein) 22.7 
B-factor (ligand) 25.5 
B-factor (water) 33.3 
Mean I/σI 4.8 
Highest resolution bin 
Highest resolution bin (Å) 1.77-1.82 
Completeness (%) 91.6 
Rmerge 0.304 
Mean I/σI 2.6 
 
4.5 Structure solution and maps 
As the data for crystal CCS16A11 gave the most promising preliminary electron density map, the 
structure solution for this set only is described here. Structure solution and model building was 
performed as previously described in Chapter 3. Isomorphism was sufficient to allow the 
coordinates of a previously determined structure of a trimeric SP-D fragment (PDB accession code 
1PW9) to be used as a starting model for the structure solution of all processed data sets.  
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A rigid body refinement was accomplished through CCP4 program REFMAC using the 
native protein structure without water molecules (PDB accession code 1PW9), at a resolution of 
1.77Å (see Table 4-6). 20 cycles of refinement were performed automatically and reduced the R-
factor from 32.2% to 18.5% and the R-free (equivalent to R-factor for a 4.87% subset of reflections 
not used in the refinement) from 32.2% to 22.1%. The improved phases gave a significantly 
clearer position of the anKdo tail group - and defined its orientation towards Arg343 (see figures 
4-16 and 4-17).  
B-factors, calculated using CCP4i program BAVERAGE, were 23.6 for protein in the A chain, 21.1 
for the B chain, 23.4 in the C chain, 25.5 for the ligand (averaged over both ligand-binding chains B 
and C), and 33.3 for water molecules.  
 
4.5.1 CCS16A11 - S. minnesota R7-bound structure 
The overall structure of the recombinant head and neck fragment of human SP-D reveals a 
trimeric structure of three C-terminal globular head domains, linked by an extended α-helical 
coiled coil neck region, with an N-terminal collagen domain that is not visible in the electron 
density. The structure contains residues 205-355 in chains A and B, and 206-355 in chain C. 
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Figure 4-12 Crystal structure of S. minnesota R7 polysaccharide-bound SP-D showing three 
calcium ions per CRD in green, and the asymmetric tyrosine positioned into the central pore. 
Chain A is shown in yellow, chain B in cyan and chain C in red. Ligand is seen in the B and C 
chains. Image generated using CCP4MG. 
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Figure 4-13 Crystal structure of S. minnesota R7 polysaccharide-bound SP-D in ribbon form, 
showing three calcium ions per CRD in green, and the asymmetric tyrosine positioned into the 
central pore. Ligand is seen in the B and C chains. Image generated using CCP4MG. 
 
Similar to structures elucidated by Shrive et al., 2003, the electron density suggested alternative 
conformations of the sidechains of Cys353 and Cys345 which formed disulphide bridges with 
Cys261 and Cys331 respectively. These features are consistent with radiation damage to thiol 
groups of cysteine residues, even at cryogenic temperatures, using moderate-intensity 
synchrotron radiation (Weik et al., 2000). 
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4.5.1.1 Calcium ions 
Three calcium ions per CRD were clearly visible in the electron density: calcium 1 in the ligand 
binding vicinity which is coordinated by the sidechains of Glu321, Asn323, Glu329, Asn341, 
Asp342 and hydroxyl groups 6 and 7 of the bound ligand. Calcium 2 is coordinated by the 
sidechains of Asp297, Glu301, Asp324 and Asp330 as well as the main-chain carbonyl of Glu329. 
Calcium 3 is coordinated by the sidechains of Glu301, Asp330 and Asp330 as well as four water 
molecules. The distances between calcium ions and coordinating amino acid residues are given in 
the table below: 
Table 4-7 Coordination of calcium ions, water molecules or ligand residues by atoms of amino 
acid sidechains in the CRD of all three chains. Distances in Å 
Calcium Atom A B C 
Ca1 
Glu321OE1 2.56 2.57 2.66 
Asn323OD1 2.42 2.45 2.36 
Glu329OE1 2.46 2.41 2.30 
Asn341OD1 2.39 2.39 2.45 
Asp342OD1 2.31 2.30 2.26 
Water/ligand W388 2.53 O6 2.51 O6 2.50 
Water/ligand W389 2.37 O7 2.51 O7 2.52 
Ca2 
Asp297OD1 2.70 2.61 2.71 
Asp297OD2 2.71 2.46 2.41 
Glu301OE1 2.49 2.55 2.52 
Glu301OE2 2.54 2.59 2.51 
Asp324OD1 2.39 2.55 2.59 
Glu329O 2.45 2.32 2.38 
Asp330OD1 2.26 2.39 2.39 
Ca3 
Glu301OE1 2.25 2.39 2.33 
Asp330OD1 2.49 2.52 2.52 
Asp330OD2 2.41 2.47 2.47 
Water W386 2.29 W31 2.37 W21 2.37 
Water W104 2.36 W58 2.40 W46 2.31 
Water W87 2.37 W73 2.10 W13 2.24 
Water W53 2.23 W94 2.24 W385 2.38 
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4.5.1.2 The asymmetric tyrosine 228 and the neck-CRD interaction 
There is a marked asymmetry in the conformation of tyrosine residues at position 228 in the neck 
region. The sidechain of Tyr228 in the C chain is shifted into the centre of the coiled-coil, with the 
remaining two remaining directed outward (see Fig 4-13). 
The fourth calcium ion, Ca4, in the central pore (previously demonstrated in the maltose-bound 
structure elucidated by Shrive et al., 2003) is absent in this structure, and as such two of the three 
glutamic acid residues at 232 interact with each other as well as with Lsy246 in the same chain, 
while the third (in the B chain) adopts a conformation whereby it interacts with the asymmetric 
tyrosine 228 in the central pore. 
4.5.1.3 The ligand binding site 
 
Figure 4-14 Fo-Fc difference map of bound S. minnesota R7 polysaccharide in chains B (left, 
blue) and C (right, red), calculated prior to adding ligand or water molecules into the model. The 
maps were contoured at 2.5σ. HepIII, which was not visible in the map, is linked to HepII via the 
O7 group, labelled with the red asterisk. The outer core region of LPS that is not present in this 
strain is connected via the O3 group of HepII, labelled with the blue asterisk. Image generated 
using CCP4MG. 
 
* 
* 
* 
* 
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Density corresponding to the ligand was well defined in the B chain, and to a lesser extent in the C 
chain, and showed the inner most heptose (HepI) binding to Ca1 by the 6 and 7 hydroxyl groups. 
The positions of the glycerol OH groups of the bound heptose (HepII) in the complex were similar 
to those of the equatorial 3 and 4 hydroxyl groups in previous ligand structures such as maltose 
and mannobiose (see Fig 1-20, replicated below).  
 
Figure 1-20 (replicated) Binding of glucose via vicinal hydroxyl groups O3 and O4 (Glc, blue) and 
heptose via hydroxyl groups of the glycerol side chain O6 and O7 (Hep, red). Bonds shown in 
alternate colours share the same coordinates in binding. OH1 can be the O2 of galactose, O3 of 
α1-2mannobiose and α1-4mannobiose (in chain A only), O4 of α1-4mannobiose (in chains B and 
C), O4 of inositol-1-P (in chains B and C) and the O3 of maltose. OH2 can be the O1 of galactose, 
O4 of α1-2mannobiose and α1-4mannobiose (in chain A only), O3 of α1-4mannobiose (in chains 
B and C), O5 of inositol-1-P (in chains B and C) and the O4 of maltose. Binding of myoinsoitol 
utilises the O1 and O6 hydroxyl groups which can take positions OH1 and OH2 reversibly. Image 
generated using CCP4MG using PDB accession codes 1PWB and 2RIB. 
 
Evidence of the orientation and positions of the two adjacent carbohydrate residues HepII and 
Kdo was also clear, but density was lacking for the anhydro-Kdo (anKdo) tail group in both chains - 
and only weak, broken density was observed round hydroxyl groups 3, 4 and 6 of the second 
OH
1
 
Glc O3 
Hep O6 OH
2
 
Glc O4 
Hep O7 
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heptose in chain C. HepIII is linked through the O7 hydroxyl group of HepII, but is not visible in the 
electron density. 
 The structure of the ligand was apparent however, and comprised two α1-3 linked 
heptose residues - the first of which linked to an anhydro, five-membered (rather than six-
membered) Kdo residue known to form during mild acid hydrolysis.  
 
Figure 4-15 Structure of the polysaccharide from hydrolysed Salmonella minnesota R7 
lipopolysaccharide visible in the electron density. It consists of two heptose saccharides and an 
anhydro-Kdo residue. Binding by SP-D occurs via the O6 and O7 hydroxyl pairs of HepI. HepIII, 
which was not visible in the map, is linked to HepII via the O7 group, labelled with the red 
asterisk. The outer core region of LPS that is not present in this strain is connected via the O3 
group of HepII, labelled with the blue asterisk. 
 
 
 
 
 
 
 
 
HepII 
HepI 
Kdo 
2 
3 
4 
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7 
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Figure 4-16 Top - 2Fo-Fc map of bound S. minnesota R7 polysaccharide in the binding site of the 
B chain. Bottom - 2Fo-Fc map clipped round the ligand only. The map was contoured at 1σ after 
restrained refinement of the structure containing ligand and water. HepIII, which was not 
visible in the map, is linked to HepII via the O7 group, labelled with the red asterisk. The outer 
core region of LPS that is not present in this strain is connected via the O3 group of HepII, 
labelled with the blue asterisk. Images generated using CCP4MG. 
* 
* 
* 
* 
Chapter 4  Results 
122 
 
 
 
Figure 4-17 Top - 2Fo-Fc map of bound S. minnesota R7 polysaccharide in the binding site of the 
the C chain. Bottom - 2Fo-Fc map clipped round the ligand only. The map was contoured at 1σ 
after restrained refinement of the structure containing ligand and water. HepIII, which was not 
visible in the map, is linked to HepII via the O7 group, labelled with the red asterisk. The outer 
core region of LPS that is not present in this strain is connected via the O3 group of HepII, 
labelled with the blue asterisk. Images generated using CCP4MG. 
 
* 
* 
* 
* 
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The ligand was coordinated mainly via HepI, by sidechains that also coordinate the calcium 1 ion - 
the OE2 atom of Glu321, ND2 of Asn323, OD1 atoms of Asn323 and Asn341 interact with the O6 
hydroxyl group on the glycerol side chain, while the OE2 of Glu329, ND2 of Asn341 and the main-
chain carbonyl of Asp342 interact with the O7 group (distances are shown in Table 4-6). 
Interactions were also seen between the furanose O6 and tail O1 hydroxyl groups of 
anKdo - with sidechains of Asp325 and Arg343, respectively. Hydrogen bond distances between 
the O6 hydroxyl group and OD2 atom of Asp325 were 2.78 Å in the B chain and 2.69 Å in the C 
chain; Bonds between the O1 tail hydroxyl and NH2 atom of Arg343 were 2.69 Å and 2.45 Å. 
 
Table 4-8 Coordination of ligand by sidechains in the CRD of chains B and C. Distances in  Å 
Ligand OH group Protein atom B chain C chain 
HepI O6 
Glu321OE2 2.54 2.48 
Asn323ND2 2.96 2.96 
Asn323OD1 3.02 3.02 
Asn341OD1 3.18 3.19 
HepI O7 
Glu329OE2 2.59 2.51 
Asn341ND2 2.92 3.02 
Asp342O 2.95 2.88 
anKdo O1 Arg343NH2 2.69 2.45 
anKdo O6 Asp325OD2 2.78 2.69 
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Figure 4-18 Ligand coordinating water molecules and amino acid sidechains in the B chain CRD. 
The protein is shown in cyan, water molecules as red spheres and the bound S. minnesota R7 
polysaccharide in green. Labels show the amino acid sidechain atoms and water molecules that 
interact with the ligand. HepIII, which was not visible in the map, is linked to HepII via the O7 
group, labelled with the red asterisk. The outer core region of LPS that is not present in this 
strain is connected via the O3 group of HepII, labelled with the blue asterisk. Image generated 
using CCP4MG.  
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Figure 4-19 Ligand coordinating water molecules and amino acid sidechains in the C chain CRD. 
The protein is shown in red, water molecules as red spheres and the bound S. minnesota R7 
polysaccharide in green. Labels show the amino acid sidechain atoms and water molecules that 
interact with the ligand. HepIII, which was not visible in the map, is linked to HepII via the O7 
group, labelled with the red asterisk. The outer core region of LPS that is not present in this 
strain is connected via the O3 group of HepII, labelled with the blue asterisk. Image generated 
using CCP4MG.  
 
Notably, binding was exclusively mediated by the side chain of HepI and the O6 and O1 groups of 
anKdo - and no direct interactions were observed between the protein and the second heptose, 
HepII, in either chain. The conformation of this residue consequently differs between the B and C 
chain; there is a 44° rotation round the O1-C1 bond, as well as a slight rotation of the pyranose 
ring of HepII in the C chain with respect to HepI. There is also a significant 175° rotation of the C6-
C7 glycerol side-chain away from the binding pocket (see Fig 4-20). 
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Figure 4-20 Conformational change of HepII relative to HepI in the B chain (solid green 
backbone) and C chain (semi-transparent ice-blue backbone). HepII in the C chain is rotated 
round the O1-C1 bond by roughly 44° compared to that in the B chain, as well as a slight 
rotation of the pyranose ring and a 175° rotation of the glycerol sidechain. Image generated 
using CCP4MG. 
 
Interestingly, and in addition to the primary protein binding site, sidechains of the symmetry-
related trimer were also in close proximity to the ligand. Interactions were weaker than those 
seen in the CRD and involved two sidechains in the C subunit of the neighbouring trimer 
interacting with ligand in the B chain, and sidechains in the A chain of the trimer interacting with 
ligand in the C chain. 
Table 4-9 Coordination of ligand by symmetry-related sidechains. Distances in Å 
Ligand OH group Protein atom B chain C chain 
HepI O2 CSer226OG 3.17 - 
HepII O4 CLys229NZ 2.94 - 
HepII O4 AGly241O - 3.10 
HepII O6 ASer239OG - 3.00 
 
 
HepI 
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In addition to direct interactions between the symmetry-related protein and ligand, a total of six 
hydrogen-bond bridges are formed between the ligand, water molecules and the neighbouring 
protein in the crystal form. These bridges are exclusively seen in the B chain, and involve the non-
bound HepII and anKdo residues only. 
Table 4-10 Hydrogen bond bridges between the ligand and symmetry-related trimer. Distances 
in Å. 
Ligand atom Water molecule Protein atom 
Distance 1 
Ligand-water 
Distance 2 
Water-protein 
HepII O2 W10 CSer226O 2.79 2.88 
HepII O2 W140 CGly241O 3.27 2.55 
HepII O3 W140 CGly241O 3.24 2.55 
HepII O4 W34 BTyr228OH 2.59 2.69 
HepII O7 W130 AGln263O 3.02 2.81 
anKdo O8 W130 AGln263O 2.89 2.81 
 
The position and orientation of the ligand resulted in interactions occurring between residues that 
differed between chains. In the B CRD-bound ligand a 2.39 Å hydrogen bond is formed between 
the HepII O7 hydroxyl group and the O8 hydroxyl group of the non-adjacent anKdo; in the C chain 
a 2.77 Å hydrogen bond is formed between the O4 hydroxyl group of terminally bound HepI and 
the O1 tail group of the adjacent anKdo monosaccharide (see Fig 4-21). 
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Figure 4-21 Showing interactions that form between residues of the ligand. The top image, in 
the B chain CRD, shows a 2.39 Å hydrogen bond formed between the O8 hydroxyl group of 
anKdo and the O7 hydroxyl group of non-adjacent HepII. The bottom image, in the C chain CRD, 
shows a 2.77 Å hydrogen bond formed between the O1 tail hydroxyl of anKdo with the O4 
hydroxyl group on the pyranose ring of neighbouring HepI. HepIII, which was not visible in the 
map, is linked to HepII via the O7 group, labelled with the red asterisk. The outer core region of 
LPS that is not present in this strain is connected via the O3 group of HepII, labelled the blue 
asterisk. Image generated using CCP4MG. Image generated using CCP4MG.  
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Table 4-11 Refinement statistics for the SP-D - S. minnesota R7 complex (crystal CCS16A11) 
Refinement 
Resolution range (Å) 55.65 – 1.77 
R-factor (%)a 18.71 
R-free* (%)b 22.05 
Protein atoms 3466 
chain A 1154 
chain B 1154 
chain C 1149 
Other atoms 
Calcium ions 9 
Ligand  82 (41 in B, 41 in C) 
Waters  386 
Average B values (Å2) 
Protein main chain 22.8 
Calcium ions 17.1 
Ligand  25.5 
Water  33.3 
Ramachandran plot values (%) 
Most favoured 97.31 
Additional allowed 2.47 
Disallowed  0.22 
a Rconv = h ||Foh| - |Fch|| /h |Foh| , where Foh and Fch are the observed and calculated structure 
factor amplitudes, respectively, for the reflection h.  
b Rfree is equivalent to R-factor for a 4.87% subset of reflections not used in the refinement. 
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Chapter 5: Discussion  
5.1 Crystal growth 
The late addition of calcium to pre-existing sitting drops of protein preparation 3 - which had 
undergone affinity purification and size-exclusion chromatography as well as additional endotoxin 
removal - was the only condition to produce crystal growth. Whether successful growth was a 
consequence of purer protein, or due to the late addition of calcium is unknown.  
Gram-negative bacteria are widely used to produce recombinant protein and endotoxins 
(LPS) are major contaminants of recombinant protein production. Although found on the bacterial 
cell wall, LPS is continuously liberated and its removal is often crucial when producing a sample of 
sufficient purity. In addition to isolation and purification of the macromolecule itself, preparation 
3 was the only sample to be treated with endotoxin. As previously stated, a real crystal is rarely a 
single crystal, but rather a mosaic of near perfectly aligned domains. Misalignments of no more 
than a few tenths of a degree are useful for diffraction, but in some cases contamination may be 
severe enough to hinder crystal growth entirely.  
Figure 2-4 (replicated) Schematic drawing of a highly mosaic crystal growing in solution. Protein 
molecule (blue spheres) are interrupted by small impurities (red) and debris (green). New 
molecules preferentially attach to ledges or steps, shown with red arrows. Contamination 
occurring within the growing crystal causes defects and misalignment, in this case of around 6°.  
Image taken from Rupp, 2010. 
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Endotoxin treatment of the protein sample was, in this case, necessary for formation of 
diffraction quality crystals. This same preparation which had been dialysed in to calcium-
containing buffer also failed to produce crystals.  
Slowing the rate of crystal growth is a common method of obtaining larger, and superior 
quality crystals. Typical approaches include addition of reagents that solubilise the sample - such 
as detergents and salts; coating the reservoir solution with paraffin or silicon oil to reduce the rate 
of vapour diffusion between it and the drop; or by diluting the drop itself, which supresses 
excessive nucleation (Blow et al., 1994). It has also been noted that addition of cofactors or 
ligands can modify the crystallisation behaviour of proteins - and this may be the case when 
adding calcium late; certain non-protein chemical compounds that are bound to macromolecules 
are often required for biological activity, and crystallisation may require their presence in solution 
for crystal nuclei to form (Borisenko & Kolesnikov, 2012).  
Whilst the metastable zone is considered to be an optimal zone for crystal growth, it may 
be possible to sustain but not initiate growth. Before addition, no calcium was present in the drop 
and as SP-D is a calcium dependent C-type lectin - It can be inferred that the presence of calcium 
is not only necessary for carbohydrate binding, but also for protein stabilisation. Amino acids 
Asp325 and Arg343 are directly implicated in forming crystal contacts, and are located within 
close proximity to the binding pocket and the carbohydrate-binding Ca1 ion (see Fig 5-1). It may 
be plausible that a lack of calcium at this site causes increased flexibility of the surrounding 
protein residues, and decreased ability to form the crystal contacts necessary for the protein to 
aggregate and a crystal to grow. 
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Figure 5-1 Showing the proximity of Asp325 and Arg343 to the ligand-binding Ca1 ion in the CRD 
of the B chain. Distances to the primary carbohydrate binding calcium ion, Ca1, are also shown. 
Image generated using CCP4MG. 
 
Unlike the trials presented here, previously solved structures of SP-D were crystallised by Shrive et 
al., 2003; Shrive et al., 2009 in sitting drops consisting of equal volumes of protein solution and 
precipitant buffer, with the protein in a buffer containing 10mM CaCl2. The protein stock provided 
was produced in the same manner as that used here, but at a different time and date and by a 
different research group - which may account for differences seen during crystallisation attempts. 
Sitting drops used to grow SP-D crystals also consisted of larger volumes of protein and 
precipitant buffer - 5μl - compared to 1μl here. Different volumes of protein and precipitant may 
be tried as part of the optimisation process highlighting the temperamental nature of crystal 
growth. For instance, using more protein may result in a net increase in concentration of the 
protein in the drop after equilibrium is reached, which can be desirable for dilute protein samples, 
or to slow crystal nucleation or growth (Dessau & Modris, 2011). It is interesting that only this 
batch of protein yielded crystals so unconventionally with late addition of calcium a serendipitous 
Asp325 
Arg343 
Ca1 
5.92 Å 
6.06 Å 
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after-thought - when crystallisation trials of other protein batches in calcium buffer before and 
after this as described by Shrive et al., 2003; 2009 produced crystals of equal quality. 
Once the late addition procedure was discovered, and tests proved it to be reproducible in 
extensive screening round the successful conditions, certain wells repeatedly yielded crystal 
growth. Conditions that consistently produced diffraction quality crystals included 16% 
weight/volume PEG 10,000, and 0.1M Tris at pH7, as well as 16% weight/volume PEG 4,000, and 
0.1M Tris at pH8. 
5.1.1 Cocrystallisation trials  
Cocrystallisation is a common method of obtaining crystals of a protein-ligand complex, and is 
often the technique of choice when the compounds are insoluble or aggregate easily (Hassell et 
al., 2006). There are however, many factors that may influence successful cocrystallisation 
including temperature, whereby incubation may facilitate complex formation; and protein/ligand 
concentration - as sometimes it may be possible to concentrate the protein then add the ligand to 
form a complex, but insoluble ligands may cause the protein to precipitate at higher 
concentrations. None of cocrystallisation trials yielded crystals. In each well of trays CCS7 and 
CCS14 and wells C1 and D1 of CCS16, thick brown precipitate formed and no crystal growth was 
seen.  
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Figure 4-1 (replicated) Well CCS7D2 showing typical formation of cloudy precipitate during 
cocrystallisation. 
All cocrystallisation samples were allowed to incubate and were laid down at room temperature. 
Heat-treating the protein-ligand is a technique that may improve the quality of the protein by 
reducing macromolecules that may not be properly folded, giving a more homogenous sample. 
Typically, 1:3 to 1:10 protein to ligand ratios are used to achieve stable complexes that yield well-
diffracting crystals (hamptonresearch.com, 2015). All trials (excluding CCS7 which contained 
diluted protein that was concentrated along with intact H. influenzae Eagan 4A) consisted of a 
protein to ligand ratio of 1:4 to 1:5, with calcium present in the solution. This may have been too 
high a ligand concentration, causing the protein to precipitate out.  
 Tray CCS7 contained protein that had been incubated with intact LPS, including the 
hydrophobic and insoluble lipid A moiety. LPS molecules have limited or no water solubility, and 
successful complexation may have been improved by dissolving the ligand in a solubilising agent 
such as DMSO (dimethyl sulphoxide) or a small amount of low molecular weight polyethylene 
glycol.  
5.2 Unsuccessful ligand soaks 
Unlike the aforementioned cocrystallisation trials which saw no crystal growth at all, other trays 
yielded growth but showed no ligand binding after soaks and cryoprotection. Once data was 
collected and maps were calculated, no electron density was present in the binding site for 
Chapter 5  Discussion 
135 
 
crystals soaked with intact H. influenzae Eagan 4A LPS, hydrolysed smooth LPS from E. coli B4 and 
B6, and rough LPS from E. coli F583. As previously mentioned this ligand contains a large, 
hydrophobic lipid A moiety which is not water soluble (see Fig 5-3) - and either was too insoluble 
to dissolve in to the protein solution or was too large to enter the crystal. Packing of protein 
molecules in the crystal forms channels through which a ligand must pass to enter the ligand 
binding pocket (see Fig 5-2).  
Figure 5-2 Showing protein molecule packing within a crystal of SP-D, viewed along the BC face. 
Due to the formation of crystal contacts in close proximity to the binding pocket, access to the 
CRD is only possible if a ligand passes through a series of channels formed by the symmetry-
related protein. Chain A is shown in yellow, chain B in cyan and chain C in red. No ligand or 
calcium ions are shown. Image generated using CCP4MG. 
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Figure 5-3 General structure of the diphosphorylated lipid A moiety from H. influenzae LPS. It 
consists of a double-glucosamine backbone, each with two amide-linked 3-
hydroxytetradecanoic (myristic) acids and a single phosphate group. A single myristic acid 
residue measures approximately 17.4 Å in length as measured in Coot. Image taken from 
Mikhail et al., 2005. 
 
Just as glycosylated proteins are notoriously difficult to crystallise, it can be inferred that longer 
ligands would be too. Typically, crystallisation requires removing floppy ends, disordered loops or 
intrinsically unstructured (natively unfolded) regions – to minimise flexibility and disorder. 
Smooth strains of lipopolysaccharides contain repeating oligosaccharide O-antigens, with an 
average molecular weight six-times that of rough LPS (Backhed et al., 2001) - and no smooth LPS 
tested during soaks was visible in any structure.  
 Smooth E. coli B4 and B6 LPS strains were initially chosen for soaks due to SP-D’s 
preferential binding to heptose residues, and that the outer core and O-antigen would effectively 
be ignored. This was not the case however, and no evidence of binding was seen.  
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E. coli O111:B4 LPS strains are believed to contain a full inner and outer core and between 18 and 
27 repeating O-antigen units (see Fig 5-4) with a molecular weight of roughly 7,000Da (Morrison 
& Leive, 1975) and SP-D has been shown to exhibit significant binding to the strain in solid-state 
binding assays (Yamazoe et al, 2008). Even without the large, hydrophobic lipid A moiety, the 
ligand may have been too large to successfully penetrate the crystal channels and access the 
binding pocket. 
  
α-Col-(1→6) 
| 
→4)-a-D-Glc-(1→4)- α -D-Gal-(1→3)-β-D-GlcNAc-(1→ 
| 
α -Col-(1→3) 
Figure 5-4 Structure of the O-antigen repeat unit of E. coli B4 LPS. Glc - glucose; Gal - galactose; 
Col - colitose; GlcNAc - N-acetyl glucosamine. Colitose is a carbohydrate product of mannose 
and is found in the O-antigen of certain Gram-negative bacterial LPS such as E. coli, Yersina, 
Salmonella and Vibrio species (Samuel & Reeves, 2003). Structure taken from Stenutz et al., 
2006. 
 
E. coli O26:B6 exhibits short-chain length behaviour on SDS-PAGE and shows low 
molecular weight bands and low critical micelle concentration which is considered to be directly 
proportional to polysaccharide chain length (Mangoni et al., 2008; Aurell & Winstrom, 1998). 
Peterson et al., 1985, separated various smooth E. coli strains by gel filtration in to short- and 
long-chain fractions containing an average of 1 and 18 O-antigen repeat units respectively. By 
demonstrating short-chain-like behaviour, the B6 strain LPS is likely to contain only one repeat 
unit, shown below (see Fig 5-5). SP-D has shown significant binding to the strain in solid-state 
binding assays (Leth-Larsen et al., 2005; Yamazoe et al., 2008), but the whole ligand may be too 
large to successfully penetrate the crystal channels and access the binding pocket. 
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→2)-β-D-Man-(1 →3)- β -D-Gal-(1 →3)- α -D-GlcNAc-(1 →3)- β -D-GlcNAc-(1→ 
                                                            | 
                                                             α -L-Fuc-(1→2) 
Figure 5-5 Structure of the O-antigen repeat unit of E. coli B6 LPS. Man - mannose; Gal - 
galactose; GlcNAc - N-acetyl glucosamine; Fuc - fucose. Structure taken from Stenutz et al., 
2006. 
 
No density was seen in the ligand binding site for F583-soaked crystals. This ligand, known 
to exist as a small Rd2 mutant, has not been well characterised however, and is believed to 
comprise only of Kdo and a single heptose residue - HepI. Crystals deteriorated rapidly during 
tests and were frozen very quickly after exchange, suggesting that the ligand may be disrupting 
interactions between protein molecules in the crystal. This may be plausible if the ligand is small 
enough to pass through the solvent channels in the crystal, but contains additional groups such as 
negatively charged phosphates that may alter the crystal environment. SP-D was shown to bind 
Rd1 mutant S. minnesota R7 which contains two additional heptose residues that would not 
interact with the protein, compared to that of F583. Given the structurally conserved inner core 
of Salmonella and E. coli LPS, it can be presumed that binding by SP-D would occur in a similar 
manner - that is, by heptose HepI. Also only 10mM F583 ligand was present in the cryobuffer - 
significantly lower than other tests and less than half that of successful S. minnesota R7 soaks. 
5.3 Overall structure of R7-bound SP-D  
The overall structure of the recombinant head and neck fragment of human SP-D reveals a 
trimeric structure of three C-terminal globular head domains, linked by an extended α-helical 
coiled coil neck region, with a short N-terminal collagen domain that is not visible in the electron 
density. The structure contains residues 205-355 in chains A and B, and 206-355 in chain C. 
The head and neck domains of the protein were very well defined, as were the locations 
of known calcium ions. Calcium presence was clearly visible in the electron density for sites 1, 2 
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and 3 in the CRD, with a marked absence at the fourth location in the central pore (see figure 4-
13, replicated below). 
Figure 4-13 (replicated) Crystal structure of ligand-bound SP-D in ribbon form, showing three 
calcium ions per CRD in green, and the asymmetric tyrosine positioned into the central pore. 
Ligand is seen in the B and C chains. Image generated using CCP4MG. 
 
The absence of Ca4 at this site has previously been demonstrated in the maltose-bound structure 
elucidated by Shrive et al., 2003, and is consistent with lower concentrations of calcium ions in 
the cryoprotectant. The final calcium concentration was ~0.17mM due to an absence of calcium in 
the cryoprotective agent. Other factors that may contribute to this absence may include the 
presence of high concentrations of R7 LPS ligand (22.2mM) and the varying pH and PEG molecular 
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weight in the crystallisation conditions and cryobuffer - which may alter the electrochemical 
environment within the crystal that is otherwise conducive to calcium occupancy at certain sites 
in the protein. These results (coupled with structures that have this ion present) suggest that a 
minimum calcium concentration greater than that included in the protein solution or 
cryoprotectant is required for occupancy of the Ca4 site (Shrive et al., 2003). 
Also concurrent with the studies by Shrive et al., is the resulting asymmetry of residues 
Glu232 and Tyr228 in the Ca4-depeletd structure. The position of the C chain tyrosine sidechain 
into the centre of the coiled-coil allows it to interact with one of the three glutamate residues at 
position 232 (at a distance of 2.42 Å), that otherwise interact with glutamates at this position in 
other subunits and with Lys246 in the same chain. The intrachain interactions of Glu232 and 
Lys246 between the neck and head region of chains A and C are relatively strong (2.99 Å and 2.91 
Å, respectively) compared to that in the B chain (5.59 Å), and suggest a significant charge transfer 
to the two lysine residues. It is unlikely that this fourth calcium ion is present in other collectins 
other than bovine SP-D, since no acidic residues equivalent to Glu232 are present; nonetheless, a 
basic residue at position 246 is a common feature of SP-D proteins across species. The asymmetry 
of Tyr228 and resulting asymmetry of Glu232 does not disturb the geometry of the neck-CRD 
interface.  
Chapter 5  Discussion 
141 
 
 
Figure 5-6 Showing the close proximity of the neck region to the ligand binding site of a 
symmetry-related trimer. Arrows indicate the contact region. Chain A is shown in yellow, chain 
B in cyan and chain C in red. Ligand is shown here in the C chain only, in ice-blue. Image 
generated using CCP4MG. 
 
An interesting feature that may support the suggestion that asymmetry in the neck occurs as a 
result of crystal packing is the close proximity of the ligand and the asymmetric tyrosine at 
position 228 in the same chain in a symmetry-related trimer (see Fig 5-7) that may help to 
stabilise the ligand in the crystal and define it in the electron density. 
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Figure 5-7 Showing the close proximity interaction between the hydroxyl group of tyrosine 228 
in the B chain and the O4 group of HepII from a symmetry-related trimer. Protein chain B of 
both molecules is shown in cyan ribbon-form, with the protruding tyrosine in circles. The ligand 
in the CRD is shown in ice-blue, with three calcium ions in green. There is a hydrogen bond 
bridge formed between the ligand, a water molecule (red sphere) and symmetry-related trimer, 
due to the protein molecule packing within the crystal. Image generated using CCP4MG. 
 
5.3.1 The ligand binding site 
As previously mentioned, SP-D demonstrates a significant ability to recognise natural ligands such 
as bacteria and viruses, as well as cell surface receptors (Gardai et al., 2003) - and the structure 
presented in this thesis provides insight in to the mechanism of bacterial lipopolysaccharide 
binding at the primary binding site in the CRD. 
The two heptose residues visible in the electron density conform to the structure previously 
solved by Wang et al., 2008 (see Fig 5-8 and Table 5-1), whereby the inner-most heptose (HepI) is 
bound in a calcium-dependant manner and interacts directly with the protein. HepI is bound in a 
specific manner via the glycerol tail O6 and O7 hydroxyl groups, and is coordinated by residues of 
Tyr228 OH 
HepII O4 
2.59Å 
2.69Å 
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the CRD that also coordinate the Ca1 ion. There was no ligand-protein interaction between the 
second heptose saccharide (HepII) and the protein - implicating the inner-most heptose as the 
primary site of the carbohydrate interaction. 
 
Figure 5-8 Comparison of binding and ligand orientation of heptose disaccharide in the B chain 
between the R7 data presented in this thesis (left, Kdo residue not shown), and the structure 
previously reported by Wang et al., 2008 (right, PDB accession code 2RIC). Binding is essentially 
identical with regards to position and coordination of HepI by the calcium ion Ca1, with a slight 
rotation round the glycosidic bond. Calcium ions are shown as grey spheres. Image generated 
using CCP4MG.   
Table 5-1 Comparison of ligand coordination in the B chain between the R7 data presented in 
this thesis and the structure previously reported by Wang et al., 2008 (PDB accession code 
2RIC). Distances in Å 
Ligand OH group Protein atom Distance (R7 data) Distance (2RIC) 
HepI O6 
Glu321OE2 2.54 2.61 
Asn323ND2 2.96 3.07 
Asn323OD1 3.02 3.33 
Asn341OD1 3.18 3.28 
HepI O7 
Glu329OE2 2.59 2.62 
Asn341ND2 2.92 3.08 
Asp342O 2.95 3.26 
HepII HepII 
HepI HepI 
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This binding mechanism leaves hydroxyl groups available for participation in glycosidic linkages to 
Kdo residues and longer chain saccharides, when placed in the context of full-length, physiological 
LPS (see Fig 5-9 and Fig 1-8, replicated below).  
 
Figure 5-9 Model of the ligand in the B chain CRD, showing the sites of attachment for the LPS 
outer core not present in this strain, and that of HepIII which is not visible in the electron 
density map. Image generated using CCP4MG. 
The figure below represents the remaining portions of LPS not present in the R7 strain: 
 
Figure 1-8 (replicated) The general structure of LPS showing hydrophilic region (lipid A), core 
region made up of an inner and outer portion, and the O-antigen. The terminal structure 
(hashed box) is the repeating unit of the O-antigen. GlcN - glucosamine; Kdo - 3-deoxy-D-
manno-octulosonic acid; Hep - D-glycero-D-manno-heptose. Image adapted from Alexander & 
Rietschel, 2001. 
Site of outer 
core attachment 
 
Site of HepIII 
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HepII 
 
HepI 
 
Kdo 
 
O-antigen            Core region      Lipid A 
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Considering the restricted size of the binding pocket and close proximity of neighbouring 
molecules in the crystal (see Fig 5-2), a longer LPS mutant would be too large to access the CRD in 
the crystal form. 
5.3.2 Non-binding pocket interactions  
In addition to direct binding of the ligand in the CRD, other interactions occur between symmetry-
related trimers in the crystal and within the ligand itself which contribute to contribute to the 
electron density being better defined in the B chain compared to the C chain (see Fig 4-14 
replicated below). 
 
Figure 4-14 (replicated) Fo-Fc difference map of bound S. minnesota R7 polysaccharide in chains 
B (left, blue) and C (right, red), calculated prior to adding ligand or water molecules into the 
model. The maps were contoured at 2.5σ. Image generated using CCP4MG 
 
5.3.2.1 Symmetry-related protein interactions 
Along with the primary site of ligand binding, symmetry-related neighbouring protein 
trimers also contribute to LPS coordination in the crystal form. As previously stated, molecules 
packed in the crystal impose constraints on binding of ligands in subunit A, and as such no ligand 
was visible in the electron density in this chain. Unlike the maltose-bound structure, where the 
full ligand could only be seen in chain A due to a stabilising water-bridge between the second 
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saccharide unit and the symmetry-related protein, the longer R7 ligand is hindered from entering 
the more constricted binding pocket. Sidechains of the symmetry-related trimer are also in close 
enough proximity to the ligand in chains B and C to interact: Ser226 and Lys229 of the C chain 
formed weak bonds with heptose residues in the B chain, while Gly241 and Ser239 form weak 
bonds with heptose in the C chain.  
 
Figure 5-10 Showing interactions that form between residues of the symmetry-related trimer 
and the ligand in the B chain. The ligand is shown in green, the binding pocket in cyan, and the 
neighbouring trimer is shown in red. Two residues of the neighbour which form direct bonds 
with the polysaccharide, Ser226 and Lys229, are magenta. Image generated using CCP4MG. 
 
As mentioned previously, there is also an interaction between the hydroxyl group of 
tyrosine 228 in the B chain and the O4 group of HepII from a symmetry-related trimer (see Fig 5-
7). The electron density round HepII is very well defined in the B chain compared to that in C, but 
the symmetry-related contacts alone may not explain the reason for this - the cause becomes 
apparent when examining the hydrogen-bond bridges that form between the ligand and the 
symmetry-related trimer that are only seen in the B chain (see table 4-10).  
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Table 4-10 (replicated) Hydrogen bond bridges between the ligand and symmetry-related 
trimer. Distances in Å. 
Ligand atom Water molecule Protein atom 
Distance 1 
Ligand-water 
Distance 2 
Water-protein 
HepII O2 W10 CSer226O 2.79 2.88 
HepII O2 W140 CGly241O 3.27 2.55 
HepII O3 W140 CGly241O 3.24 2.55 
HepII O4 W34 BTyr228OH 2.59 2.69 
HepII O7 W130 AGln263O 3.02 2.81 
anKdo O8 W130 AGln263O 2.89 2.81 
 
Again, although these interactions arise as a direct consequence of protein packing within 
the crystal, it does demonstrate SP-D’s inherent flexibility and ability to form additional 
interactions that may occur during agglutination of microbes. It is a well-documented 
phenomenon that SP-D aggregates microbes to create a clumped mass that inhibits colonisation 
and enhances clearance by alveolar macrophages. Independent, trimeric subunits display only a 
weak affinity for saccharides, suggesting that higher-order multimers are required for strong 
binding and to allow multivalent binding to ligands, or to simultaneously bind both a pathogenic 
surface structure and receptors to initiate an immune response.  
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5.3.2.2 Ligand-ligand interaction 
In addition to protein-ligand interactions, the R7 ligand also forms intramolecular bonds. It has 
previously been demonstrated that the extent of heptose branching in lipopolysaccharides of 
Haemophilus influenzae directly influences binding of collectins (Orgeig et al., 2010) - and that 
higher-order arborisation effectively shields the inner core heptose residues from being bound. It 
was suggested that bacteria may have adapted by developing surface structures which hinder, or 
in some cases fully resist, collectin binding - and successfully subvert the innate immune response, 
but the manner by which they do so was not determined (Orgeig et al., 2010). The interactions 
between saccharide units of the LPS demonstrated in this thesis are relevant in that they illustrate 
the ability of longer ligands to fold back, and potentially sterically hinder heptose accessibility. The 
fact that two distinct examples of these interactions can be seen in the structure, further supports 
the suggestion. 
 
Figure 4-21 (replicated and edited) Showing interactions that form between residues of the 
ligand. The left-hand image, the B chain CRD, shows a 2.39 Å hydrogen bond formed between 
the O8 hydroxyl group of anKdo and the O7 hydroxyl group of non-adjacent HepII. The right-
hand image, the C chain CRD, shows a 2.77 Å hydrogen bond formed between the O1 tail 
hydroxyl of anKdo with the O4 hydroxyl group on the pyranose ring of neighbouring HepI. 
HepIII, which was not visible in the map, is linked to HepII via the O7 group, labelled with the 
red asterisk. The outer core region of LPS that is not present in this strain is connected via the 
O3 group of HepII, labelled with the blue asterisk. Intramolecular interactions are shown as 
hashed lines. Image generated using CCP4MG. Image generated using CCP4MG. 
* 
* 
* * 
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5.3.3 Non-terminal binding 
Monosaccharide binding by SP-D has been studied extensively, but the precise mechanism by 
which longer, physiological polysaccharides are recognised is poorly understood – particularly 
with regards to binding of non-terminal residues. Studies by Allen et al., 2001 used automatic 
docking and inhibition analysis to demonstrate binding of non-terminal glucosyl residues, but a 
crystal structure demonstrating such feat is yet to be published. The data presented in this thesis 
provide an accurate and novel binding mechanism and offer insight in to SP-D recognition of a 
range of microbial surface carbohydrates – by direct binding to an internal carbohydrate residue. 
Salmonella Rd1 mutant lipopolysaccharides contain two Kdo units and three inner core 
heptose residues (Yoshii et al., 2013); but only the first two heptoses are visible in the map 
presented in this thesis, with a marked absence of a third. As HepII shows no direct interaction 
with the protein, and the orientation of the O7 hydroxyl group of HepII (that HepIII is linked to) is 
angled away from the CRD, it is likely that a further heptose would also show no direct binding 
(see Fig 5-10). The O7’ group of the glycerol tail is not coordinated by any direct interaction with 
the protein, allowing conformational flexibility round the HepII-HepIII bond. This flexibility renders 
HepIII too mobile to be seen in the electron density. 
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Figure 5-11 Site of attachment of HepIII to the O7 hydroxyl group of HepII. Both HepI and Kdo 
interact directly with the protein, while HepII interacts only with water molecules and residues 
of the symmetry-related trimer (not shown). Ligand coordinating residues are shown in cyan. 
Image generated using CCP4MG. 
 
There is vast similarity between LPS inner-core structures of Gram-negative bacteria; and the 
ligand structure presented here is identical to LPS structures found in various other genera, such 
as: 
 Bordetella – pertussis (Caroff & Karibian, 2000) 
 Burkholderia – pneumonia (Ortega et al., 2009) 
 E. coli - gastroenterological diseases (Heinrichs et al., 1998) 
 Klebsiella - pneumonia, septicaemia, meningitis (Vinogradov et al., 2002) 
 Neisseria - meningitis, gonorrhoea (Cox et al., 2003) 
 Providencia – UTIs (Kondakova et al., 2006) 
 Pseudomonas – sepsis (Bystrova et al., 2004) 
 Serratia – respiratory and urinary tract infections (Vinogradov et al., 2003) 
 Shigella – dysentery (Kondakova et al., 2010) 
 Yersinia – Bubonic plague (Vinogradov et al., 2002) 
Site of HepIII 
attachment 
HepII 
HepI 
Kdo 
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Given this similarity, the binding mechanism presented here may be applicable when discussing 
the recognition of the many different bacteria by SP-D, and provides an understanding of how 
such a broad range of pathogens are bound – i.e. that despite vast variation in outer-core and O-
antigen structures present on Gram-negative microbial surfaces, the inner core (and in particular, 
non-terminal HepI) is a conserved binding target for SP-D. 
5.3.4 Anhydro-Kdo formation 
Acid hydrolysis of intact LPS yields oligosaccharides with anhydro-Kdo on the reducing terminus 
rather than intact Kdo (Auzanneau et al., 1991). Formation of anhydro-Kdo structures in H. 
influenzae lipopolysaccharides have been previously proposed when the phosphate moiety from 
C-4 of Kdo is β-eliminated (Danan et al., 1982; Caroff et al., 1987). Loss of phosphate from the 4-
position of Kdo proceeds readily under these conditions because the C-4 substituent is β to the C-
2 (anomeric) carbon. The reaction is believed to give rise to olefinic Kdo derivatives, which 
rearrange to form anhydro ring structures. This mechanism of elimination is thus only possible 
with H. influenzae-type lipid A structures that contain a phosphorylated single Kdo residue linked 
to lipid A. E coli and Salmonella LPS contains an unphosphorylated double-Kdo (Horstman et al., 
2004) and so cannot undergo this modification. Electron density of the structure reveals that a 
five-, not six-membered, ring exists adjacent to the bound-heptose (see Fig 5-11). The density 
suggests that this Kdo residue also undergoes a structural change during mild acid hydrolysis. The 
mechanism of anhydro-Kdo formation is replicated below. 
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Figure 3-2 (replicated) Formation of the structures formed during mild acid hydrolysis of 3-
Deoxy-D-manno-oct-2-ulosonic acid (Kdo, a); D-arabino-3-en-2-ulonic acid open-chain (b), the 
diasteromeric forms of the 4,8-anhydro (c and c’) and the 4,7-anhydro (d and d’) derivatives. R 
represents the extended inner core of LPS. Image adapted from Sioud et al., 2010. 
 
Anhydro-Kdo residues (anKdo), rather than intact Kdo, as reducing terminal monosaccharides 
produced after acid hydrolysis have previously been determined for numerous 
lipopolysaccharides - and contain structures of either ‘Salmonella-type’ with a Kdo at position C4, 
or ‘Haemophilus-type’ with a phosphate group. Bacterial LPS species that display the former 
include Aeromonas, Bordetella and Vibrionaceae and produce core oligosaccharides that contain a 
mixture of diastereomeric 4,8- and 4,7-anhydro acids and an open-chain olefinic Kdo residue 
(Sioud et al., 2010; Danan et al., 1982; Banoub et al., 2010). Species of bacteria with similar Kdo 
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arrangements to that of the tested Salmonella R7 strain include Burkholderia, Chlamydia, Coxiella, 
E. coli, Klebsiella, Neisseria, Pseudomonas and Yersinia. (Isshiki et al., 2003; Kosma et al., 1988; 
Schramek et al., 1985; Yethon et al., 2000; Fresno et al., 2006; Kahler, 2004; Bystrova et al., 2004; 
Vinogradov et al., 2002). This is, however, the first instance of an anhydro-Kdo moiety from an LPS 
other than H. influenzae is seen in an electron density map. Although intact Kdo may assume a 
different position and orientation compared to that presented here, there will still be ample 
opportunity for interaction of Asp325 and Arg343 with the Kdo although these interactions may 
differ from those seen here - Asp325 with O6 hydroxyl group, and Arg343 with the tail group of 
the five-membered, anhydrous ring structure. 
Figure 5-12 Electron density map of the anhydro-Kdo residue. There is clear evidence that this 
saccharide adopts a five-membered ring conformation, rather than the conventional six-
membered structure. Image generated using CCP4MG. 
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6 Conclusions and future work 
6.1 Conclusions  
The role of SP-D in pathogen recognition involves binding of carbohydrate structures on the 
microbial surface, and a recombinant fragment containing just the head and neck regions has 
been proven therapeutically active (Sh rive et al., 2009). Crystals of this recombinant portion of 
SP-D were grown in an unconventional manner, by which calcium was added after the initial tray 
setup. Chosen crystals were flash-frozen after being soaked with a buffer containing MPD 
cryoprotectant and ligand, then the drop solution fully exchanged for 20% MPD cryobuffer. In the 
case of well CCS16A1, crystals were subjected to successive aliquots of 5-15% MPD and showed 
immediate degradation, and so were exchanged prior to the final additions of 20% cryobuffer. 
Three crystals were frozen and despite only soaking for 1 to 5 minutes, a data set was collected 
for crystal CCS16A11 which was processed at 1.77 Å and revealed a well-defined ligand in the 
binding pocket of chains B and C. Molecules packed in the crystal impose constraints on binding of 
longer structures in subunit A, and as such no ligand was visible in the electron density in this 
chain.  
6.1.1 Investigating the binding of bacterial LPS by SP-D – recognition of heptose in the inner 
core. 
This data provides insight in to the binding mechanism of bacterial lipopolysaccharide by SP-D, 
and the preferential binding to heptose 1 over heptose 2 in the inner core, as well as further 
interactions involving saccharides other than that bound at the Ca1 site. 
In chains B and C, ligand binding was primarily observed via the glycerol sidechain 
hydroxyl groups of heptose 1, by amino acids in the CRD which also coordinate calcium ion Ca1; 
the OE2 atom of Glu321, ND2 of Asn323, OD1 atoms of Asn323 and Asn341 interact with the O6 
hydroxyl group on the glycerol side chain, while the OE2 of Glu329, ND2 of Asn341 and the main-
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chain carbonyl of Asp342 interact with the O7 group. The anhydro-Kdo monosaccharide also 
formed hydrogen bonds with residues Asp325 and Arg343, but no direct interaction was seen 
between the second, outer heptose and the protein. However, two direct hydrogen bonds and 
numerous hydrogen-bond bridges between HepII and the symmetry-related trimer were 
observed, as well as a single bond between saccharides of the ligand itself that vary between the 
B and C chain.  
This structure confirms that SP-D binding of LPS and subsequent agglutination and 
clearance of Gram-negative bacteria is achieved through recognition and binding of inner core 
heptose residues. The inner core structure described here is conserved across a wide range of 
bacterial genera including Bordetella, Burkholderia, E. coli, Haemophilus, Helicobacter, Klebsiella, 
Neisseria, Pasteurella, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Vibrio and 
Yersinia species, and thus demonstrates the importance of SP-D as a pathogen-recognition 
molecule. A possible mechanism of immune system evasion is also suggested here, whereby 
lipopolysaccharide molecules effectively fold back on themselves to shield the inner core heptose 
residues that are typical targets of collectin binding. The structure also confirms the ability of SP-D 
to recognise non-terminal monosaccharides, which has previously not been shown structurally. 
Overall, this work represents high-resolution structural insights into binding of bacterial 
lipopolysaccharides by surfactant protein-D, and provides a detailed binding mechanism and 
preference of the innermost heptose residue - as well as further interactions with the terminal 
anhydro-Kdo. 
6.3 Future work 
The ligand present in the binding site here consists of two heptose saccharides and an anhydro-
Kdo residue resulting from the mild acis hydrolysis of the intact LPS. While this does not represent 
the structure of the R7 LPS in vivo due to the presence of the anhydro KdO, it provides valuable 
insights and data on the recognition of the triheptosyl inner core of a range of bacterial targets of 
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SP-D. This may be enhanced by the presence of an intact Kdo rather than the 5-membered 
anhydro Kdo although it seems likely that the major binding determinant is the inner heptose 
HepI as demonstrated here. The delipidation procedure of Phillips et al., 1992 does not involve 
beta-elimination of phosphate from the Kdo and subsequent rearrangement to a 5-membered 
ring, and as such is capable of providing the true physiological ligand. The indication from the 
structure presented here is that the crystal would allow binding of this ligand in 2 of the three 
chains, and that interaction with Arg343 would form part of the binding mechanism.  
In addition to the small ligands and monosaccharides previously crystallised in complex with SP-D, 
crystal structures of bound pathogen surface molecules such as fucose glycoconjugates, 
lipoarabinomannan and α1-2-linked trimannose are yet to be elucidated. Revealing the 
mechanism by which these ligands are bound may provide a deeper understanding of SP-D 
neutralisation of schistosomes, mycobacteria and influenza A viruses, respectively. Given the 
relative sizes of these example ligands, they are also small enough to be soaked in to crystals of 
the physiologically relevant, biologically and therapeutically active recombinant protein used in 
the present study.    
Detailed insights such as those presented here into exactly how SP-D binds pathogens suggest 
routes towards the design of recombinant fragments with modified binding pockets (and flanking 
residues) capable of enhanced or altered specificity for bacterial and viral ligands. Designer 
recombinant fragments targeted at specific diseases offer a potential route to the treatment of 
disease and infection. An example pf this is provided by Nikolaidis et al., 2014, where mutation of 
SP-D residues Asp325 and Arg343, as D325A+R343V and D325S+R343V, showed a marked 
increase in SP-D antiviral activity against seasonal strains of influenza A virus. A wealth of 
literature confirms that these binding-pocket flanking residues are a key part of both recognition 
and function.  
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An interesting and well-researched area of SP-D function is its ability to recognise and bind to 
receptors to stimulate an immune response. There are however, no structural studies of SP-D in 
complex with molecules other than small ligands, which is in part responsible for the incomplete 
understanding of the basis of receptor specificity and of the activation of immune mechanisms by 
SP-D. It may be possible that SP-D utilises the same site, but at distant locations on the 
physiological dodecameric cruciform SP-D molecule, for both bacterial and receptor binding. This 
possiblility is suggested by the calcium-dependent binding of the receptor SIRPα (Fournier et al., 
2012). While X-ray structural studies are inherently unable to show such a scenario due to the 
nature of the physiological SP-D molecule, structural studies aimed at revealing a receptor 
fragment bound by the SP-D CRD would be a significant step forward in our understanding.  
It may, however, be that binding of a physiological ligand is required to reveal the receptor 
binding mechanism, consistent with another key molecule in innate immunity, C-reactive protein, 
which appears to be unable to recognise receptors or activate complement unless a true 
physiological ligand is also bound (Agrawal et al., 2001). This presents a significant challenge. Park 
et al., (2009), successfully cocrystallised intact, rough lipopolysaccharide bound to a TLR4-MD2 
complex - a feat accomplished by sonication of an LPS solution, followed by incubation with the 
protein mixture. Repeating this experiment using SP-D and a relevant intact LPS could shed light 
on the mechanism by which an immune response is provoked once presented with a microbe.  
More generally, the roles of SP-D include far more than pathogen recognition; for instance, 
surfactant therapy has been highly successful in reducing mortality from neonatal respiratory 
distress syndrome, commonly seen in premature infants born less than 28 weeks' gestation (Clark, 
2010) and from meconium aspiration syndrome (Dargville & Mills, 2005). Current surfactant 
therapies do not include SP-A or SP-D, but considering the roles of reducing lung inflammation, 
surfactant homeostasis and lipid regulation, inclusion of recombinant SP-D fragments in this 
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treatment may help offset the risk of development of respiratory distress and chronic lung 
disease.  
The research presented in this thesis is a major advance towards the definition of the 
recognition properties of surfactant protein D, a key element of innate immunity and front-line 
host defence. It represents a further and significant step towards the exploitation of the 
biologically and therapeutically recombinant fragment in the prevention, management and 
treatment of a variety of respiratory and lung diseases.   
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Appendix 
Protein preparations used: 
1. Affinity purified, 0.5ml, 11.29mg/ml (in TBS and 5mM EDTA) 
2. Affinity purified + size exclusion chromatography, 0.45ml, 10.97mg/ml (in TBS and 5mM 
EDTA) 
3. Affinity purified + size exclusion chromatography + endotoxin treatment, 0.6ml, 
8.76mg/ml (in PBS) 
Unless otherwise stated all protein to reservoir ratios in drops are 1μl:1μl. 
 
Table 1 
CCS1, 16/12/10 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 1 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 7.49mg/ml 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
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Table 2 
CCS2, 17/12/10 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 1/2/11 
Column 6 added 22/2/11. Calcium added to A6 and C6 1/3/11. Calcium added to B6 and D6 
8/3/11 
  1 2 3 4 5 6 
 pH/PEG 2000 4000 6000 8000 10000  
A 6    
 
  6000 
pH6 
B 7      6000 
pH6 
C 8      10000 
pH7 
D 8.5      10000 
pH7 
 
 
 
Table 3 
CCS3, 1/2/11 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 8.39mg/ml 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
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Table 4 
CCS4, 23/2/11 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 2 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 8.16mg/ml 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
 
 
 
Table 5 
CCS5, 13/5/11 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 23/5/11 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
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Table 6 
CCS6, 10/6/11 
Non-variable conditions: 0.1M Tris 
Variable conditions: % w/v PEG, molecular weight PEG, pH Tris 
Wells A and B 1-3 Protein prep 1 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 
7.49mg/ml 
Wells A and B 5-6 Protein prep 3 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 
8.39mg/ml 
Wells C and D 5-6 Protein prep 2 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, 
8.16mg/ml 
 1 2 3 4 5 6 
A 15% PEG 6K 
pH6 
16% PEG 6K 
pH6 
17% PEG 6K 
pH6 
 16% PEG 2K 16% PEG 4K 
B 15% PEG 6K 
pH6 
16% PEG 6K 
pH6 
17% PEG 6K 
pH6 
 16% PEG 2K 16% PEG 4K 
C     16% PEG 8K 
pH6  
16% PEG 8K 
pH7 
D     16% PEG 8K 
pH6 
16% PEG 8K 
pH7 
 
Table 7 
CCS7, 7/7/11 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 1 dialysed in 10mM Tris, 10mM CaCl2 and 140mM NaCl at pH 7.5, incubated with 
intact Haemophilus influenzae Eagan 4A lipopolysaccharide and reconcentrated 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
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Table 8 
CCS8, 5/12/11 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 13/12/11 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
 
Table 9 
CCS9, 30/3/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 6/4/12 
 
 1 2 3 4 5 6 
A 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
B 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
C       
D       
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Table 10 
CCS10, 14/5/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 21/5/12 
 
 1 2 3 4 5 6 
A 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
B 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
C       
D       
 
 
Table 11 
CCS11, 11/6/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop 18/6/12 
 
 1 2 3 4 5 6 
A 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
B 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
  
C       
D       
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Table 12 
CCS12, 21/6/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop as stated 
Wells A and B 5-6, laid down 29/6/12, calcium added immediately 
Wells C and D 5-6, laid down 15/8/12, calcium added 22/8/12 
Wells C and D 2-3, laid down 27/9/12, calcium added immediately  
 1 2 3 4 5 6 
A 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
B 16% PEG 6K 
pH6 
16% PEG 8K 
pH7 
16% PEG 10K 
pH6 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
C  16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
D  16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
 
Table 13 
CCS13, 11/7/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop immediately 
 
 1 2 3 4 5 6 
A 16% PEG 10K 
pH7 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
B 16% PEG 10K 
pH7 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
C 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
D 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
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Table 14 
CCS14, 12/7/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 6.52mg/ml, 0.18mM hydrolysed E. coli B6 lipopolysaccharide and 11.1mM CaCl2, 
incubated for 2 hours at room temperature. 
  1 2 3 4 5 
 pH/PEG 2000 4000 6000 8000 10000 
A 6      
B 7      
C 8      
D 8.5      
 
Table 15 
CCS15, 20/11/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drop immediately, excluding A and B 
5-6 & C and D 1-4 where calcium was added 26/11/12; and C and D 3-4 after 24 hours. 
 1 2 3 4 5 6 
A 16% PEG 10K 
pH7 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
B 16% PEG 10K 
pH7 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
C 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
 
D 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 4K 
pH8 
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Table 16 
CCS16, 7/2/12 
Non-variable conditions: 16% w/v PEG, 0.1M Tris 
Variable conditions: molecular weight PEG, pH Tris 
Protein prep 3 8.76mg/ml, 0.5μl 50mM CaCl2 added to each drops in column 1 after 1 day, 
column 2 after 4 days, columns 3 and 4 after 1 week, and to columns 5 and 6 immediately.  
Wells C1/D1 protein prep 3 7.42mg/ml incubated with 0.18mM hydrolysed S. minnesota 
lipopolysaccharide and 10mM CaCl2 8/3/12 
 1 2 3 4 5 6 
A 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
B 16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
16% PEG 10K 
pH7 
16% PEG 4K 
pH8 
C 16% PEG 10K 
pH7 
     
D 16% PEG 10K 
pH7 
     
 
 
Table 17 Details of crystals which were tested or soaked along with collected data sets and 
subsequent processing. Fast - automatically reduced by fast_dp and XIA2 immediately following 
data collection using the Automatic Software Pipeline; Full - data integrated and reduces 
through MOSFLM and scaled using SCALA. Resolution in Å. 
Crystal Procedure Soak time 
(exchange to 
freeze) 
Result Processing 
(Fast/Full) 
CCS2 B5 
TEST 
+ 1µl 6.7mM Eagan 
4A LPS 28/4/11 
- -  
CCS2 A3 1 
CCS2 A3 2 
Exchanged and frozen 
Native 4/5/11 
- Snap 1.75 Å 
Snap 1.8 Å 
 7/5/11 
I03 
- 
CCS2 A3 3 
CCS2 A3 4 
CCS2 A3 5 
Exchanged and frozen 
+ 12µl 6.7mM Eagan 
4A LPS 
4/5/11 
- 
1h18m 
1h24m 
Snap 9 Å 
Collected 1.8 Å    
Collected 1.8 Å   
7/5/11 
I03 
- 
Fast 2.38 
Fast 1.92 
CCS2 A3 6 
CCS2 A3 7 
CCS2 A3 8 
Reexchanged 
+ 6µl 6.7mM Eagan 
4A LPS 
18/5/11 
22m 
27m 
32m 
Snap 2.5 Å 
Collected 1.5 Å     
Snap 2.86 Å 
20/5/11 
I04-1 
- 
Fast 1.68 
- 
CCS2 B1 1 
CCS2 B1 2 
CCS2 B1 3 
CCS2 B1 4 
Exchanged and frozen 
1/7/11 
- No diffraction   4/7/11 
I04-1 
 
CCS8 B5 
TEST 
5-20% MPD buffer 
containing 30mM E. 
coli B4 PS 28/2/12 
- -  
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Table 18 Details of crystals which were tested or soaked along with collected data sets and 
subsequent processing. Fast - automatically reduced by fast_dp and XIA2 immediately following 
data collection using the Automatic Software Pipeline; Full - data integrated and reduces 
through MOSFLM and scaled using SCALA. Resolution in Å. 
      
CCS8 C1 
TEST 
5-20% MPD buffer 
containing 30mM E. 
coli B4 PS 29/2/12 
- -  
CCS8 B4 5-20% MPD buffer 
containing 30mM E. 
coli B4 PS 6/3/12 
- Dissolved 7/3/12  
CCS2 A1 1 
CCS2 A1 2 
Moved to CCS8 C1 - Dissolved instantly  
CCS3 C1 1 
CCS3 C1 2 
Exchanged (native) 
and frozen 7/3/12 
 DC 2.5 Å  
Snap 4.2 Å 
6/5/12 
I04 
Unprocessed 
- 
CCS4 C1 Moved to 
CCS8 C1 
 - Dissolved after 4 hours  
CCS5 C1 Moved to 
CCS8 C1 
7/3/12 - Very degraded 15/3/12  
CCS8 B3 Moved to 
CCS8 C1 
 - Dissolved instantly  
CCS2 C2 1 
CCS2 C2 2 
CCS2 C2 3 
CCS2 C2 4 
CCS2 C2 5 
5-20% MPD buffer 
containing 30mM E. 
coli B4 PS  
Exchange after 3h 
45m  
15/3/12 
5m 
10m 
13m 
17m 
23m 
DC 2.4 Å 
DC 2 Å 
DC 2.4 Å 
DC 2.5 Å 
DC 2 Å 
17/3/12 
I03 
Fast 3.14 
Fast 2.79 
Fast 3.05 
Fast 3.55 
Fast 2.98 
CCS2 D6 1 
CCS2 D6 2 
5-20% MPD buffer 
containing 30mM E. 
coli B4 PS. Exchanged 
after 56m 15/3/12 
9m 
12m 
DC 1.6 Å 
DC 1.7 Å 
17/3/12 
I03 
Fast 1.74 
Fast 2.39 
CCS9 B3 1 
CCS9 B3 2 
CCS9 B3 3 
5-20% MPD buffer 
containing 30mM E. 
coli B6 PS. Exchanged 
immediately. 4/5/12 
36m 
41m 
44m 
DC 1.9 
DC 2.0 
DC 1.9 
6/5/12 
I04 
Full 2.09 
Full 2.83 
Full 2.68 
CCS9 A4 1 5-20% MPD buffer 
containing 30mM E. 
coli B6 PS. Exchanged 
immediately. 4/5/12 
10m DC 2.0 6/5/12 
I04 
Unprocessed 
CCS3 D4 1 
CCS3 D4 1a 
CCS3 D4 2 
CCS3 D4 3 
5-20% MPD buffer 
containing 30mM E. 
coli J5 PS. Exchanged 
after 40 minutes. 
17/7/12 
44m 
44m 
46m 
51m 
DC 2 
DC 2.5 
DC 2.5 – 2.35 
No diffraction 
22/7/12 
I04 
Full 2.97 
Fast 2.36 
Full 3.45 
- 
CCS8 C 1 Re-exchanged with 
20% MPD cryo 
containing 30mM E. 
coli J5 PS (10µl out, 
10µl in) 17/7/12 
1h5m DC 1.5 22/7/12 
I04 
Full 1.65 
CCS13 B6 1 
CCS13 B6 2 
CCS13 B6 3 
CCS13 B6 4 
5-20% MPD 
containing 30mM E. 
coli J5 PS. Exchanged 
after 40 minutes. 
6/8/12 
3m 
5m 
6m 
9m 
- 
DC 1.9 
DC 2.14 
DC 1.7 
9/8/12 
I03 
- 
Unprocessed 
Unprocessed 
Unprocessed 
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Table 19 Details of crystals which were tested or soaked along with collected data sets and 
subsequent processing. Fast - automatically reduced by fast_dp and XIA2 immediately following 
data collection using the Automatic Software Pipeline; Full - data integrated and reduces 
through MOSFLM and scaled using SCALA. Resolution in Å. 
 
CCS12 A6 
TEST 
5-15% MPD buffer 
containing 30mM E. 
coli F583 
- -  
CCS13 C3 
TEST 
5-15% MPD buffer 
containing 15mM E. 
coli F583 
- -  
CCS13 C6 
TEST 
5-15% MPD buffer 
containing 10mM E. 
coli F583 
- -  
CCS12 D5 1 
CCS12 D5 2 
CCS12 D5 3 
CCS12 D5 4 
CCS12 D5 5 
CCS12 D5 6 
5-20% MPD buffer 
containing 10mM E. 
coli F583. Exchanged 
immediately. 
10/10/12 
3m 
4m 
7m 
9m 
11m 
14m 
DC 2.4-3 
DC 3.18 
- 
- 
DC 3.0 
- 
14/10/12 
I02 
Unprocessed 
Fast 3.88 
- 
- 
Unprocessed 
- 
CCS12 A3 1 
CCS12 A3 2 
CCS12 A3 3 
5-20% MPD buffer 
containing 10mM E. 
coli F583. Exchanged 
immediately. 
10/10/12 
3m 
5m 
8m 
DC 1.4 
- 
DC 2-3 
14/10/12 
I02 
Unprocessed 
- 
Fast 2.03 
CCS13 D2 
TEST 
5-15% MPD buffer 
containing 22mM S. 
minnesota R7 
13/03/13 
- -  
CCS2 C6 1 
CCS2 C6 2 
CCS2 C6 3 
CCS2 C6 4 
CCS2 C6 5  
CCS2 C6 6 
CCS2 C6 7 
CCS2 C6 8 
CCS2 C6 9 
5-20% MPD buffer 
containing 22mM S. 
minnesota R7. 
Exchanged 
immediately. 15/3/13 
1m 
3m 
4m 
13m 
15m 
18m 
21m 
24m 
26m 
No diffraction 20/3/13 
I04 
 
 
- 
 
 
 
CCS16 A5 1 5-20% MPD buffer 
containing 22mM S. 
minnesota R7. 
Exchanged 
immediately. 15/3/13 
6m No diffraction 20/3/13 
I04 
- 
CCS16 A1 1 
CCS16 A1 2 
CCS16 A1 3 
5-15% MPD buffer 
containing 22mM S. 
minnesota R7. 
Crystals degrading – 
exchanged before 
20% aliquots  
1m 
2m 
5m 
 
DC 1.63 
DC 2.13 
- 
19/5/13 
I03 
Full 1.75 
Fast 2.13 
- 
CCS16 A1 4 
CCS16 A1 5 
CCS16 A1 6 
CCS16 A1 7 
CCS16 A1 8 
CCS16 A1 9 
As above. Xtals okay. 
1µl 20% added. 20µl 
removed from drop. 
Total volume of 
remaining 15% cryo 
(plus 1µl 100mM 
CaCl2) added 
27m 
29m 
1h7m 
1h10m 
1h35m 
1h38m 
- 
DC 2.4 
- 
- 
DC 1.7 
DC 2.0 
19/5/13 
I03 
- 
Fast 2.40 
- 
- 
Unprocessed 
Unprocessed 
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Table 19 Amino acid structures along with their abbreviations, molecular formulae and atom 
nomenclature 
Amino acid Abbreviation 
Molecular 
formula 
Atom nomenclature 
Alanine Ala, A 
  
Arginine Arg, R 
 
 
Asparagine Asn, N 
 
 
Aspartic acid Asp, D 
 
 
Cysteine Cys, C 
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Glutamine Gln, Q 
 
 
Glutamic acid Glu, E 
 
 
Glycine Gly, G 
  
Histidine His, H 
 
 
Isoleucine Ile, I 
 
 
Leucine Leu, L 
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Lysine Lys, K 
 
 
Methionine Met, M 
 
 
Phenylalanine Phe, F 
 
 
Proline Pro, P 
 
 
Serine Ser, S 
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Threonine Thr, T 
 
 
Tryptophan Trp, W 
 
 
Tyrosine Tyr, Y 
 
 
Valine Val, V 
 
 
 
 
 
